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Abstract
Cancer-induced bone pain (CIBP), resulting from primary sarcoma in the bone or 
metastatic spread to bone, is a common complaint among cancer patients and a major 
clinical problem. Recent innovations in rodent models of CIBP have facilitated 
investigation of novel drug treatments and of the mechanisms underlying this condition. 
The aim of this project was to characterize behavioural and dorsal horn neuronal 
alterations in a rat model of CIBP, and to study the effects of these alterations on 
different pharmacological systems.
Following intratibial injection of MRMT1 mammary carcinoma cells to induce CIBP, 
behavioural testing revealed that cancer animals developed significant mechanical and 
cold allodynia, as well as ambulatory-evoked pain, commencing on post-operative day 9. 
Sham-operated animals (injection of cell medium alone) showed no behavioural 
alterations. In vivo electrophysiological characterization of superficial dorsal horn (SDH) 
neuronal responses to natural (mechanical, heat, brush and cold) and electrical stimuli in 
the halothane anaesthetized rat revealed neuropathological alterations correlating 
temporally with the behavioural alterations. There was a marked shift in SDH neuronal 
populations such that in shams the ratio of wide dynamic range (WDR) to nociceptive 
specific (NS) cells was 26%:74% whereas in animals with CIBP it was 47%:53%. 
Furthermore, WDR cells in animals with CIBP had significantly increased responses to 
mechanical, thermal, and electrical-evoked stimuli compared to shams.
These first studies show that the spinal cord is hyperexcitable in CIBP, probably driven 
by changes in populations of SDH neurons, and that there is a clear temporal link 
between behavioural and neuronal alterations proving the latter to be a viable substrate 
for pharmacological testing in this pain model.
Acute electrophysiological study using the selective 5-HT3 receptor antagonist 
ondansetron showed that descending facilitatory serotonergic pathways are enhanced in 
CIBP. Gabapentin and morphine worked both acutely and chronically to normalise the 
evoked dorsal horn neuronal responses in rats with CIBP. Chronic behavioural studies 
showed that these drugs also significantly reduced pain behaviour to the pre-operative 
baseline response and, furthermore, gabapentin shifted the abnormal WDR:NS SDH cell 
ratio back towards the sham ratio. These investigations therefore confirmed that pain 
behaviour in CIBP is strongly linked to changes in populations and excitability of SDH 
neurones, and highlighted gabapentin as a possible novel treatment for CIBP in the 
clinic.
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Chapter 1.
INTRODUCTION
8
1.1 Pain
“All pain is one malady with many names. ” - Antiphanes 414 -c .  369 BC
“An unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage” -  standard 
definition given by the International Association for the Study of Pain (IASP).
A definition of pain may seem unnecessary as it is a sensation that the vast 
majority of people will experience. This very fact suggests, quite rightly, that 
some pains serve an important purpose, but people suffering from intractable 
persistent pain would argue very strongly against any benefit from these 
sensations. Clearly there are many types of pain, but whatever the cause it is 
always an unpleasant experience and in this sense Antiphanes was right.
The modern understanding of pain involves a much more complex system than 
the first description of a ‘pain pathway5 by French philosopher Rene Descartes 
(Figure 1.1) who, in 1644, used the example of Tire particles” coming into contact 
with the foot setting in motion a single pathway to the brain.
"If for example fire (A) comes near the foot (B), the minute 
particules of this fire, which as you know move with great 
velocity, have the power to set in motion the spot of the skin of 
the foot which they touch, and by this means pulling upon the 
delicate thread (cc) which is attached to the spot of skin they 
open up at the same instance the pore (d.e.) against which the 
delicate thread ends, just as by pulling at one end of a rope 
makes to strike at the same instance a bell which hangs at the 
other end."
V I(From Melzack and Wall, 1965) /ff; j U 'jgJB
Figure 1.1 The Descartesian model of pain. A single pain pathway that, when 
triggered, results in a unified proportional response. This has been replaced by a 
much more complex system which can be modulated at various levels.
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We now know that pain perception is multifaceted with sensory-discriminative, 
affective-motivational, and cognitive-evaluative components (Melzack 1999), 
involving numerous pathways at the level of the periphery, spinal cord, and 
higher brain centres, which can be modulated by excitatory and inhibitory 
systems.
Pain can be divided broadly into two categories according to its duration: acute 
and chronic. Acute pain, which does not outlast the causal injury, serves as a 
warning for potential tissue damage and thus has an important physiological 
purpose. The adaptive response to acute pain is motor withdrawal and/or ‘flight’ 
reaction such that there is no longer exposure to the potentially damaging 
(noxious) stimulus (Millan 1999). The importance of acute pain is demonstrated 
by the morbidity of conditions resulting in insensitivity to pain, with sufferers 
tending to die in childhood as a consequence of failure to notice tissue injury or 
illness (Nagasako et al. 2003). Chronic pain, which outlasts tissue or nerve 
damage, or where damage is unresolved due to ongoing disease, has no 
obvious physiological value and thus no adaptive value. Furthermore, chronic 
pain is often accompanied by hyperalgesia (increased pain sensation to a 
noxious stimulus), allodynia (pain sensation to a normally innocuous stimulus), 
paresthesias (abnormal sensations, both evoked and spontaneous, that are not 
unpleasant), and dysthesias (abnormal sensations, both evoked and 
spontaneous, that are unpleasant). The characteristics of these two major 
classes of pain are summarized in Table 1.1
A systematic review has found severe chronic pain to have a prevalence of 
around 8% in children and 11% in adults (Harstall and Ospina 2003) representing 
an immense number of people worldwide. It is clear that improved 
understanding of processes underlying chronic pain states, and subsequently 
better management in the clinic, is an area of utmost importance. The 
introductory chapter of this thesis gives a general discussion of nociceptive 
processing, that is to say the processes by which pain information is transmitted
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from the periphery to the central nervous system (CNS), as a preface to the 
studies which will be described on cancer-induced bone pain, a type of chronic 
pain of major clinical importance.
Table 1.1 Classification of major pain types.
Type Duration Temporal features 
in relation to cause
Major
characteristics
Adaptive
response
Examples
Acute Seconds
Instantaneous
Simultaneous
Proportional to 
cause
Withdrawal
‘flight’
Escape
Contact with 
hot surface
Chronic Months to 
years
Persistent 
Long-term disease 
May exceed tissue 
damage
Hyperalgesia
Allodynia
Spontaneous
Paresthesias
Dysthesias
Psychological 
and cognitive
CNS injury, 
arthritis, 
metastatic 
disease.
Adapted from (Millan 1999)
1.1.1 Cancer-Induced Bone Pain (CIBP) Pain from metastatic
disease, as listed in the table above, represents one of the major classes of 
chronic pain which, in the presence of ongoing illness, is very difficult to treat 
effectively with the drugs currently available. It is estimated that up to 75% of 
cancer patients in the advanced stages of disease have severe pain (Foley 
2004). There are many types of cancer pain which can be sub-classified 
according to cause:
• Pain from treatment -  chemotherapy-induced neuropathy and the 
associated pain, for example, present a problem in treatment of cancer.
• Pain from procedures -  there are a number of potentially painful 
procedures that might be employed, including lumbar punctures and bone 
marrow aspirations.
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• Pain from disease -  many metastatic diseases are associated with 
ongoing pain, and CIBP represents the most common cancer-related pain 
(Mercadante 1997).
CIBP, which can affect patients with primary sarcomas of the bone or metastatic 
invasion of bone, consists of a triad of pain states: tonic pain (this background 
pain, often described as a ‘dull ache’, increases in intensity with disease 
progression), spontaneous pain, and movement-evoked pain (Mercadante 1997; 
Portenoy et al. 1999). The movement-evoked pains, also known as incident 
pain, are acute severe episodes of pain and pose the main clinical problem in 
treatment of CIBP as doses of analgesics, such as opioids, which would control 
these episodes result in unacceptable side-effects (Bruera et al. 1995; 
Mercadante et al. 1992). Hence, this type of pain is sometimes referred to as 
‘breakthrough pain’, due to the fact that it breaks through the analgesic barrier.
There has been a paucity of information surrounding the neurobiology of CIBP 
due to a lack of suitable and reliable animal models. Previously, the models 
entailed systemic injection of carcinoma cells, resulting in systemically unwell 
animals with multiple randomly sited metastases (Kostenuik et al. 1993; Sasaki 
et al. 1998) thus precluding systematic investigation of any neuronal and 
pharmacological alterations. Recently, however, a murine model of CIBP was 
described that mimicked the clinical condition in terms of bone destruction and 
development of pain, but where the tumour was confined to a single bone 
(Schwei et al. 1999). The model involves injection of a sarcoma cell line into the 
femur and characteristically shows progressive bone destruction, elevated 
osteoclast activity (see 1.6 Structure and innervation of bone), and progressive 
behaviour indicative of pain (both spontaneous and evoked). Development and 
alteration of the model by other groups include using different species (rats), 
cancer lines (fibrosarcoma, melanoma, adenocarcinoma), and bones (humerus, 
calcaneus) (Medhurst et al. 2002; Sabino et al. 2003; Wacnik et al. 2001; Wacnik 
et al. 2003). All of these investigations have begun to shed light on the 
mechanisms underlying CIBP and have shown that, although sharing some
12
features with neuropathic and inflammatory pain, it is in fact a unique pain state. 
Studies in this area will hopefully provide better drug targets for use in the clinic.
1.2 Primary afferent fibres
The primary afferent fibres are the specialized fibres responsible for conveying 
sensory information from the periphery to the CNS. Their cell bodies are located 
in the dorsal root ganglia (DRG) and they synapse within the CNS at the level of 
the dorsal horn of the spinal cord, entering via the dorsal root (see 1.3 Dorsal 
horn architecture, and Figure 1.3). The fibres that selectively respond to noxious 
stimuli and are thus responsible for transmitting pain information are termed 
nociceptors.
1.2.1 Classification of primary afferent fibres The cutaneous
primary afferents have been grouped into three main types according to their 
structure, diameter, and conduction velocity:
AfJ fibres thickly myelinated, large diameter (>10^ im), fast conduction (30-100 m s'1)
A8 fibres thinly myelinated, medium diameter (2-6^ im) and conduction (12-30 m s'1)
C fibres unmyelinated, small diameter (0.4-1.2nm), slow conduction (0.5-2 m s'1)
Normally the low threshold A(3 fibres transmit only information regarding 
innocuous stimuli to the brain, but it is thought that under pathological conditions 
they are responsible for mediating mechanical allodynia (Ma and Woolf 1996).
The nociceptors have been sub-classified according to their response 
characteristics. Many nociceptors respond to a variety of stimulus modalities, 
including mechanical, thermal, chemical, and cold for example. However, 
mainly heat and mechanical stimuli have been used in their classification and as 
a result the terms CMH and AMH have been adopted to refer to the C-fibre 
mechano-heat sensitive nociceptors and A-fibre mechano-heat sensitive
13
nociceptors respectively (Meyer et al. 1994). Table 1.2 summarizes the main 
characteristics of the primary afferent fibres.
Table 1.2 Characteristics of primary afferent fibres.
Fibre Activation Sensation Diameter (pm) Myelination Conduction
class threshold mediated Velocity (ms1)
Ap low innocuous >10 thick 30-100
A8 high noxious
COICM thin 12-30
C high noxious 0 1 ho none 0 .5 -2
Two subtypes of AMH nociceptors have been identified. Type I AMH nociceptors 
have high heat thresholds (>50°C) and low conduction velocities of between 30 - 
55 m s'1 putting them somewhere between typical Ap and A8 fibre categories. 
Type II AMH nociceptors have lower heat thresholds and lower conduction 
velocities of around 15 m s'1. The activation of type II AMH nociceptors is 
responsible for the ‘sharp’, rapid, first phase of pain, whilst activation of the CMH 
nociceptors, whose responses increase monotonically with stimulus intensity, is 
responsible for the ‘dull’ second wave of pain (Millan 1999).
A third type of ‘silent’ nociceptors has been identified. These small diameter 
primary afferents are, under normal conditions, irresponsive to noxious stimuli 
but under pathological conditions such as nerve injury or inflammation they may 
become sensitive to a variety of chemical mediators (Millan 1999).
1.2.2 Inflammatory mediators There is a plethora of substances
produced and released during inflammation and tissue damage that can activate 
and, moreover, sensitize primary afferent fibres. Although a full account of these
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mediators is beyond the scope of this introduction they cannot go without 
mention as cancer cells produce an inflammatory infiltrate and release a cocktail 
of growth factors, cytokines, chemokines, prostanoids and endothelins leading to 
a reduction of pH to acidic levels. The results of this are activation, sensitization 
and direct deformation of primary afferents (Griffiths 1991; Safieh-Garabedian et 
al. 1995; Sorkin et al. 1997; Woolf et al. 1997). Figure 1.2 gives a pictorial 
summary of the inflammatory mediators acting on nociceptors. For more detailed 
accounts of the roles of these mediators the reader is directed to the following 
reviews: (Apfel 2000; Dray 1995; Dray 1997; Funk 2001; McMahon 1996; Ueno 
and Oh-ishi 2002).
1.2.3 Ion channels The excitability of nerve cells that allows them to 
transmit information throughout the body is a result of electrical potentials across 
the cell membrane maintained by ion pumps and ion channels contained therein, 
the principal ions being Na+, K+, Ca2+, and Cl'. The resting membrane potential 
is negative as a result of the ion distribution maintained by the pumps and 
channels: low Na+ and Cl' and high K+ inside the cell, and high Na+ and Cl' and 
low K+ outside the cell. An action potential, which is basically a brief wave of 
reversal of the membrane potential propagated along the axon away from the cell 
body, occurs when Na+ channels open and allow Na+ ions to flow along the 
concentration gradient into the cell. Ca2+ channels then open allowing Ca2+ to 
enter the cell initiating neurotransmitter release and K+ outflow which eventually 
brings the action potential to an end. As excitable membranes, and thus 
neuronal activity, are dependent on ion channels, it is obvious that they should 
have a major role in pain processing.
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Figure 1.2 Schematic 
representation of the influence 
of inflammatory mediators on 
primary afferent fibre.
Following injury and 
inflammation a cocktail of
mediators is secreted by blood 
vessels and immune cells 
activating primary afferent
terminals by increasing
conductance of sodium (gNa+)
and calcium (gCa2+) channels, 
increasing intracellular calcium, 
decreasing conductance of
potassium channels (gK+) and 
activation of second messenger 
systems (adenylate cyclase 
(AC), phospholipase C (PLC)). 
This peripheral sensitization
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neurotransmitter release and 
neuronal excitability which in turn 
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prostaglandins, NO -  nitric oxide, 
ATP -  adenosine triphosphate, 
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calcitonin gene-related peptide, 
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1.2.3 (i) Sodium channels All voltage-gated sodium channels
(VGSCs) have a similar structure consisting of a large pore-forming 
functional a-subunit, comprised of four domains of six transmembrane 
segments, and two auxiliary p-subunits - p1, p1A, p2 and/or p3 (Catterall 
2000a). VGSCs are responsible, as described above, for the depolarization 
phase of the action potential and local anaesthetics act by blocking these 
channels. Sodium currents in sensory neurones can be differentiated by 
their gating kinetics, voltage dependence, and sensitivity to the non­
competitive inhibitor tetrodotoxin (TTX). Table 1.3 details the nine a-subunits 
expressed by sensory neurones.
The sodium channel subunits expressed almost exclusively by small 
diameter sensory neurones are the subjects of much interest with respect to 
nociceptive processing and they have been shown to have important roles in 
both inflammatory and neuropathic pain states as the expression and 
function of the channels changes in these pathologies (Benham 2001; Lai et 
al. 2003). The Nav1.8 channel is of particular interest, its level of expression 
and its TTX-r sodium current are increased in models of inflammation, an 
increase which persists for months and is consistent with a role for this 
channel in the maintenance of hyperalgesia (Gold 1999; Khasar et al. 1998). 
Furthermore, knockdown of Nav1.8 does not alter baseline sensitivity to 
noxious thermal stimuli of otherwise normal rats, but in a model of 
mononeuropathy reverses neuropathic pain normalising responses to 
thermal and mechanical stimuli thus providing direct evidence of a role for 
this channel in neuropathic pain (Lai et al. 2002). This brief discussion of 
sodium channels is enough to make clear that selective blockers of TTX-r 
sodium currents, in particular Nav1.8, could provide very useful tools for the 
treatment of pain. For detailed discussions of the role of sodium channels in 
pain processing see the following reviews: (Benham 2001; Cummins et al. 
2000; Gold 1999; Lai et al. 2003; Wood et al. 2002).
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Table 1.3 Mammalian cloned voltage-gated sodium channel a-subunits 
of sensory neurones. Adapted from (Baker and Wood 2001) and (Lai et al. 
2003).
Channel TTX-
sensitivity
Tissue localization Null phenotype Abundance 
in DRG
Nav1.1 TTX-s Mainly CNS but also DRG Epilepsy, Present
and motorneurones. seizures
Nav1.2 TTX-s Predominantly CNS Lethal Present
Nav1.3 TTX-s Embryonic nervous system, Upregulated
adult CNS, injured DRG in axotomy
Nav1.4 TTX-s Skeletal muscle Absent
Nav1.5 TTX-r Heart Absent
Nav1.6 TTX-s DRG and motorneurones, Multiple Abundant
also CNS neurological and
neuromuscular
dysfunctions
Nav1.7 TTX-s Predominantly DRG, also Abundant
CNS
Nav1.8 TTX-r DRG (80% small diameter, Moderate Abundant
20% large diameter) analgesia, may
be due to Nav1.7
upregulation.
Nav1.9 TTX-r DRG (small diameter), also Abundant
in hippocampus
TTX-r - TTX resistant, TTX-s -  TTX sensitive
1.2.3 (ii) Acid-Sensing Ion Channels (ASICs) ASICs are H+-
gated receptor channels that were first cloned based on their homology to 
ENaC/degenerin (ENaC/DEG) channels, a family of epithelial sodium 
channels identified from a genetic screen of the mechanosensory pathway of 
the nematode worm Caenorhabditis elegans (Kellenberger and Schild 2002). 
There are four ASIC genes (ASIC1-4) with two isoforms of ASIC1 (ASICIa 
and ASICIb) and two isoforms of ASIC2 (ASIC2a and ASIC2b) (Krishtal
18
2003). ASICs have widespread distribution in the mammalian nervous 
system, both central and peripheral (Kellenberger and Schild 2002; Krishtal 
2003). In the PNS ASICs are found mainly in small diameter primary 
afferents (Chen et al. 1998) suggesting a role in pain processing. 
Electrophysiological studies show a role for ASIC3 in pain from cardiac 
ischemia and transient global ischemia induces expression of ASIC2a protein 
in neurones that survive the event (Kellenberger and Schild 2002). ASIC 
expression has also been shown to be facilitated by inflammation and in 
addition pro-inflammatory mediators such as NGF, 5-HT, interleukin-1 and 
bradykinin have been shown to excite primary afferents via expression of 
ASICs (Mamet et al. 2002; Voilley et al. 2001)
As these channels belong to the same family as mechanosensitive channels 
it follows that they might also have a role in mechanotransduction. ASIC 
distribution studies have indeed shown that they are expressed in sensory 
terminals, consistent with a possible role in mechanosensation (Price et al.
2001). Also, in ASIC2 knockouts Ap fibres have reduced firing rates in 
response to suprathreshold stimulation whilst other fibre types maintain 
normal responses suggesting that ASIC2 plays a role in setting the sensitivity 
of low threshold mechanoreceptors (Price et al. 2000). Furthermore, ASIC3 
null mutant mice have deficits in neuronal response to mechanical stimulation 
as well as protons (Price et al. 2001). These studies clearly show a role for 
ASICs in mechanotransduction and nociception, although the mechanisms 
by which they perform these roles are still unclear. For reviews of the 
involvement of ASICs in pain see (Kellenberger and Schild 2002; Krishtal 
2003; Waldmann et al. 1999).
1.2.3 (iii) Calcium channels Calcium entry into cells through
voltage-gated calcium channels (VGCCs) mediates a plethora of responses 
including muscle contraction, gene transcription, neurotransmitter release 
and regulation of neuronal excitability (Snutch et al. 2001). VGCCs are made 
up of a number of subunits; the ai-subunit forms the basic structure of the 
channel containing amino acids that form the pore and voltage sensor, and
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there are also auxiliary subunits - (3, 0128, and y - which modulate the function 
of the arsubunit (Catterall 2000b) which itself determines the major 
functional properties of the channel and defines its subtype. A number of 
VGCC subtypes have been identified and classified according to their 
electrophysiological and pharmacological properties into T-, N-, L-, P/Q- and 
R-types, also referred to according to the order in which the mRNA was 
cloned (A-l) and gene homology (Catterall 2000b):
L-type (skeletal muscle) o tis Cav1.1
L-type (cardiac muscle) o tic Cav1.2
L-type (endocrine) OtlD Cav1.3
L-type (retina) 0C1F Cav1.4
P/Q-type (X1A Cav2.1
N-type <X1B Cav2.2
R-type 0C1E Cav2.3
T-type 0C1G Cav3.1
T-type 0C1H Cav3.2
T-type OC11 Cav3.3
The Cav2 channels are those of interest with respect to nociceptive 
processing as they are primary neuronal, found in the soma, dendrites, and 
nerve terminals (Elmslie 2004). The Cav2.2 channel has been the focus of 
particular attention as it seems to have a pathological role in pain conditions, 
selective blockade of the channel through intrathecal administration of co- 
conotoxin GVIA or co-conotoxin MVIIA having been shown to depress thermal 
hyperalgesia, mechanical allodynia, and post-surgical pain (Snutch et al.
2001). Furthermore, the Cav2.3 channel, which is expressed at high levels in 
the superficial dorsal horn as well as primary afferent neurones of the DRG, 
has been suggested to have a role in inflammatory pain as cxie mutant mice 
show a lowered formalin phase 2 response (Saegusa et al. 2000).
As with the VGSCs discussed above, selective blockers for the calcium 
channels implicated in pain states provide an attractive target for 
pharmacotherapy but at present specificity and pharmacodynamics are
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problematic (Elmslie 2003). However, there are a couple of Cav2.2 blockers 
that show promise: ziconotide which has antinociceptive actions in animal 
models of persistent, post-operative, and neuropathic pain with potency 
several orders of magnitude higher than morphine after intrathecal 
administration (Snutch et al. 2001), is now under consideration by the FDA 
as a treatment for neuropathic pain, and AM336 which after intrathecal 
dosing in rats inhibited substance P release and produced potent 
antinociception (Scott et al. 2002; Smith et al. 2002) is currently in phase I 
clinical trials (Elmslie 2003). Furthermore, Gabapentin, an anticonvulsant 
drug which binds to the 0C28 subunit of VGCCs, selectively inhibits noxious- 
evoked responses of dorsal horn neurones in models of neuropathy and after 
inflammation (Chapman et al. 1998a; Matthews and Dickenson 2002; Stanfa 
et al. 1997) and is used widely in clinical neuropathies. The actions of this 
drug with respect to pain processing will be discussed further in chapter 5, 
whilst detailed reviews of the roles of VGCCs in pain can be found in the 
following: (Elmslie 2004; Kochegarov 2003; McGivern and McDonough 2004; 
Snutch et al. 2001; Wallace 2000).
1.3 Dorsal horn architecture
The grey matter of the spinal cord is organized into 10 layers, or laminae, 
according to the functional characteristics of the cells found therein (Sorkin 
and Carlton 1997). The dorsal horn of the spinal cord is made up of laminae 
I -  VI and receives sensory input whilst laminae VII -  IX make up the ventral 
horn which contains motor neurones. Lamina X surrounds the central canal.
1.3.1 Termination pattern of primary afferent fibres Primary
afferent fibres carrying sensory information from the periphery to the CNS 
enter the dorsal horn via dorsal roots, terminating in the segment of entry or 
sending rostro-caudal projections out of this segment. The thickly myelinated 
Ap fibres, carrying non-noxious information, terminate mainly in laminae lll-V 
onto non-nociceptive neurones which project into spinal tracts -  SCT and
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STT -  and the postsynaptic dorsal column (PSDC). Terminations in lamina V 
are also made onto WDR neurones receiving C-fibre input via interneurones. 
The thinly myelinated AS fibres, mediating transmission of noxious 
information, terminate ipsilaterally in laminae I and II, and contralaterally in 
lamina V on WDR neurones projecting to spinal tracts and the PBN. Finally, 
unmyelinated C fibres carrying noxious information terminate superficially in 
laminae I and II of the dorsal horn, with very weak input to lamina V and 
possibly lamina X (see Millan (1999) and Sorkin & Carlton (1997)). The 
laminar organization of the dorsal horn and primary afferent termination 
pattern as discussed above is shown in Figure 1.3.
1.3.2 Lamina I - t h e  marginal layer Lamina I is the area where
the first synapses occur in the nociceptive pathway. It is the main region of 
the dorsal horn receiving monosynaptic input from AS- and C fibres, and the 
main source of output from the superficial dorsal horn (SDH). Lamina I is 
therefore of intrinsic importance in pain processing. The cells found within 
lamina I have been classified into three major morphological types:
pyramidal, fusiform and multipolar (Lima and Coimbra 1986). Most of the
cells found in the marginal layer are nociceptive specific (NS) responding 
only to noxious pinch and/or heat with a smaller population of polymodal 
nociceptive (HPC) cells also responding to cold (Andrew and Craig 2002; 
Bester et al. 2000a; Bester et al. 2000b; Craig and Andrew 2002). The 
cutaneous receptive fields of lamina I neurones are usually restricted over a 
small area and thus suitable for signaling localized pain (Gauriau and 
Bernard 2002). Interestingly, there are subpopulations of lamina I neurones 
that specifically encode innocuous thermal stimuli (Light et al. 1993) and itch- 
inducing stimuli (Andrew and Craig 2001). Recently, a small population of 
wide dynamic range (WDR) cells has been identified in the SDH, which 
respond from the innocuous through to the noxious range to mechanical and 
thermal stimuli, as well as cold (Seagrove et al. 2004).
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Figure 1.3 (A) Primary afferent 
entry to the dorsal horn of the 
spinal cord and connection via 
spinal tracts to supraspinal 
pain centres. Adapted from 
(Snyder 1996).
Figure 1.3 (B) Laminar
organization of the spinal cord 
and termination pattern of 
primary afferent fibres.
Adapted with permission from 
(Matthews 2001).
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This same study showed that lamina I cells lack typical NMDA-mediated 
wind-up showing instead a slow incremental potentiation (SIP) to repeated C- 
fibre stimulation, and suggested a vital role for AMPA receptors in the 
neuronal responses, as well as GABAergic control of A8 fibre and 
mechanical-evoked responses.
The injection of retrograde tracers into target nuclei has been used to study 
the projection of Lamina I neurones which have been shown to send 
processes, mainly contralaterally, to various central sites including the 
thalamus, periaqueductal grey (PAG), lateral parabrachial area, nucleus 
tractus solitarius (NTS) and medullary reticular formation (Todd 2002). The 
largest number of labelled cells was observed after injection into the region 
between the lateral reticular nucleus and the spinal trigeminal nucleus in the 
caudal ventrolateral medulla (CVLM), and in the lateral parabrachial area. 
The majority of lamina I projection neurones (up to 80%) have been shown to 
express the neurokinin receptor NKi (Todd et al. 2000). Furthermore, it has 
been found that ablation of NKi-containing neurones in the dorsal horn by 
intrathecal administration of substance P conjugated to saporin (see section
1.4.2 Substance P) results in a significant reduction of hyperalgesia 
suggesting that these lamina I cells are vital to the maintenance of 
hyperalgesia (Mantyh et al. 1997). It is these same neurones that form the 
origin of the spinal-supraspinal loop regulating spinal excitability through a 
descending serotonergic pathway (Suzuki et al. 2002). Serotonergic 
innervation is in fact highest in lamina I compared to any other layer of the 
dorsal horn, and neurones expressing the NKi receptor receive significantly 
more contacts (Polgar et al. 2002).
Comparatively little is known about the population of lamina I neurones that 
do not express the NKi receptor. However, a group of non-NKi-expressing 
giant cells projecting to the parabrachial area and showing high levels of the 
glycine receptor-associated protein gephyrin have been characterized 
(Puskar et al. 2001). The cells express c-fos following intradermal injection 
of formalin to the ipsilateral hindpaw showing that they respond to acute 
noxious stimuli. Most of the gephyrin sites on the cells are adjacent to axons
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containing glutamate decarboxylase implying that they are GABAergic 
inhibitory cells (glutamate decarboxylase catalyses the removal of the 
carboxyl group adjacent to the a-amino group from L-glutamic acid to 
produce GABA and carbon dioxide).
1.3.3 Lamina II -  The Substantia Gelatinosa Lamina II, also known
as the substantia gelatinosa (SG) owing to its gelatinous appearance, is 
divided into an outer (ll0) and an inner (lli) layer. The SG is comprised of two 
main types of cells: stalk and islet (Sorkin and Carlton 1997). Stalk cells are 
so called due to their short stalk-like spines and are predominately located in 
llo near the border with llj. The axons of stalk cells project mainly to lamina I 
although some ramifications have been observed in deeper layers. Islet cells 
are found predominately in Hi and their dendrites extend longitudinally within 
lamina II. These are thought to be inhibitory cells. Their dendrites contain 
vesicles and are capable of forming dendroaxonic and dendrodendritic 
synapses. The outer layer of lamina II contains neurones that respond to 
noxious stimulation whereas the inner layer contains neurones responding 
mainly to non-noxious inputs (Li et al. 1999).
1.3.4 The Deep Dorsal Horn (DDH) Laminae lll-V make up the
nucleus proprius, whilst laminae V and VI (defined only in lumbo-sacral and 
cervical region) together are the deep dorsal horn (DDH) layers (Millan 
1999). Most DDH neurones are WDR and have peripheral fields much larger 
than those in the SDH (Gauriau and Bernard 2002). These cells signal the 
intensity of pain as well as a variety of mechanical stimuli (Besson and 
Caouch 1987). Anterograde tracing studies have shown dense projections 
from the DDH to the caudal reticular nuclei (Raboisson et al. 1996): the 
Lateral reticular nucleus (LRN) and the subnucleus reticularis dorsalis (SRD). 
As the LRN is a motor area closely linked to the cerebellum it suggests that 
DDH neurones play a role in the motor response to noxious stimuli (Gauriau 
and Bernard 2002). The majority of SRD neurones are nociceptive and their 
main thalamic target is the ventromedial thalamic nucleus (Villanueva et al.
1998) which in turn projects to the dorsolateral prefrontal cortex (Desbois and 
Villanueva 2001) as well as the ventral horn and motor nuclei of the brain
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stem (Villanueva et al. 1995). Labelling studies have also identified the 
gigantocellular/lateral paragigantocellular reticular nuclei (NGc) and the 
parabrachial internal lateral subnucleus (PBil) as areas receiving projections 
from DDH neurones (Bernard et al. 1995). NGc neurones respond to 
noxious stimuli and evoke escape behaviour and PBil neurones have marked 
wind-up and post-discharge after noxious stimulation (Gauriau and Bernard
2002).
1.4 Neurotransmitters and neuromodulators of nociception
The classification of primary afferent fibres according to the physiological 
characteristics of their axons has been outlined; however they can also be 
distinguished according to the neurotransmitters that they release. The 
neurochemical composition of primary afferents may vary according to tissue 
type, normal state versus inflammation or nerve injury, and also between the 
different fibre types (Millan 1999). In addition, there may be variation within a 
fibre type where, for example, peptidergic and non-peptidergic 
subpopulations exist. Of the many neurotransmitters and neuromodulators 
involved in nociceptive transmission a few of the main players are detailed 
below.
1.4.1 Glutamate Glutamate, released by both large and small
diameter primary afferents, is the main excitatory neurotransmitter in the 
mammalian nervous system. Receptors mediating its effects are located 
throughout the CNS (Ozawa et al. 1998) as well as on peripheral sensory 
terminals (Carlton 2001) and can be divided into two main categories: fast 
ligand-gated ion channels (ionotropic receptors) and slow G-protein coupled 
metabotropic glutamate receptors (mGluRs). Three subtypes of ionotropic 
glutamate receptors have been identified:
• a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)
• A/-methyl-D-aspartic acid (NMDA)
• Kainate
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AMPA receptors located postsynaptically in the spinal cord (Ye and Westlund 
1996) set the baseline level of nociception transmitting the intensity and 
duration of the peripheral stimulus (Dickenson et al. 1997). Kainate 
receptors play a facilitatory role and are located both pre- and 
postsynaptically, their presynaptic role being upgraded after inflammation, 
possibly as a result of increased glutamate release (Stanfa and Dickenson
1999). The AMPA receptors are made up of four subunits, GluR1-4, whilst 
the kainate receptors are made up of subunits GluR5-7 and KA1-2, and are 
arranged as either homo- or heteromeric pentamers (Hollmann and 
Heinemann 1994). Most AMPA receptors are impermeable to Ca2+ due to 
the presence of the GluR2 subunit (Burnashev et al. 1995), absence of this 
subunit resulting in permeability to Ca2+. AMPA receptors permeable to 
Ca2+ have been reported in the superficial dorsal horn suggesting a role in 
nociceptive transmission and it is also suggested that there is a link between 
these receptors and inhibitory systems of the dorsal horn of the spinal cord 
(Kerr et al. 1998; Stanfa et al. 2000a).
The NMDA receptor has been the most widely studied glutamate receptor 
due to availability of pharmacological tools, and a significant role for NMDA 
receptors in nociceptive transmission has been revealed. The receptors are 
heterogeneous structures capable of responding to selected agonists and 
antagonists in multiple ways. This diversity in functional response suggests 
that these channels are comprised of unique combinations of receptor 
subunits which determine a cell's functional NMDA signature (Kutsuwada et 
al. 1992). There are three subunit families which (in rat and human) are 
termed NR1-3. Within the NR2 subunit family there are four types - NR2A, 
NR2B, NR2C and NR2D whilst NR3 has two subtypes -  NR3A and NR3B. A 
tetrameric structure comprising two NR1 subunits and any two NR2 subunits 
has been proposed for functional NMDA receptors (Laube et al. 1998).
The channel has high Na+ and Ca2+ permeability and, along with glutamate, 
binding of glycine is necessary for the channel to open (Johnson and Ascher 
1987), which under normal conditions is plugged by a magnesium ion
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(Johnson and Ascher 1990) so that, initially, noxious inputs to the CNS are 
not transmitted via the NMDA receptor. With repeated stimulation, however, 
peptidergic-mediated depolarizations (discussed below) remove the 
magnesium block thus recruiting the NMDA channels. The result of this is 
hugely increased neuronal depolarizations leading to increased excitability of 
the neurone, such that its response to subsequent stimuli is enhanced - a 
phenomenon called ‘wind-up’ (Mendell 1966). Electrophysiology studies 
using AP5, a selective NMDA receptor antagonist, to drastically reduce wind­
up have confirmed the pivotal role of NMDA receptors in this event 
(Dickenson and Sullivan 1987), which contributes to ‘central sensitization’, a 
class of mechanisms fundamental to chronic pain (Melzack et al. 2001). 
Furthermore, the physiological role of NMDA receptors has been highlighted 
in a number of pathological states such as inflammation, peripheral and 
central ischemia, and nerve injury, where NMDA receptor antagonists have 
been shown to reduce neuronal hypersensitivity and/or behavioural 
responses indicative of allodynia (Coderre and Melzack 1992; Dickenson and 
Aydar 1991; Eisenberg et al. 1994; Seltzer et al. 1991; Sher and Mitchell 
1990).
These findings highlight the NMDA receptor as an ideal target for the 
pharmacological control of pain. However, NMDA receptors are important for 
normal CNS functioning and the use of antagonists is therefore limited by 
side effects including memory impairment, psychotomimetic effects, and 
ataxia (Petrenko et al. 2003). Despite this, NMDA antagonism still 
represents an area of ongoing interest as NR2B antagonists are better 
tolerated and have high efficacy. More selective antagonists of this subunit 
will hopefully provide a new class of drug for the treatment of pain.
Eight mGluR receptor subtypes have been identified and classed into three 
groups based on sequence homology, signal transduction mechanisms, and 
pharmacological profile (Neugebauer 2002): group I (mGluRs 1 and 5), group 
II (mGluRs 2 and 3) and group III (mGluRs 4, 6, 7 and 8). A major difference 
between the groups is their signal transduction pathways. Group I couples 
through Gq/n proteins activating phospholipase C (PLC) leading to hydrolysis
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of phosphoinositide (PI), protein kinase C (PKC) activation, and release of 
Ca2+ from intracellular stores. Groups II and III, negatively coupled to 
adenylyl cyclase via Gj/G0 proteins, inhibit cyclic AMP (cAMP) formation and 
cAMP-dependent protein kinase (PKA) activation. Furthermore, through a 
number of intracellular effector systems, mGluRs can regulate 
phosphorylation of various kinases, receptors, and ion channels 
(Neugebauer 2002). At the cellular level activation of mGluRs modulates 
high voltage-activated (HVA) Ca2+ channels, K+ channels, and non-selective 
cation channels. The overall effect of group I mGluR activation is enhanced 
neuronal excitability, whilst activation of group II and III mGluRs produces 
inhibitory effects, although agonists of group III mGluRs do not distinguish 
too well between nociceptive and antinociceptive processing (Neugebauer
2002). Thus, selective antagonists of group I mGluRs and agonists of group 
II mGluRs provide attractive targets for pharmacotherapy.
1.4.2 Substance P The neuropeptide Substance P (SP) belongs to
the same tachykinin family as neurokinins A and B (NKA and NKB), and is 
released from central and peripheral endings of small diameter primary 
afferents (Otsuka and Yoshioka 1993) to mediate its actions via the G- 
protein-coupled NK receptors. It has been shown that the effects of 
glutamate and SP on dorsal horn neurones may result from co-release from 
the same afferent terminals (De Biasi and Rustioni 1988).
There are three subtypes of NK receptors: NKi which exhibits preference for 
SP, NK2 exhibiting preference for NKA, and NK3 with preference for NKB 
(Regoli et al. 1994). In the CNS NKi receptors are expressed at high levels 
in the olfactory bulb, medial amygdala, dentate gyrus, superior colliculus, 
dorsal parabrachial nucleus and locus coeruleus, with moderate densities 
being found in the nucleus accumbens, striatum, periaqueductal grey, 
caudate-putamen and superior coliculus, and in the dorsal horn of the spinal 
cord (Quirion et al. 1983; Shults et al. 1984). In the peripheral nervous 
system (PNS) NKi receptors have been located in rat and mouse DRGs, and
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unmyelinated axons in glabrous skin (Andoh et al. 1996; Carlton et al. 1996; 
Li and Zhao 1998).
As mentioned previously, the peptidergic transmitters are involved in 
removing the magnesium block of the NMDA receptors. This is by virtue of 
co-release of the tachykinins with glutamate from the small diameter primary 
afferent fibres. The activation of the NK receptors produces a slow 
summating depolarization the result of which, in addition to the AMPA- 
mediated effects, is a depolarization sufficiently large to remove the 
magnesium block (Dickenson 1995; Urban et al. 1994).
Activation of the NKi receptor by SP leads to internalization of the receptor 
and investigations into the role of NKi receptors in pain have made use of 
this by conjugating the neurotoxin saporin to SP in order to ablate neurones 
expressing the receptor (Mantyh et al. 1997). It has been shown that NKi 
receptor deletion blocks wind-up and central sensitization (De Felipe et al. 
1998; Khasabov et al. 2002; Laird et al. 2000; Suzuki et al. 2002), and knock­
out studies have shown the NKi receptor to have a role in the maintenance 
of hyperalgesia in severe inflammatory pain (Kidd et al. 2003). Furthermore, 
it has been demonstrated that NKi receptors are vital for normal neuronal 
coding of high threshold mechanical and thermal stimuli (Suzuki et al. 2002). 
The role of SP in pain processing has also been established in behavioural 
studies where intrathecal injection of SP results in nocifensive behaviour, 
such as scratching and biting, which is resolved by NKi receptor antagonists 
(Gamse and Saria 1986; Hylden and Wilcox 1981). Also, noxious stimulation 
results in increased NKi receptor protein and the receptor seems to have a 
role in inflammatory pain and nerve injury (Abbadie et al. 1996; De Felipe et 
al. 1998; Honore et al. 1999). However, despite the significant role of NKi 
receptors in nociceptive processing highlighted by these animal studies, 
there has been no clinical success with NKi receptor antagonists (Hill 2000), 
which is difficult to reconcile with species differences as the same models 
have been reliably predictive of analgesia in humans for other drug classes 
such as cyclooxygenase 2 (COX2) inhibitors. It may be that the clinical and 
laboratory studies are not in alignment in terms of the stimulus intensities and
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modalities of painful stimuli, as mentioned above NKi receptors seem to be 
particularly important in coding suprathreshold mechanical and thermal 
stimuli (Suzuki et al. 2002).
1.4.3 Calcitonin Gene-Related Peptide (CGRP) Another 
important neuropeptide in pain transmission is CGRP, although 
comparatively little is known about it due to a lack of agonists. CGRP is 
released by small diameter primary afferent neurones and activation of 
CGRP receptors is thought to enhance the actions of SP. As with SP, the 
activation of the neuropeptide receptors produces a slow depolarizing 
response increasing Ca2+ levels through influx and release from internal 
stores (Wimalawansa 1996).
1.4.4 Serotonin / 5-hydroxytryptamine (5-HT) 5-HT is a monoamine 
neurotransmitter that produces antinociceptive and pronociceptive effects 
depending on which receptors it is acting on; more than 15 receptor subtypes 
have been identified so far, this fact in itself suggests a diverse role of 5-HT 
systems in pain processing (Suzuki et al. 2004b). Recently a spinal 5-HT 
pathway has been shown to play a role in mediating excitations from the 
brainstem to the dorsal horn of the spinal cord via 5-HT3 receptors (Suzuki et 
al. 2002). These excitatory ionotropic receptors are located on the terminals 
of a subset of small diameter primary afferents (Zeitz et al. 2002) and their 
activation enhances neurotransmitter release in the dorsal horn of the spinal 
cord (Farber et al. 2004). The involvement of 5-HT systems in nociceptive 
processing is discussed further in section 1.5, and in chapter 4.
1.4.5 y-aminobutyric acid (GABA) This is the major inhibitory
neurotransmitter in the mammalian CNS, ubiquitously distributed and present 
in more than 50% of central synapses (Ashton and Young 2003). GABA is 
essential for limiting excitation through modulation of the release of excitatory 
transmitters, including glutamate and the monoamines. It exerts its effects 
via three subtypes of receptors, GABAa and GABAc which are ligand-gated 
chloride channels, and GABAb which is a G-protein-coupled receptor. Thus, 
activation of the ionotropic GABA receptors causes a chloride-driven
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hyperpolarization of the cell and activation of GABAb receptors causes 
hyperpolarization via an efflux of potassium ions. The highest concentration 
of GABA receptors in the spinal cord is found in the superficial dorsal horn 
where they are co-localized with a number of transmitter receptors including 
glycine, 5-HT, neuropeptide Y (NPY) and NKi (Bohlhalter et al. 1996; Castro 
et al. 2004; Keller et al. 2001; Li et al. 2000; Maxwell et al. 1996; Parker et al. 
1998; Yang et al. 2002; Zheng et al. 2003). GABAergic terminals also make 
reciprocal synapses with primary afferent fibre terminals which provide an 
important drive for GABAergic neurones -  GABA inhibitions control small 
diameter fibre inputs, blockade of the receptors resulting in nociceptive 
responses to what would normally be innocuous stimulation (Dickenson et al. 
1997). Evidence of GABAergic roles in pain transmission has also come 
from behavioural studies where intrathecal injection of GABAa receptor 
antagonist bicuculline produces tactile allodynia (Yaksh 1989) and 
electrophysiological studies have shown that loss of GABAergic control may 
be important in neuropathic pain states (Kontinen and Dickenson 2000; 
Kontinen et al. 2001). GABA is also involved in nociceptive processing 
supraspinally -  a significant proportion of fibres descending from the 
rostroventromedial medulla (RVM), a brain area of major importance in 
descending control of pain, are GABAergic (Antal et al. 1996).
1.4.6 Opioids The fact that opioids are effective in many pain
states demonstrates the importance of the inhibitory opioid system in 
nociceptive processing. The main groups of endogenous opioid peptides are 
endorphins, enkephalins and dynorphins which act on the jn-opioid receptor 
(MOR), 6-opioid receptor (DOR), and K-opioid receptor (KOR) respectively. 
These represent the three classic types of opioid receptors belonging to the 
G-protein-coupled receptor family, all sharing extensive structural homology, 
and were cloned in the early 1990s (Chen et al. 1993; Fukuda et al. 1993; 
Minami et al. 1993). The receptors couple via PTX-sensitive Gj/G0 proteins 
to inhibit adenylate cyclase, activate inwardly rectifying K+ channels, and 
inhibit voltage-gated calcium channels (VGCC -  N, P, Q and R-type). 
Recently an orphan opioid-like receptor (ORL1) was cloned having close to 
70% sequence homology with the classic opioid receptors and the
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endogenous ligand was identified and named orphanin FQ (OFQ), or 
nociceptin (Meunier 1997). Table 1.4 lists the opioid receptor families along 
with their ligands.
Table 1.4 Opioid receptor families and their ligands.
Receptor type p(Mu) 5 (Delta) k  (Kappa) ORL1
Agonists Endorphins
Morphine
DAMGO
Enkephalins 
DPDPE 
SNC 80
Dynorphins 
U-50488 
U-69593
Nociceptin/OFQ
Antagonists Naloxone
CTAP
Naloxone
Naltrindole
Naloxone
Nor-binaltorphimine
Ac-Arg-D-Cha- 
Qaa-D-Arg-D-p- 
CIPhe-NH(2) 4
Endogenous opioid peptide-containing neurones are highly represented in 
regions involved in nociceptive processing such as the thalamus, 
periaqueductal grey (PAG), limbic system, cortex, and spinal cord 
(Przewlocki and Przewlocka 2001). In the spinal cord the classic opioid 
receptors are expressed mainly in the superficial layers of the dorsal hom 
with lower levels in deeper layers (Besse et al. 1990; Rahman et al. 1998), 
MOR accounting for 70% of total receptors, DOR 24% and KOR 6% (Besse 
et al. 1990). Opioid receptors have also been found in the PNS (Wittert et al.
1996) and are expressed by a variety of immune cells (Carr et al. 1988; 
Sibinga and Goldstein 1988).
Most of the receptors are located presynaptically on C- and AS-fibre 
afferents, thus opioids selectively inhibit nociceptive transmission whilst the 
innocuous-evoked activity in Ap-fibres is not significantly affected (Dickenson 
1990). ORL1 receptors are expressed in the amygdala septum, 
hypothalamus and thalamus, in the perikarya in DRG, and in the grey matter 
of the spinal cord (Monteillet-Agius et al. 1998), thus they are located in some 
neurones in which the classic opioid receptors are not expressed.
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The effects of opioids in persistent pain states have been studied widely and 
will be discussed in more detail in chapter 6.
1.5 Descending pain pathways
Experiments carried out in the 1960s showed that electrical stimulation of the 
PAG provides sufficient analgesia to carry out abdominal surgery in the rat in 
the absence of general anesthesia (Reynolds 1969). We now know that 
descending pathways from the brain to the DH play vital roles to either 
increase (descending facilitation) or decrease (descending inhibition) the 
passage of nociceptive information, and this descending control of pain has 
been an area of much investigation and recent review (Gebhart 2004; Millan 
2002; Suzuki et al. 2004b). Serotonergic and noradrenergic pathways 
comprise the major components of descending control, although there is a 
host of other transmitters that are delivered to the spinal cord by descending 
pathways including histamine, vasopressin, oxytocin, acetylcholine (ACh), 
GABA, opioid peptides, nociceptin, galanin, glutamate, and substance P 
(Millan 2002). Electrophysiological, anatomical, and pharmacological studies 
of descending pathways have highlighted areas of the medulla, particularly 
the rostroventral medulla (RVM), as the major output for descending 
influences (Gebhart 2004).
1.5.1 Descending Inhibition Up until recently most of the work on
descending control of pain has concentrated on inhibitory pathways which 
are often tonically active, and descend the spinal cord in the dorsolateral 
funiculi (Gebhart 2004). Some investigations have suggested that 
descending inhibition preferentially targets excitation of WDR neurones by 
noxious rather than innocuous stimuli, which may be explained by 
presynaptic inhibition of release of neurotransmitters from nociceptive fibres 
and not Ap fibres, indirect inhibition of nociceptors via inhibitory 
intemeurones, inhibition of excitatory intemeurones selectively targeting 
nociceptors, or effects on second messenger systems selectively interfering 
with actions mediated by NMDA or other receptors coupled to nociceptors
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(Millan 1999). On the other hand, electrophysiological studies have 
suggested that descending inhibitory actions on WDR neurones in the DDH 
are non-selective between noxious and innocuous inputs, which could imply 
an antinociceptive role for descending inhibitory pathways against Ap fibre- 
mediated mechanical allodynia in pathological states (Millan 1999).
1.5.2 Descending Facilitation As discussed previously (section
1.4.4 Serotonin), an individual transmitter may have multiple actions 
depending on the receptor that it is acting on, thus it is clear that descending 
pathways cannot only exert inhibitory effects. There is in fact a growing body 
of evidence to highlight a vital role for descending excitations in spinal pain 
processing. Facilitatory pathways descend from the RVM in the 
ventral/ventrolateral spinal cord (Gebhart 2004). Inhibitory and excitatory 
pathways may have the same origin; it has been shown that both pathways 
run from the nucleus reticularlis gigantocellularis pars alpha of the medulla to 
WDR laminae IV-V and NS lamina I neurones respectively (Monhemius et al.
1997). It is demonstrated that descending excitatory pathways can act on 
terminals of primary afferent fibres as well as intrinsic DH neurones. The 
intrinsic DH neurones may be inhibitory interneurones, excitatory 
intemeurones, or projection neurones, and the effects of descending 
facilitation on the latter will be enhancement of nociceptive transmission 
(Millan 1999).
Recently a 5-HT3-mediated descending facilitatory pathway acting on and 
originating from NK1 -expressing lamina I DH neurones, and relaying in the 
RVM, has been found to be involved in the modulation of mechanical and 
thermal nociceptive transmission, and is also necessary for full coding of 
inputs by deep DH neurones (Suzuki et al. 2002; Suzuki et al. 2004a; Suzuki 
et al. 2004b). As this pathway links the spinal cord to higher centres involved 
in mood and emotion it is thought that this serotonergic system may be 
important in the affective component of pain. Figure 1.4 summarises the 
influences of descending pathways on the DH. Descending facilitatory 
controls, in particular this 5-HT3-mediated pathway will be discussed in more 
detail in chapter 4.
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Figure 1.4 Schematic representation of descending pathways to the dorsal horn.
Adapted from (Millan 2002). Descending pathways (DP) originating from the rostroventral 
medulla (RVM), nucleus tractus solitarius (NTS), parabrachial nucleus (PBN), dorsal 
reticular nucleus (DRT), the hypothalamus and the cortex, interact with interneurones (IN), 
primary afferent fibres (PAF) and projection neurones (PN, which may be nociceptive 
specific (NS) or wide dynamic range (WDR)) in the dorsal horn. These interactions serve 
either to facilitate or inhibit nociceptive information to the periaqueductal grey (PAG), 
thalamus, hypothalamus, PBN, NTS, amygdala and other higher centres.
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1.6 Structure & innervation of bone
Having outlined the classes and physiological characteristics of the primary 
afferent fibres it is important to describe the innervation of bone, but first it is 
necessary to understand the function and structure of this tissue. Bones 
provide the rigid framework of the skeleton which supports and protects the 
internal organs, and works with muscles via a lever system to allow 
movement of the body. It is also a reservoir of calcium and phosphate, and 
the bone marrow is the source of all blood cells. There are two types of bone 
tissue based on structure and density:
• Cortical bone, also known as compact bone, represents most of the
skeletal mass (nearly 80%) and forms the protective outer layer of
every bone. This type of bone has high resistance to torsion and 
bending and has a slow turnover rate. It is made up of tightly packed 
osteons or haversian systems, each of which is made up of a central 
osteonic (or haversian) canal containing blood vessels running parallel 
to the long axis of the bone, and surrounded by lamellae (concentric 
rings) of matrix (see Figure 1.2). Bone cells (osteocytes) are located 
in spaces called lacunae between the rings of matrix and small 
channels called canaliculi lead from the lacunae to the osteonic 
canals, providing passageways through the hard matrix. These allow 
the blood vessels in the osteonic canals to be interconnected with 
those on the surface of the bone.
• Trabecular bone, also known as spongy or cancellous bone,
represents the remaining 20% of skeletal tissue but 80% of bone 
surface. It has a much higher turnover rate than cortical bone and is 
less dense and more elastic due to its intricate structural mesh 
consisting of plates (trabeculae) and bars of bone adjacent to irregular 
cavities containing red bone marrow. Canaliculi connect to the 
adjacent cavities (rather than osteonic canals as in cortical bone) to 
receive blood supply. Trabecular bone is found in the epipheseal 
regions of long bones and constitutes most of the bone tissue of the 
skull, ribs and spine.
37
Depending on their shape, bones can be placed into one of four categories:
• Long bones -  these structures are longer than they are wide 
consisting of a long shaft (diaphysis) with bulkier extremities 
(epiphyses). They are composed mainly of cortical bone with 
trabecular bone at the extremities. Examples of long bones are the 
femur, tibia, humerus, radius and ulna. (See Figure 1.2)
• Short bones -  roughly cube-like in shape with equal vertical and 
horizontal dimensions, these bones are largely trabecular with a just a 
thin outer layer of cortical bone. Examples of short bones include the 
carpals and tarsals.
• Flat bones -  thin, flattened and usually curved, examples include 
most bones of the cranium.
• Irregular bones -  this group consists of bones not belonging to any of 
the three categories listed above and examples include the spinal 
vertebrae.
Bones undergo constant remodelling in response to mechanical stress, a 
process which is dependent on a dynamic equilibrium between two types of 
cells; osteoclasts and osteoblasts (Blair 1998; Mackie 2003). Osteoblasts 
secrete a substance rich in collagen which is essential for mineralization of 
hydroxyapatite and other crystals. The collagen forms spiral fibres of bone 
matrix called osteoids. Osteoblasts cause calcium salts and phosphorus to 
precipitate from the blood, and these minerals bond with osteoids to 
mineralize the bone tissue. Osteoblasts that have been trapped in the 
osteoids are called osteocytes, the aforementioned bone cells. These play a 
role in controlling the extracellular concentration of calcium and phosphate. 
Osteoclasts derive from bone marrow mononuclear cells and have ruffled 
edges where active resorption takes place. The osteoclasts secrete bone- 
reabsorbing enzymes, which digest bone matrix.
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Figure 1.5 Physiology of bone -  showing typical structure of a long bone 
(left) and detail of trabecular and cortical bone (right). Adapted from 
(Warwick and Williams 1973).
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The normal process of bone remodelling can be divided into four stages:
• Activation -  under the influence of growth factors and cytokines, pre­
osteoclasts are stimulated to mature into osteoclasts.
• Resorption -  osteoclasts digest old bone matrix.
• Reversal -  the resorption process is brought to an end.
• Formation -  osteoblasts synthesize new bone matrix.
It is known that bone tissue has a very rich supply of both sensory and 
sympathetic nerves (Calvo and Forteza-Vila 1969; Hara-lrie et al. 1996; 
Mach et al. 2002; Thurston 1982). Studies in the rat have shown that the 
periosteum has the densest supply of sensory and sympathetic nerves 
followed by the bone marrow and mineralized bone (Mach et al. 2002). 
Immunohistochemical studies in rats demonstrate that small diameter 
sensory fibres innervating long bones are densest at the epiphyses where 
they come into contact with osteoclasts, suggesting that osteoclastic activity 
may be regulated in part by these sensory fibres (Hara-lrie et al. 1996). 
Pathologies of the bone, such as malignant disease of the bone, will 
obviously damage the sensory fibres innervating the bone marrow cavity, 
mineralized bone, and periosteum, and these nerves must therefore play a 
role in the pain states associated with the pathologies.
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1.7 Aims of this study
The studies mentioned in this introductory chapter have shown that pain 
processing involves a complex network of pathways at the level of the 
periphery, spinal cord, and higher brain centres, and highlight the dorsal horn 
of the spinal cord as a particularly important junction in this network. The 
pathways are under dynamic control from excitatory and inhibitory systems, 
and in pathological states this control is disrupted. The development of more 
effective pharmacological tools for the treatment of pain is reliant on better 
understanding of these pathways in the normal state and of the changes 
occurring in chronic pain states.
The aims of this thesis were to characterise the behavioural changes and to 
attempt to correlate these to potential electrophysiological alterations of 
dorsal hom neurones in a rat model of cancer-induced bone pain. 
Furthermore, to investigate the influence of selected pharmacological 
systems on CIBP-induced behaviour and neuronal alterations through use of 
a number of compounds:
• Ondansetron -  the selective 5-HT3 receptor antagonist, to study the 
role of descending excitatory pathways in CIBP.
• Gabapentin -  a novel inhibitory drug acting on VGCCs.
• Morphine -  to investigate the effects of activation of an inhibitory 
system using a ‘gold-standard’ analgesic.
The overall approach is to characterise the model, to relate neuronal activity 
to behaviour and to attempt to define possible future clinical treatments for 
CIBP.
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Chapter 2.
METHODS
2.1 Animals
All experiments were carried out on Sprague-Dawley rats, obtained from 
University College London Biological Services, weighing approximately 170g 
at the time of surgery to induce CIBP and approximately 300g at the time of 
electrophysiological testing. Animals were housed maximum 5 per cage on a 
12h day -  12h night cycle (lights on 07:30, lights off 19:30) for at least one 
week prior to the start of experiments. Food and water were available ad 
libitum. Experimental methods used were approved by the Home Office, 
performed under valid Project and Personal licenses, and according to 
ethical guidelines of the IASP (Zimmermann 1983).
2.2 Behavioural Testing
In general, the most reliable signs of pain are physical. The study of 
behavioural reactions in animals to a stimulus therefore provides an indicator 
of the perceived disagreeable sensation (Le Bars et al. 2001). Behavioural 
testing prior to induction of the model, and at regular intervals (every other 
day) throughout the post-operative period, was carried out to obtain 
information on normal baseline responses to stimuli, and to monitor 
development of hyperalgesia and allodynia evidenced by progressive 
changes in the baseline response. All animals were habituated to the 
behavioural room for at least 30 minutes before testing.
2.2.1. Von Frey Test Allodynia to tactile stimuli is one of the
most common symptoms for a number of chronic pain states including 
neuropathy, inflammation, and CIBP (Chaplan et al. 1994a; Ma and Woolf 
1996; Schwei et al. 1999), thus assessment of mechanical allodynia often 
goes hand-in-hand with in vivo pain studies whether it is the principle method 
or a tool used to verify the model. For mechanical stimulation von Frey 
filaments (North Coast Medical Inc., USA), also known as Semmes- 
Weinstein filaments, were used. These are calibrated plastic filaments of 
varying thickness that, when applied with sufficient force to make the filament
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bend, exert a known pressure usually expressed in grams. This type of 
mechanical testing has been used, both clinically and in animal 
experimentation, for over a century and is the most common method of 
assessing responses to mechanical stimuli in animal pain models. It is 
therefore unsurprising that there are various methods used for von Frey 
testing. The basic setup however is similar for most methods with the 
animals placed on metal mesh flooring, probing of the plantar surface of the 
hind paw with the von Frey providing the stimulus, and withdrawal of the paw 
upon probing or immediately afterwards considered a positive response. Von 
Frey testing has however been performed over other areas such as the 
dorsal surface of the hind paw.
As well as various methods of carrying out the test, there are a number of 
paradigms for determining the withdrawal threshold. One of the more 
commonly used is the up-down method (Dixon 1980). In this test the middle 
filament of a range of forces is used first, and depending on whether there is 
a negative or positive response, a higher or lower filament is applied 
respectively. From the pattern of negative and positive responses a 50% 
withdrawal threshold can be calculated. Another common paradigm, on 
which the tests employed in these investigations are based, is testing 
filaments in ascending order of force and basing the threshold on the 
smallest fibre required to elicit a positive response (Sato et al. 1999) or the 
fibre giving a certain response rate, varying between 40 and 100% (Kauppila 
et al. 1998; Ren 1999).
For the tests used in these investigations, rats were placed in transparent 
plastic chambers on a wire mesh floor and left to acclimatize for at least 10 
minutes (see Figure 2.1). Four von Frey filaments (bending forces of 1, 5, 9 
and 15g) were applied for 2 -3 seconds to the plantar surface of the hind paw 
in ascending order alternating between left (ipsilateral side to surgery) and 
right (contralateral side to surgery) hind paws. There was a minimum of 5 
minutes separating testing of ascending von Frey filaments for any one rat. 
The number of positive responses (taken as a brisk withdrawal of the hind 
paw during or immediately after the stimulus) observed out of the maximum
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total of 10 was expressed as percentage response. This method has been 
used reliably and reproducibly in our laboratory for a number of years 
(Chapman et al. 1998a; Flatters et al. 2002; Maie and Dickenson 2004; 
Suzuki et al. 1999).
Figure 2.1 von Frey Testing. The left hand panel shows rats acclimatizing 
to the apparatus whilst the right hand panel shows the process of von Frey 
testing at the plantar surface of the hind paw.
2.2.2. Acetone Test Allodynia to cold stimuli is another 
symptom of chronic pain states, particularly neuropathic pain, and 
behavioural responses to cooling stimuli are therefore often employed in 
studies on pain models (Zimmermann 2001). In these studies acetone was 
used as the cooling stimulus and the protocol, also having been used reliably 
and reproducibly in our laboratory for a number of years, was similar to that 
for the von Frey test. A drop of acetone was applied to the plantar surface of 
the hind paw via a syringe, again alternating between ipsilateral and 
contralateral sides. A total of 5 applications were made with at least 5 
minutes between successive acetone tests. The number of lifts observed out 
of the maximum total of 5 was expressed as percentage response.
2.2.3. Rotorod Test As discussed in chapter 1, the main clinical 
problem in treating CIBP is breakthrough pain. Thus it was necessary to test
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for the presence of this type of pain in order to validate the model. For this 
the rotorod was used. This apparatus, usually employed to assess motor 
performance, has more recently been used to study ambulatory-evoked pain 
(Honore et al. 2000; Luger et al. 2002). The rotorod (Ugo Basile model 7750, 
Linton Instruments, UK -  see figure 2.2) consists of a revolving rod with 
plastic discs providing compartments such that four animals can be tested at 
a time. When the animals are placed on the rotorod they are forced to walk 
in the forward direction to prevent falling off the rod. For these tests the 
apparatus was set to accelerate from 0 to 20 revolutions per minute (rpm) 
over 60 seconds. The time in seconds maintained on the beam before the 
rat fell was recorded with a maximum cut-off of 150 seconds. Ambulation 
was also scored as follows: 0 -  normal, 1 -  slight limping, 2 -  marked 
limping, 3 -  avoidance of use of limb. Rats received two training sessions on 
the rotorod prior to beginning an experiment and only animals scoring 
between 90 and 120 seconds at each training session were used for 
subsequent studies.
Figure 2.2 Rotorod Testing. Animals placed on the rotorod are forced to 
walk in the forward direction. Latency to fall and quality of ambulation are 
scored.
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2.3 Anaesthetic Agents
Surgery and electrophysiological experimentation were carried out under 
general anaesthesia using the volatile anaesthetic halothane in a 66%:33% 
mixture of N2O and O2. This is an ideal agent due to ease of administration 
and adjustment of depth of anaesthesia whilst maintaining spontaneous 
respiration. Also, N2O is claimed to antagonise the depressant effect of 
halothane such that when used in combination the second phase of the 
formalin response, depressed by halothane alone, is restored to the control 
baseline level (Goto et al. 1994; O'Connor and Abram 1995).
2.4 Cancer cell line
Syngeneic mammary gland carcinoma cells, kindly donated by the Novartis 
Institute (London), were prepared for injection as described in a previously 
published rat model of CIBP (Medhurst et al. 2002). The cells were cultured 
in RPMI 1640 (Gibco) with 10% foetal bovine serum (FBS), 1% L-glutamine 
and 2% penicillin/streptomycin (Gibco). Adherent cells were released by 
brief exposure (no more than 2 minutes) to 0.1% w/v trypsin and then 
quenched with an equal volume of FBS. The resulting volume was 
centrifuged for 3 minutes at 1200rpm, the supernatant tipped away and the 
pellet dissolved in 1ml of Hanks-Hepes solution (Hanks-1 OmM hepes: 1.19g 
hepes/500ml Hanks, pH 7.4 with NaOH). Ten pi trypan blue dye was mixed 
with 10pl cells and carefully added to a haemocytometer chamber. The 
number of viable cells (i.e. all those not taking up the dye) was counted and 
the cells were diluted as necessary to achieve a final injection concentration 
of 3 x 103 cells in a volume of 10pl.
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2.5 Induction of CIBP -  Osteotomy and Injection of Cells
The methods used here were adapted from previous reports (Medhurst et al. 
2002). Anaesthesia was induced by placing the animal in a sealed box with 
an inflow of halothane (3-5%) in a mixture of N20  and 0 2 (66:33) and 
maintained via a nose cone with halothane reduced to 1.5-  2%. Noxious 
pinch of the hind paw was used to confirm areflexia. The left leg was shaved 
and the skin disinfected with chlorhexidine (Animalcare Ltd, UK). A small 
incision was made over the anterio-medial surface of the distal end of the 
tibia to expose the bone. A 0.7mm dental drill attachment was used to bore a 
hole through the periosteum and a 2cm length of polythene tubing was fed 
1cm into the intra-medullar cavity of the tibia. Ten pi of cells were injected 
into the tibia via a Hamilton syringe and the tubing withdrawn. The hole was 
plugged with bone restorative material (IRM, Dentsply USA), the area was 
irrigated with 0.5mls 0.9% saline, and the wound was closed with a metal 
clip. The procedure was identical for sham-operated animals except these 
were injected with Hanks media alone. Heat-killed cells were not used in a 
separate control group in order to reduce the numbers of animals used as a 
previous publication has shown no behavioural alterations in such a control 
(Medhurst et al. 2002). After surgery rats were placed in a thermo-regulated 
recovery box until they had fully regained consciousness, upon which they 
were returned to their home cages. The whole procedure lasts an average of 
10 minutes, with rats returning to full consciousness within a further 5 to 10 
minutes.
2.6 In vivo Electrophysiology
In vivo electrophysiology was used to characterize the electrical- and natural- 
evoked responses of dorsal horn neurones in CIBP and sham-operated rats, 
and to establish the effects of pharmacological agents on these responses.
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2.6.1 Surgery Anaesthesia was induced as described above. 
The animal was removed from the sealed box and placed on a heating 
blanket (a rectal probe connected to a feedback unit maintaining a core body 
temperature of 36-36.5°C) with anaesthesia maintained (2.5-2.8% halothane) 
via a nose cone. Upon confirmation of areflexia a tracheotomy was 
performed and anaesthesia was thereafter delivered via a tracheal cannula 
(1.8-2.2% halothane). The animal was then placed in a stereotaxic frame, 
the head secured with ear bars and a tooth bar. The location of lumbar 
vertebrae L1-3 was determined in relation to the position of the ribs and a 
clamp was placed rostral to this area and secured tightly to the side bar of 
the frame. A laminectomy was performed to remove some of the dorsal arch 
of L1-3 thus exposing the dorsal surface of spinal segments L4-5. The dura 
mater, when not having been removed with the bone, was carefully peeled 
away with sharp forceps. A second clamp was then placed caudal to the 
laminectomy and secured to the opposite side bar of the frame to the first 
clamp. Anaesthesia was reduced to maintenance level of 1-1.2% halothane, 
sufficiently deep to maintain areflexia with animals still breathing 
spontaneously.
2.6.2 Neuronal Isolation Parylene-coated tungsten electrodes were 
used to make recordings. The electrode was lowered into the superficial 
spinal cord close to the central vessel using a manual micromanipulator and 
descended vertically through the cord in 10(im increments using an Epson 
Digital Stepper SCAT microdrive. Simultaneous with lowering of the 
electrode tapping of the ipsilateral hind paw, and noxious pinch to confirm C- 
fibre inputs, was used as the search stimulus to isolate a single neurone over 
background activity. Only single neurones were studied so that a unit was 
isolated by movement of the electrode and the signal to noise ratio was at 
least 4. Single neurones could be monitored, characterized and tested for 
many hours without change in the form or height of the action potential. SDH 
and DDH neurones were identified as such according to depth from the 
surface of the spinal cord (<290pm superficial, >500|im deep) as well as 
characteristic responses to electrical-evoked stimuli; lamina I neurones have
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been shown to be mainly high threshold and do not show true wind-up but 
rather a slow incremental potentiation in response to repeated stimulation 
(Seagrove et al. 2004). The depths of all of the SDH neurones in these 
studies are within the mean ± standard error depth of lamina I projection 
neurones identified by histology and antidromic stimulation (Bester et al. 
2000b).
2.6.3 Data Capture As mentioned above, parylene-coated tungsten 
electrodes were used to make single unit extracellular recordings. A 
Neurolog (Digitimer) system was used to amplify, filter, record, and analyze 
these signals. The electrode is held in a headstage which not only receives 
signal from the electrode (A) but also electrical activity from the rat and 
surroundings (B) via a clip attached to the rat and earthed to the stereotaxic 
frame. Signal B is therefore subtracted from signal A in order to minimize 
interference. The resulting signal (A-B) is amplified, filtered, and fed through 
an audio speaker and oscilloscope so that neuronal activity can be monitored 
aurally and visually (see figure 2.3). Upon isolation of a single neurone the 
window discriminator is set so that only action potentials from that neurone 
would be counted against the background activity; for this to be achievable 
for the duration of an experiment a signal to noise ratio of at least 4:1 was 
chosen. Action potentials above the set window then trigger a counting pulse 
which is relayed to the oscilloscope (appearing as a dot over the ‘spike’ -  
action potential), the latch counter (displaying a cumulative count), and to the 
CED1401 for analysis. Spike 2 software, installed on a Pentium computer, is 
used to interpret CED output.
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Figure 2.3 Schematic representation of data capture. Adapted from (Urch and Dickenson 2003)
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2.6.4 Electrical Stimuli Trains of transcutaneous electrical stimuli
were applied via stimulating electrodes placed in the centre of the peripheral 
receptive field of an isolated dorsal horn neurone. A train consisted of 16 
stimuli (frequency 0.5Hz -  set by the period generator, 2ms pulse width -  set 
by the digital width) at three times C-fibre threshold (the lowest possible 
amplitude required to evoke a C-fibre response on 3 consecutive single 
pulses -  set by the pulse buffer) and was triggered by the period generator 
which also sends signals to the delay width, latch counter modules, and CED 
from which the latency was measured. This allowed responses to be 
separated according to fibre type, such that action potentials occurring 0 -  
20ms after the stimulus are attributed to Ap fibres, 20 -  90ms to A6 fibres, 
and 90 -  350ms to C fibres.
Responses between 350 and 800ms are referred to as post-discharge and 
give a measure of neuronal excitability. The latch counters were set using 
the delay width to count action potentials occurring 90-800ms after 
stimulation thus giving a cumulative count of C-fibre activity, including post­
discharge. The primary-evoked response of the neurone multiplied by the 
number of stimuli (16) is referred to as input and is a measure of non­
potentiated activity. Wind-up, a measure of neuronal hyperexcitability 
(Dickenson and Sullivan 1987), was calculated as the total number of C-fibre 
action potentials minus the input. As this calculated value of wind-up is 
related to the input value, drugs inhibiting the non-potentiated primary- 
evoked response but not substantially affecting post-discharge (excitability) 
of the cell will give an increase in the calculated wind-up. Therefore, in 
addition to calculating wind-up the number of C-fibre action potentials was 
plotted against stimulus number. These wind-up curves (examples given in 
figure 2.4) are only plotted for a single trial from a single cell due to the fact 
that input and wind-up vary between neurones.
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Figure 2.4 Examples of typical wind-up curves for SDH and DDH neurones.
Note that the primary-evoked response of the SDH neurone is typically lower than 
that of the DDH neurone and that the increase in activity over the train of activity is 
small compared to the DDH neurone.
The neuronal response to the train of 16 stimuli is captured on the computer 
by the spike 2 software and presented as a post-stimulus time histogram 
(PSTH) -  figure 2.5.
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Figure 2.5 Example of PSTHs from SDH neurone (A) and DDH neurone (B).
Note that the SDH neurone has much a lower response compared to the DDH 
neurone which shows large A- and C-fibre bands, and sustained post-discharge.
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2.6.5 Natural Stimuli Neuronal responses to a range of natural
stimuli were characterized. All stimuli were applied to the peripheral
receptive field for 10 seconds and a rate programme in Spike 2 was used to 
record the total number of action potentials occurring during each of the 
stimuli. A range of von Frey filaments (1, 5, 9, 15, 30, and 75g) was used for 
punctate mechanical stimuli, a standard soft-bristle paint brush (Pro Arte No. 
8) for non-noxious brush, and constant water jet at a set temperature, 
delivered via a syringe, for thermal (32, 35, 38, 40, 42, 45, 48 and 50°C) and 
cold (4°C) stimuli. Any neuronal response from 32°C was used as a baseline 
and subtracted from subsequent temperatures to take into account the 
mechanical response to the water jet. Figure 2.6 shows typical examples of 
thermal-evoked responses of SDH and DDH neurones.
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Figure 2.6 Typical thermal-evoked responses of SDH (A) and DDH (B) 
neurones. Panel A shows typical responses of a NS SDH neurone to thermal 
stimuli. Panel B shows typical responses of a WDR DDH neurone to thermal 
stimuli, with the cell coding throughout the range of temperatures showing 
increasing responses from innocuous to noxious.
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2.6.6 Neuronal classification Neurones were classified as NS or
WDR according to their responses to thermal and mechanical punctate 
stimuli. Responses to brush were not taken into account for this 
classification as many superficial cells not responding to innocuous von Frey 
filaments have a paradoxical response to non-noxious brush (Seagrove et al. 
2004). NS cells were therefore taken as those responding (with more than 
10 action potentials per stimulus) at von Frey 9g and above and 42°C and 
above.
2.6.7 Quantification of peripheral receptive field The peripheral
receptive fields of the neurones characterized were mapped on diagrams of 
the plantar surface of the hind paw. For DDH neurones this was done using 
three von Frey filaments (9, 15 and 75g) and for SDH neurones noxious 
pinch was applied with forceps since many of these cells are high threshold. 
The diagrams were copied to plain paper (80g/m2) and the mapped areas 
were cut out and weighed. Receptive field areas were expressed as a 
percentage of the mean weight of the total area.
2.6.8 Testing protocol Electrical followed by natural stimuli (brush,
punctate mechanical, thermal, cold) were repeated at 20 minute intervals. 
For characterization studies the full range of von Frey filaments and 
temperatures described above were used. For pharmacology experiments 
fewer thermal stimuli were given (35, 40, 45, 48 and 50°C) in order to allow 
approximately 10 minutes between giving the last natural stimulus and 
carrying out the next electrical test so that the cell had time to recover. 
Pharmacological testing began on confirmation of stable neuronal responses 
(three consecutive trials with less than 10% variation). These responses 
were averaged to give pre-drug control values to which subsequent 
responses were compared. Drugs were administered either spinally or 
system ically.
Spinal administration was made directly onto the spinal cord, in a volume of 
50pl, via a Hamilton syringe. The drug is kept in contact with the cord due to
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the well that is formed by the muscle tissue around the laminectomy. The 
integrity of this well was checked prior to searching for a neurone by 
delivering 50pl of saline ensuring that this volume would be held without any 
leakage. Drug was left in contact with the cord for 1 hour, testing at 20 
minute intervals, and absorbent tissue paper was used to remove it before 
administering the next dose.
Systemic administration of drug was via subcutaneous injection of a volume 
of 250|il into the scruff of the back of the neck. Testing, as before, was 
carried out at 20 minute intervals, following each dose of drug for 1 hour.
2.7 Analysis of results
Data are presented as mean ± standard error of mean (sem), unless stated 
otherwise. All statistical analyses were performed using Prism 3.0 software 
and significance was set at P<0.05.
For data from behavioural testing, the non-parametric Mann-Whitney U test 
was used due to its suitability for comparing sets of ordinal data.
Electrical-evoked neuronal responses obtained post-drug administration were 
compared to pre-drug controls using one-way analysis of variance (ANOVA). 
Where a significant effect was observed with increasing doses, post-hoc 
analysis was performed using the Dunnett’s test to assess individual dose 
effects. Natural-evoked neuronal responses, where the outcome is affected 
both by dose of drug and intensity of stimulus, were analyzed using two-way 
ANOVA and the Bonferroni test for post-hoc analysis where appropriate.
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Chapter 3.
PART ONE: BEHAVIOURAL AND DORSAL 
HORN NEURONAL CHARACTERISATIONS.
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3.1 Introduction
Improvements in the detection and treatment of cancers have resulted in 
sufferers surviving longer, but severe pain is often a major contributor to the 
decreased quality of life endured by many of these patients (Portenoy et al. 
1999). Bone metastases are frequently predictive of pain and CIBP is in fact 
the most common cancer-related pain, with metastatic cancers invading the 
skeleton in 60-84% of cases (Mercadante 1997). Interestingly, the presence 
and intensity of CIBP do not correlate with the size or number of active 
malignancies. Although the majority (up to 80%) of patients with breast 
cancer have metastatic spread to the bone, about 66% of the metastatic sites 
are painless but, on the other hand, there may be severe pain reported from 
a single bone metastasis in the absence of fracture (Mercadante 1997).
As mentioned in the introductory chapter, patients experience a triad of pain 
states consisting of background pain, spontaneous pain, and incident pain. 
The intermittent nature of spontaneous and incident pains makes them hard 
to treat pharmacologically, and it is very difficult to attain freedom from pain 
on movement in patients with bone metastases (Mercadante 1997). Skeletal 
metastases are poor prognostic factors, thus current therapies are palliative 
rather than curative. A better understanding of the processes underlying 
CIBP is required to provide more effective pharmacological agents to treat it, 
and thereby improve the quality of life of many cancer patients.
3.1.1 Factors contributing to CIBP Section 1.6 on the structure
and innervation of bone described how a dynamic equilibrium between 
osteoclastic resorption of bone and osteoblastic deposition of new bone is 
necessary for normal remodelling. With osteoclastic tumour cell lines this 
equilibrium is disrupted in favour of excessive osteoclastic activity, resulting 
in decreased bone density and, ultimately, destruction of bone architecture. 
As described in the section mentioned above, bones have a rich supply of 
sensory nerves to the periosteum, bone marrow, and mineralized bone 
(Mach et al. 2002). Osteoclastic destruction of bone architecture in regions
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with sensory innervation will clearly result in direct mechanical damage of 
these afferent fibres and thus lead to pain. Furthermore, stretching of the 
periosteum due to growth of tumour within the bone, or nerve entrapment 
after pathological fracture or by the invading tumour itself may also result in 
pain (Mercadante 1997).
As well as mechanical damage or distension of primary afferents by tumours 
invading the bone, pain may arise as a result of stimulation of nociceptors by 
factors released by tumour cells and the accompanying inflammatory 
infiltrate. In addition to cancer cells, tumours are made up of a number of cell 
types including macrophages, neutrophils, and T-cells (Mantyh et al. 2002), 
and release a plethora of growth factors, cytokines, interleukins, chemokines, 
prostanoids and endothelins (Safieh-Garabedian et al. 1995; Sorkin et al. 
1997; Suzuki and Yamada 1994) resulting in activation of primary afferents 
which express receptors for many of these factors (see 1.2.2 Inflammatory 
mediators, and Figure 1.2). Furthermore, the local environment of the 
tumour is made more acidic (Griffiths 1991) and this decrease in pH can 
activate ASICs (see 1.2.3 (ii) Acid Sensing Ion Channels -  ASICs) expressed 
by primary afferents. In addition, the vanilloid receptor VR1, a cation channel 
activated by noxious heat and capsaicin and expressed by nociceptors, is 
also activated by decreases in pH and, furthermore, protons decrease the 
temperature threshold for VR1 activation (Tominaga et al. 1998). The local 
acidosis induced by cancers not only causes activation of primary afferents, 
but also facilitates osteoclastic bone destruction; osteoclast formation and 
activation are reliant on macrophage colony stimulating factor (M-CSF), and 
the interaction between the receptor activator for nuclear factor kB (RANK - 
expressed on osteoclast precursors) with the RANK ligand (RANK-L - 
expressed on various cell types including osteoblasts), in an acidic 
environment (Urch 2004). Osteoblasts secrete a soluble protein called 
osteoprotegrin (OPG) which acts as a decoy receptor for RANK-L preventing 
RANK and thus osteoclast activation (Lacey et al. 1998). It is this interaction 
between RANK -  RANK-L that is disrupted by tumours invading the bone as 
cancer cells and invading T-cells secrete RANK-L and sequester OPG (Urch
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2004). Figure 3.1 summarises the factors contributing to CIBP discussed 
above.
3.1.2 Current drug treatments The treatment of CIBP involves a
number of approaches including radiotherapy, chemotherapy, surgical 
intervention, and pharmacotherapy. In terms of pharmacotherapy, the main 
classes of drugs used are bisphosphonates, non-steroidal anti-inflammatory 
drugs (NSAIDs), and opioids.
Bisphosphonates bind strongly to hydroxyapatite crystals in bone and inhibit 
osteoclastic bone resorption (Mercadante 1997). These drugs therefore 
reduce pain in patients by decreasing destruction of the bone. 
Bisphosphonates have been reported to potentiate the effects of analgesics 
in treating CIBP, although the effect is modest and does not allow for 
reduction of the dose of analgesic (Mercadante 1997). Side effects 
associated with bisphosphonates include gastrointestinal tract toxicity, fever, 
and electrolyte abnormalities (Mantyh et al. 2002).
NSAIDs are the first step on the analgesic ladder for cancer pain relief and 
even where the severity of pain requires progression to other analgesics, 
administration of NSAIDs may continue to take advantage of possible 
additive effects (Mercadante 1997). NSAIDs inhibit the cyclo-oxygenase 
pathway of arachadonic acid breakdown to reduce the formation of 
prostaglandins. The rationale for their use in CIBP is based on preventing 
activation and sensitization of primary afferents by prostaglandins, as 
described in sections 1.2.2 and 3.1.1. However, trials of NSAIDs in cancer 
pain which include bone metastases do not specify effects on incident pain 
and there is a general lack of clinical evidence to support a significant 
analgesic effect of NSAIDs in CIBP (Urch 2004).
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Figure 3.1 Factors contributing to CIBP. Tumours invading bone alter the 
osteoclast/osteoblast balance in favour of osteoclast activity, leading to bone 
destruction. Entrapment, distension, or direct mechanical damage of nerves 
innervating the destroyed area of bone will result in pain. Furthermore, 
tumour cells and inflammatory cells in the local area release a cocktail of 
factors including nerve growth factor (NGF), tumour necrosis factor (TNF), 
interleukins (ILs), protons, and prostaglandins (PGs) which can activate 
and/or sensitize the primary afferents. The net result of this would be 
increased neurotransmitter release into the dorsal horn of the spinal cord 
and increased signalling via the spinothalamic tract and post-synaptic dorsal 
column to higher centres in the brain where pain is perceived. Adapted from 
(Mantyh et al. 2002).
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Side effects associated with NSAIDs include bleeding, gastrointestinal 
ulceration and renal toxicity (Mantyh et al. 2002). The new class of COX-2 
selective antagonists may provide better pharmacological tools for treating 
CIBP as they have been reported to inhibit cancer cell growth (Sheng et al. 
1997b).
Opioids remain the mainstay for treatment of severe pain from malignancy in 
the bone but adverse side effects including constipation, nausea and 
vomiting, sedation, and respiratory depression are highly problematic at the 
doses that would be required to combat incident pain. Opioids in CIBP will 
be discussed in more detail in chapter 6. Table 3.1 lists the main groups of 
drugs currently used in the treatment of CIBP.
Table 3.1 Current drug therapies for CIBP
Drug Class Mechanism of Action Side effects
Bisphosphonates Cause apoptosis of Gl tract toxicity, fever,
osteoclasts in electrolyte abnormalities.
mineralized bone.
NSAIDs Block synthesis of COX I Bleeding, Gl ulceration,
and COX-2. renal toxicity.
Opioids Agonists at central and Constipation, nausea and
peripheral mu-opioid vomiting, sedation,
receptors. respiratory depression.
COX, cyclooxygenase; NSAIDs, non-steroidal anti-inflammatory drugs; Gl, 
gastrointestinal. Adapted from (Mantyh et al. 2002).
3.1.3 Animal models of CIBP As mentioned in the introduction,
earlier animal models of CIBP involved systemic injection of carcinoma cells 
resulting in systemically unwell animals with multiple randomly sited 
metastases (Kostenuik et al. 1993; Sasaki et al. 1998). This precluded
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systematic investigation of mechanisms underlying this pain state. Recently 
however, more suitable models have been developed.
In 1999, (Schwei et al. 1999) described a murine model of bone cancer that 
closely resembled the clinical condition but in which the tumour was confined 
to the femur. The cancer was induced by injecting sarcoma cells (NCTC 
2472), which had previously been shown to induce lytic lesions in bone after 
intramedullary injection (Clohisy et al. 1996; Clohisy et al. 1995), into the 
femur of adult mice. The injection site was then plugged with a bone 
restorative material confining the tumour to the femur for the duration of the 
experiment. Over the next 21 days mice showed behavioural signs indicative 
of pain progressing at the same time as osteoclastic destruction of the bone. 
In addition, the study showed unique neurochemical and cellular alterations 
in segments of spinal cord receiving afferent input from the damaged bone: 
massive astrocyte hypertrophy and elevated expression of dynorphin (pro- 
hyperalgesic peptide) in the dorsal horn of the spinal cord -  changes which 
were almost exclusive to the side of the spinal cord ipsilateral to the tumour­
laden femur. Furthermore, non-noxious palpation of the bone resulted in 
nocifensive behaviours as well as SP receptor internalisation and increased 
c-Fos protein expression in lamina I neurones, providing evidence that 
primary afferent fibres are sensitised after malignant destruction of the bone.
Hypertrophy of astrocytes, increased expression of dynorphin and c-Fos, and 
internalisation of SP-R have all been reported in models of neuropathic 
and/or inflammatory pain (Abbadie et al. 1996; Draisci et al. 1991; Honore et 
al. 1995; Nichols et al. 1997; Wagner et al. 1993). Conversely, whilst SP 
levels in primary afferent neurones are elevated in models of inflammation 
and decreased in models of neuropathy, they are not altered in the murine 
bone cancer model (Schwei et al. 1999). Thus, the neurochemical 
alterations occurring in this model are unique, reflecting a unique pain state 
but one that shares some features of neuropathy and inflammation.
Subsequent studies in this same model have further suggested CIBP to be 
distinct as efficacy of systemic morphine at reducing pain-related behaviour
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was far lower than in a chronic inflammatory model (Luger et al. 2002). This, 
and other investigations in CIBP models, has shown that with acute opioid 
administration high doses are necessary to significantly reduce pain 
behaviour (Menendez et al. 2003a; Vermeirsch et al. 2004). This is 
consistent with the clinical problem of high doses of opioids being necessary 
to combat incident pain as discussed previously, and thus further validation 
of this as a suitable animal model of CIBP closely mimicking the clinical 
condition.
Other pharmacological studies in the 2472 murine model have demonstrated 
that chronic bisphosphonate treatment reduces destruction of bone and 
sensory nerves innervating the bone, as well as movement-evoked bone pain 
(Sevcik et al. 2004). In addition, selective inhibition of COX-2 has been 
shown to reduce pain, bone destruction, and tumour growth in the model 
(Sabino et al. 2002) supporting the previously reported evidence for anti- 
tumorigenic properties of this class of drug (Sheng et al. 1997a; Sheng et al. 
1997b) and the involvement of prostaglandin sensitisation of primary 
afferents in this pain state. Chronic administration of OPG also diminished 
movement-evoked pain and bone destruction as well as spinal 
neurochemical markers of sensitisation, showing reductions in palpation- 
induced SP-R internalisation, c-Fos expression, and dynorphin expression 
(Luger et al. 2001). This study highlights the pivotal role of osteoclastic 
destruction of bone in the 2472 murine model of CIBP.
The original protocol has been further developed to involve different bones 
such as calcaneus (Wacnik et al. 2001), humerus (Wacnik et al. 2003), and 
tibia (Menendez et al. 2003a), as well as different cell lines -  fibrosarcoma 
(Wacnik et al. 2003), melanoma and adenocarcinoma (Sabino et al. 2003). 
The latter study showed that the different cell lines caused distinct 
localisation and extent of bone destruction, type of pain behaviour, and 
neurochemical reorganisation of the spinal cord demonstrating that multiple 
mechanisms are involved in generating and maintaining CIBP.
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A recent development has been the description of a rat model of CIBP where 
injection of syngeneic MRMT-1 mammary gland carcinoma cells into the tibia 
of Sprague-Dawley rats resulted in astrocyte hypertrophy, progressive bone 
destruction, and pain behaviour thus having parallels to the murine models 
(Medhurst et al. 2002). This study showed acute treatment with morphine to 
reduce pain behaviour and subsequent investigation demonstrated, again 
similar to findings in the 2472 murine model, that bisphosphonate treatment 
attenuated pain behaviour whilst inhibiting tumour proliferation and 
preserving bone architecture (Walker et al. 2002). Although the initial rat 
study showed acute dosing with COX-2 antagonist celebrex to be ineffective 
against CIBP (Medhurst et al. 2002), a subsequent pharmacological 
investigation in the same model showed chronic administration of COX-2 
antagonists lumiracoxib and valdecoxib to significantly reduce pain behaviour 
(Fox et al. 2004). This discrepancy could be due to acute versus chronic 
administration regimes or perhaps differing selectivity for COX-2. 
Regardless, it is clear that further investigation is necessary to evaluate the 
use of this class of drug in CIBP.
Translational research is a key to gain knowledge of mechanisms 
contributing to chronic pain states and improving clinical treatments. The 
models described above have begun to shed light on neurochemical and 
cellular changes occurring in CIBP. The aim of the following study was to 
use in vivo electrophysiology to characterise superficial and deep dorsal horn 
neuronal responses in a rat model of CIBP, in order to provide a description 
of potential neuronal correlates of the behavioural alterations.
3.2 Methods
Behavioural tests were carried out pre-operatively (to establish the baseline) 
and on post-operative days 2, 4, 7, 9, 11, 14, 16 and 18 as described in 
chapter 2, testing for ambulatory-evoked pain using the rotorod, for 
mechanical-evoked pain using von Frey filaments, and for cold-evoked pain 
using acetone. Preparation of MRMT-1 cells, surgery to induce CIBP, sham
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surgery, behavioural testing, and dorsal horn neurone characterisations were 
also carried out as described previously. Dorsal horn neuronal responses to 
repetitive electrical stimuli and natural stimuli (punctate mechanical with von 
Frey, innocuous brush with artist’s paintbrush, thermal and cold with water jet 
at set temperature) were recorded between post-operative days 15-17 at the 
time of maximum behavioural changes, and the peripheral receptive fields 
were mapped and quantified. Neurones were classed as superficial or deep 
based on depth from the surface of the cord and characteristic responses, 
and as either NS or WDR based on responses to punctate mechanical and 
thermal stimuli with neurones only responding at von Frey 9g and above and 
42°C plus being NS. No more than six neurones were characterised in a 
single rat. Neuronal responses characterised in MRMT-1-injected rats were 
compared to those in sham-operated animals.
3.3 Results
3.3.1 Behaviour
All rats showed normal grooming behaviour and weight gain (weight at time 
of electrophysiology for sham-operated rats was 311 ± 40g and 302 ± 31 g for 
MRMT-1-injected rats) throughout the post-operative period. Sham-operated 
rats showed no change to the baseline behavioural responses to von Frey or 
acetone at any point of the post-operative period whilst there was a 
significant increase in time maintained on the rotorod from day 7 onwards 
(Figure 3.2).
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Figure 3.2 Behavioural responses in sham operated rats. (A) Sham- 
operated rats show no alteration in the baseline response to mechanical 
punctate or cooling stimuli at any point of the post-operative period. (B) There 
is a significant improvement in performance on the rotorod in sham-operated 
rats from post-operative day 7 onwards. Each point represents mean ± SEM, 
n > 7. *P<0.05, **P<0.01.
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However, the tests revealed progressive development of hyperalgesia and 
allodynia in the MRMT-1-injected rats as von Frey filaments 9g and 15g 
induced withdrawal responses significantly higher (P<0.05) on the ipsilateral 
side compared to the contralateral side from day 9 onwards (Figure 3.3A), 
and to von Frey 1g and 5g from day 11 onwards (Figure 3.3B). The 
withdrawal responses to acetone were also significantly increased from day 
11 onwards (data not shown). Furthermore, the rats showed increasing 
ambulatory-evoked pain throughout the post-operative period evidenced by a 
significant decrease in latency to fall from the rotorod by day 18 (Figure 
3.3C), and increased ambulatory-evoked pain score from day 9 onwards 
(Figure 3.3D).
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Figure 3.3 A. Withdrawal responses to von Frey 1g and 5g in MRMT-1-injected 
rats. Rats receiving intratibial injection of MRMT-1 show increasing responses to 
von Frey 1g and 5g, significant from post-operative day 11 onwards. Each point 
represents mean ± SEM, n > 7. *P<0.05, **P<0.01.
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Figure 3.3 B. Withdrawal responses to von Frey 9g and 15g in MRMT-1 - 
injected rats. Rats receiving intratibial injection of MRMT-1 show increasing 
responses to von Frey 9g and 15g, significant from post-operative day 9 onwards. 
Each point represents mean ± SEM, n > 7. *P<0.05, **P<0.01.
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Figure 3.3 C. Latency to fall from the rotorod in MRMT-1-injected rats. Rats 
receiving intratibial injection of MRMT-1 show significant improvement on the 
rotorod by days 7 to 9, but a significant decrease in time maintained on the rotorod 
by day 18. Each point represents mean ± SEM, n > 7. *P<0.05, **P<0.01.
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Figure 3.3 D. Ambulatory-evoked pain score in MRMT-1-injected rats. Rats 
receiving intratibial injection of MRMT-1 show significant ambulatory-evoked pain 
from day 7 onwards. Each point represents mean ± SEM, n > 7. *P<0.05, 
**P<0.01.
3.3.2 Electrophysiology Cells were divided into groups based on 
surgical procedure and location in the dorsal horn. A total of 67 neurones in 
sham-operated rats and 58 in MRMT-1-injected rats were characterised.
(i) Deep dorsal horn neurones A total of 33 neurones in sham-
operated rats and 28 in MRMT-1-injected rats were characterised with mean 
depths of 685 ± 34pm and 675 ± 32pm, respectively. All neurones in this 
population were WDR. Fifteen percent of cells in the sham-operated group 
and 18% in the MRMT-1-injected group showed low levels of spontaneous 
activity (<1.5Hz). All of the cells had peripheral receptive fields over the 
plantar surface of the hind paw, typically located centrally over the toes. 
Table 3.2 shows the mean areas of peripheral receptive fields for the two 
groups.
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Table 3.2 Peripheral receptive field (% of total hind paw area) of DDH 
neurones in MRMT-1-injected and sham-operated rats.________________
Group Von Frey 9g Von Frey 15g Von Frey 75g
MRMT-1 16 ± 3 17 ± 3 30 ± 6
Sham 13 ± 2 16 ± 3 25 ± 5
There was no significant difference in receptive field size between MRMT-1 - 
injected and sham-operated rats at any of the von Frey forces.
The mean thresholds for C-fibre activation by electrical stimulation were also 
similar for the two groups, 1.5 ± 0.1mA and 1.3 ± 0.1mA for sham and 
MRMT-1 animals respectively. However, the C-fibre-evoked responses 
(including input and post-discharge) were significantly greater (P<0.05) in the 
MRMT-1-injected group (Table 3.3).
Table 3.3 Comparison of mean electrical-evoked responses of DDH 
neurones in MRMT-1-injected and sham-operated rats.
Sham MRMT-1
Input 322 ± 40 433 ± 35 *
A-beta 113 ± 7 116 ± 7
A-delta 89 ± 8 91 ±8
C-fibre 359 ± 23 430 ± 28 *
Post-discharge 191 ±16 272 ± 27 *
Wind-up 295 ± 29 376 ± 57
Values presented as mean action potentials ± SEM.
The post-discharge responses are indicators of neuronal excitability, as are 
wind-up values, however, the wind-up of neurones in MRMT-1-injected
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animals only showed a tendency to be increased compared to sham animals, 
whereas for post-discharge the difference was significant. Observation of 
individual wind-up curves (Figure 3.4) revealed large increases in the initial 
responses of the neurones (reflected in the increased input value for the 
population). The shift in the baseline accounts for the apparent lack of 
significant increase in calculated wind-up.
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Figure 3.4 Wind-up curves for individual DDH neurones in MRMT-1 - 
injected and sham-operated rats. An increase in the primary-evoked 
response results in a shift of the wind-up curve in the positive direction of the 
Y-axis but with the general shape and slope of the plot remaining the same. 
This may explain why notable changes in calculated wind-up were not 
significantly different.
The response to brush and noxious cold was not significantly different 
between the groups. In the sham-operated group 94% responded to brush 
and 91% responded to noxious cold, compared to 96% and 89% respectively 
in MRMT-1-injected rats. All of the cells characterised responded to 
mechanical and thermal stimuli with increasing responses throughout the
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innocuous to the noxious range (thus they were all classified as WDR). The 
mean response to thermal stimulation was significantly higher (P<0.05) in the 
MRMT-1 group compared to shams at 35, 38, 40 and 48°C (Figure 3.5). The 
mechanical-evoked responses also showed a tendency to be higher in the 
MRMT-1 group but the difference was not significant (Figure 3.6).
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Figure 3.5 Response of DDH neurones in MRMT-1-injected and sham- 
operated rats to thermal stimulation of the peripheral receptive field.
The mean response of DDH cells in MRMT-1-injected rats was significantly 
higher (P<0.05) than in sham-operated rats between 35 and 42 °C, and at 48 
°C. Data are presented as mean number of action potentials ± SEM evoked 
during the 10 s duration of stimulus.
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Figure 3.6 Response of DDH neurones in MRMT-1-injected and sham- 
operated rats to punctate mechanical stimulation of the peripheral 
receptive field. The mean responses of DDH neurones in MRMT-1-injected 
rats to von Frey stimulation tended to be higher than in sham-operated rats, 
but the difference was not significant at any force. Data are presented as 
mean number of action potentials ± SEM evoked during the 10 s duration of 
stimulus.
(ii) Superficial dorsal horn neurones A total of 34 neurones in
sham-operated rats, and 30 neurones in MRMT-1-injected rats were 
characterised. The mean depths of the neurones in the two groups were 
similar: 292 ± 10pm in sham animals and 295 ± 9pm in MRMT-1 animals. 
These depths fit within the range of depths of lamina I projection cells verified 
by antidromic stimulation and histology (Bester et al. 2000b). The responses 
of the neurones characterised here were also similar to those in the 
aforementioned study and it is therefore likely that the populations of cells 
described here were in lamina I of the dorsal horn.
All of the neurones had peripheral receptive fields over the plantar surface of 
the hind paw, which were mapped by response elicited by noxious pinch.
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Unlike the DDH cells, there was a significant difference (P<0.05) between 
sham-operated and MRMT-1-injected animals with mean receptive field sizes 
of 20 ± 4% and 38 ± 7% respectively. Twenty-one percent of cells in the 
sham group and 17% of cells in the MRMT-1 group showed low levels of 
spontaneous activity (<3.0Hz).
SDH cells were classified as NS or WDR based on their responses to von 
Frey and heat as described previously. In the sham-operated rats 74% of the 
cells characterised were NS with the remaining 26% being WDR. In MRMT- 
1-injected rats 53% were NS and 47% WDR, indicating a substantial shift 
from NS to WDR response in CIBP.
The mean C-fibre thresholds of SDH cells were greater than those of DDH 
neurones, but similar between the sham (3.2 ± 0.1mA) and MRMT-1 (3.1 ± 
0.1 mA) groups. There was no difference in electrical-evoked responses of 
NS neurones between the groups, whilst for WDR neurones Aj3- and C-fibre 
responses were significantly elevated (P<0.05) in the MRMT-1 group 
compared to shams (Table 3.4). The increased Ap-fibre-evoked response is 
of particular note as this was not altered in the DDH neurones.
Similar to DDH neurones, the calculated wind-up mean was notably higher in 
the MRMT-1-injected group but not significantly different. Analysis of 
individual wind-up curves (Figure 3.7) revealed that in these populations this 
was also a result of an elevated primary-evoked response mirrored in the 
increased mean input for MRMT-1 rats.
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Table 3.4 Comparison of mean electrical-evoked responses of SDH 
neurones in MRMT-1-injected and sham-operated rats.
Sham NS MRMT-1 NS Sham WDR MRMT-1 WDR
Input 103 ±16 124 ±26 139 ±36 239 ± 26 *
A-beta 86 ± 6 93 ±12 75 ± 8 120 ± 1 3 *
A-delta 23 ± 4 33 ± 6 46 ±13 42 ± 6
C-fibre 124 ±15 162 ±29 147 ±17 243 ± 24 *
Post-discharge 47 ±10 62 ±15 41 ±10 121 ± 2 8 *
Wind-up 85 ±16 119 ±32 73 ±14 176 ±47
Values presented as mean action potentials ± SEM.
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Figure 3.7 Wind-up curves for individual SDH neurones in MRMT-1- 
injected and sham-operated rats. An increase in the primary-evoked 
response results in a shift of the wind-up curve in the positive direction of the 
Y-axis but with the general shape and slope of the plot remaining the same. 
This may explain why notable changes in calculated wind-up were not 
significantly different.
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The majority of SDH neurones responded to brush and noxious cold, and the 
proportions were similar in the sham-operated (76% and 79% respectively) 
and MRMT-1-injected (77% and 97% respectively) rats. However, the mean 
brush-evoked response in SDH WDR neurones of MRMT-1-injected rats at 
403 ± 39 action potentials was significantly greater (P<0.05) than in the sham 
group (239 ± 26). The response of SDH NS cells to mechanical and thermal 
stimulation did not differ between the two groups (Figure 3.8) whilst the WDR 
cells showed significantly greater (P<0.05) mechanical and thermal evoked 
responses in MRMT-1-injected rats compared to shams (Figure 3.9).
400 -i
MRMT-1
300 •
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32 35 40 42 45 48 5038
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Figure 3.8 Responses of NS SDH neurones to mechanical and thermal stimuli 
in MRMT-1-injected and sham-operated rats. The mean responses of superficial 
NS cells to von Frey or thermal stimuli did not differ between MRMT-1-injected and 
sham-operated rats. Data are presented as mean number of action potentials ± 
SEM evoked during the 10 s duration of stimulus.
500 600 -|
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75 400- 400 -MRMT-1 MRMT-1
Sham -©- Sham*  300- 300 -
O 200- 200 -
100 - 100 -
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Figure 3.9 Responses of WDR SDH neurones to mechanical and thermal 
stimuli in MRMT-1-injected and sham-operated rats. The mean responses of 
superficial WDR cells to von Frey and thermal stimuli were significantly greater 
(P<0.05) in MRMT-1-injected compared to sham-operated rats. Data are presented 
as mean number of action potentials ± SEM evoked during the 10 s duration of 
stimulus.
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3.4 Discussion
The results demonstrate clearly that localised injection of MRMT-1 mammary 
carcinoma cells into the tibia of Sprague-Dawley rats results in the 
progressive development of mechanical hyperalgesia and allodynia and cold 
allodynia as shown by the increasing withdrawal responses to von Frey 
filaments and acetone. The behavioural changes emerge by day 9 and are 
significant for all stimulus modalities by day 11. The mechanical and cold 
allodynia are paralleled by the emergence of ambulatory-evoked pain 
assessed on the rotorod, maximal 18 days after inoculation with MRMT-1. 
The pain behaviours and their temporal development, and the absence of 
any pain behaviours in sham-operated rats, are comparable to other models 
of CIBP in mice and rats (Medhurst et al. 2002; Sabino et al. 2003; Schwei et 
al. 1999; Wacnik et al. 2003).
The studies presented here are the first electrophysiological 
characterisations of dorsal horn neuronal responses in a model of CIBP. 
Around the time of maximum pain behaviour in MRMT-1-injected rats, there 
are also altered evoked responses of WDR neurones in the deep and 
superficial dorsal horn. Neuronal responses in sham-operated rats were the 
same as in normal animals, extensively characterised within this laboratory 
(Flatters et al. 2002; Stanfa et al. 2000b; Suzuki et al. 2001).
The results show that dorsal horn neurones are hyperexcitable in the CIBP 
state, in agreement with the idea of an ongoing central sensitization (Clohisy 
and Mantyh 2003). As the periosteum, mineralised bone, and bone marrow 
all receive sensory innervation, it is clear that there would be primary afferent 
nerve damage within a tumour-bearing bone. Inflammatory mechanisms 
must also contribute to CIBP, as described previously cancer cells release a 
cocktail of growth factors, cytokines, interleukins, chemokines, prostanoids, 
and endothelins, resulting a reduction of pH to below 5 and thus deformation 
of primary afferents (Griffiths 1991; Safieh-Garabedian et al. 1995; Sorkin et 
al. 1997; Suzuki and Yamada 1994; Watkins et al. 1994; Woolf et al. 1997). 
In spite of this, the dorsal horn neuronal response was not the same as in
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neuropathy or inflammation. Repetitive stimulation of primary afferent fibres 
generates long-lasting post-discharge, and this excitability is increased in 
various models of chronic pain including the chronic constriction injury (CCI) 
model of neuropathic pain (Palecek et al. 1992), but only in some neurones 
in the carrageenan model of inflammatory pain (Stanfa et al. 1997) and was 
robust in this model of CIBP. Other features however are different from 
neuropathy, such as the significant increase in peripheral receptive field only 
in SDH neurones and not in the DDH, in contrast to findings in the sciatic 
nerve ligation (SNL) model of neuropathic pain (Suzuki et al. 2000). 
Responses to natural stimuli and the electrical C-fibre-evoked response in 
CIBP also differ from the SNL model where there is a significant reduction in 
responses of DDH neurones (Chapman et al. 1998b). This contrast may be 
explained by the differing degrees of denervation in the two models, being far 
more substantial in the SNL model. The increased neuronal responses to 
thermal stimuli reported here are in contrast to findings of initial thermal 
hypoalgesia in a murine model of CIBP (Menendez et al. 2003a) but are 
consistent with the enhanced neuronal responses to natural and electrical 
stimuli. Although less is known about the dorsal horn neuronal response in 
models of inflammation, pharmacological studies do suggest fundamental 
differences in the mechanisms driving CIBP and inflammatory pain (Luger et 
al. 2002). The data presented here are therefore in agreement with CIBP 
being a unique pain state.
Perhaps the most interesting finding in these investigations is the alteration of 
the NS:WDR ratio in the SDH, with the increased WDR population in CIBP 
driving the dorsal horn hyperexcitability. The sham group reflected the 
normal SDH ratio with 74% of cells being NS, as reported by other groups 
(Bester et al. 2000b; Han et al. 1998). In animals with CIBP on the other 
hand the WDR population almost doubled to 47% and, in addition, the 
responses of these cells were hyperexcitable. This is a change that had not 
previously been reported in any chronic pain model. Recently however, 
studies in a murine model of CIBP have also shown hyperexcitability in WDR 
neurones and not NS cells confirming my results (Khasabov et al. 2004). Of 
particular note among the hyperexcitable responses is the increased Ap-fibre
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response to electrical stimulation in WDR SDH neurones, consistent with the 
increased brush-evoked response in this group.
The increased input responses and spinal hyperexcitability may result in a 
reduced threshold for activation which could explain the shift from NS to 
WDR in SDH neurones, as well as the increased peripheral receptive field 
area in this population. Changes in the GABAergic system may also 
contribute to neuronal hyperexcitability (Reeve et al. 1998). Furthermore, the 
increased excitability may be generated in both spinal and supraspinal 
pathways as lamina I NKi-expressing neurones have recently been shown to 
be the origin of a spinal-supraspinal loop important in evoking descending 
facilitation (and inhibition) back down to superficial and deep dorsal horn 
laminae (Suzuki et al. 2002). Thus the changes in the SDH in CIBP may 
contribute to the increased excitability of the DDH. Also, lamina I project 
preferentially to the PAG, parabrachial area and CVM which are important 
circuits contributing to the affective and nocifensive responses to noxious 
stimuli (Bernard et al. 1995; Craig 1995; Hylden et al. 1985; Mouton and 
Holstege 1998). This suggests that in CIBP there is increased activation of 
these areas as well as access of lower threshold inputs.
In summary, these results show that intra-tibial injection of MRMT-1 results in 
a reliably reproducible model of CIBP in which mechanical and cold 
allodynia, and ambulatory-evoked pain, can be measured behaviourally. 
Electrophysiological characterisations reveal a significantly hyperexcitable 
dorsal horn in MRMT-1-injected rats compared to shams, probably driven by 
a population of WDR SDH neurones. The dorsal horn pathophysiology is 
different to that in both inflammatory and neuropathic models confirming that 
CIBP is a unique pain state.
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Chapter 3.
PART TWO: TEMPORAL CORRELATES OF 
BEHAVIOURAL AND NEURONAL 
ALTERATIONS.
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3.5 Introduction
The relationship between behavioural and neuronal alterations has not yet 
been widely studied in chronic pain states, a void that is also present in other 
areas of neuroscience. However, in murine and rat models of CIBP unique 
neurochemical changes in segments of spinal cord receiving afferent input 
from the tumour-bearing bone have been found to occur concurrently with 
osteoclastic destruction of the bone and pain behaviour (Medhurst et al. 
2002; Schwei et al. 1999). The dorsal horn neurone characterisations in the 
previous study revealed interesting changes that seem to be driven by 
shifting populations of SDH neurones, a phenomenon not reported before in 
other pain models.
As discussed in previous chapters, NKi-expressing SDH neurons form the 
origin of a spinal-supraspinal loop modulating excitatory and inhibitory 
pathways to the dorsal hom (Suzuki et al. 2002). These neurons have also 
been shown to be involved in the generation of pain behaviour following 
spinal cord injury, as their ablation resulted in significant decreases in the 
onset and severity of pain-related behaviour after intraspinal injection of 
quisqualic acid (Yezierski et al. 2004).
The aim of the next investigation was therefore to monitor the time course of 
behavioural hyperalgesia and allodynia in parallel with evoked SDH neuronal 
responses in the rat model of CIBP, in order to assess possible temporal 
correlates of neuronal and behavioural alterations.
3.6 Methods
Behavioural testing and electrophysiological characterisations of SDH 
neurones were carried out as described previously. In MRMT-1-injected rats 
electrophysiological studies were performed on post-operative day 7 before 
significant behavioural changes, day 9 at which point there is the emergence 
of hyperalgesia, and day 11 by which time significant hyperalgesia and
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allodynia are evoked by all stimulus modalities. These data were compared 
also to the results from characterisations on days 15-17 at the time of 
maximal pain behaviour. In order to reduce the number of animals used, 
electrophysiological characterisations in shams were only done between 
days 15 to 17 as there were no behavioural alterations at any time point.
3.7 Results
At least 30 SDH neurones were characterised at each time point. The mean 
depths in the MRMT-1 and sham-operated groups were 290 ± lOpm and 300 
± 12jim respectively. As with the previous characterisations these depths fit 
within the range for lamina I neurones, verified by antidromic stimulation and 
histology (Bester et al. 2000b).
On day 7 in the MRMT-1 group, 23% of SDH neurones were characterised 
as WDR and the remaining 77% NS (Figure 3.10).
Day 7
Day 11
Day 9
WDR
NS Day 15-17
Figure 3.10 Ration of WDR : NS neurones in the SDH following intratibial 
injection of MRMT-1 in rats. There is a marked shift from NS to WDR in the 
superficial dorsal horn in CIBP occurring in parallel with behavioural signs of 
allodynia.
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By day 11 the WDR population in the MRMT-1 group had increased to 44% 
(Figure 3.10) and the cells showed significantly elevated responses to 
electrical, mechanical and thermal stimuli (Figures 3.11 - 3.13), akin to the 
characterisations made on days 15-17 (Table 3.4 and Figures 3.9 and 3.11- 
3.13). At this time point also, the evoked responses of NS cells in the 
MRMT-1 group were not different to shams.
Day 7 Day 9
300
200 j
Day 15-17
Input A-beta C-fibre Post-discharge Input A-beta C-fibre Post-discharge
Figure 3.11 The temporal development of increased electrical-evoked 
responses in Lamina I WDR neurones MRMT1-injected rats.
At days 7 and 9 post-surgery, MRMT1-injected rats (solid black bars) show 
no difference to sham-operated animals (diagonally striped) in the electrical- 
evoked neuronal response. By day 11 the input, C-fibre and post-discharge 
responses are significantly increased in MRMT1-injected compared to sham 
rats and between days 15 to 17 the A-beta fibre electrical-evoked response is 
also significantly increased. (*P<0.05).
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Figure 3.12 The temporal development of increased response to 
mechanical stimuli of Lamina I WDR neurones in MRMT1-injected rats.
At days 7 and 9 post-surgery there is no difference in response between 
MRMT1-injected (solid black) and sham-operated rats. By day 11, the 
MRMT1-injected rats show significantly increased neuronal responses to von 
Frey 9g and above, and between days 15 to 17 the response to von Frey 5g 
was also significantly increased. (*P<0.05)
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Figure 3.13 The temporal development of increased response to 
thermal stimuli of Lamina I WDR neurones in MRMT1-injected rats.
At days 7 and 9 post-surgery there is no difference in response between 
MRMT1-injected (solid black) and sham-operated rats. By day 11 the 
noxious intensity thermal-evoked neuronal response is significantly increased 
in MRMT1-injected animals and by days 15 to 17 the response is also 
significantly increased at lower intensities. (*P<0.05)
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3.8 Discussion
The results from this set of investigations confirm our previous findings of 
progressive development of hyperalgesia and allodynia as assessed by the 
behavioural tests, and an altered superficial dorsal horn neuronal response 
and NS:WDR ratio revealed by electrophysiological characterisation.
The temporal development of pain behaviour is very similar to another rat 
model of CIBP (Medhurst et al. 2002) where animals injected with MRMT-1 
show a significant reduction of weight bearing on the affected limb by day 11 
onwards, and general loss of activity by day 15 -  the same time points at 
which we have observed significant behavioural allodynia and increased 
neuronal responses to all stimulus modalities.
These are the first studies to show development of behavioural allodynia 
concurrently with changes in dorsal horn electrophysiology. The 
hyperexcitability of the dorsal horn seems to be driven by a shift in cellular 
populations with previously NS neurones becoming WDR. The relationship 
between behavioural alterations and neuronal responses indicates the latter 
as the most suitable substrate for pharmacological study, being 
suprathreshold responses more clinically relevant than the threshold level 
behavioural responses. Furthermore, the close correlation between the 
temporal development of pain behaviour and increased dorsal horn 
excitability suggests that this would be a suitable model in which to study 
changes in gene expression in hyperalgesia and allodynia.
Finally, these investigations contribute to evidence for a major role of SDH 
neurones in the regulation and behavioural expression of pain sensitivity 
(Mantyh et al. 2004; Yezierski et al. 2004).
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Chapter 4.
DESCENDING EXCITATORY CONTROL OF 
CIBP: A PHARMACOLOGICAL STUDY 
WITH ONDANSETRON.
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4.1 Introduction
As discussed in section 1.5, descending pathways from the brain to the 
dorsal horn of the spinal cord are important in the modulation of nociceptive 
information, and have been demonstrated to have key roles in chronic pain 
states. Study of these facilitatory and inhibitory pathways has not only 
improved our understanding of the mechanisms underlying these states, but 
also afforded new approaches to pharmacotherapy in these clinically 
important areas.
Most of the work in this area has concentrated on the often tonically active 
inhibitory pathways, but more recently there has been growing interest in a 
facilitatory pathway mediated by 5-HT3 receptors.
4.1.1 5-HT in pain 5-HT, when initially discovered in the first half of
the 20th century, was called serotonin (a name still used widely) as a 
reference to its origin and biological action; a powerful serum vasoconstrictor 
inducing muscle tone. It is now known to be located also in the Gl tract
and CNS, having important roles as a neurotransmitter and a local hormone, 
involved in an array of physiological functions including sleep, wakefulness, 
mood, and control of sensory transmission, thus 5-HT is probably a more 
appropriate name.
5-HT pathways comprise one of the major components of descending 
controls and, as mentioned in section 1.6, electrophysiological, anatomical, 
and pharmacological studies of these pathways have highlighted areas of the 
medulla, particularly the RVM (containing the nucleus raphe magnus (RMg) 
and reticular formation (including the nucleus reticularis magnocellularis - 
NRMC), as the major output for descending influences (Gebhart 2004).
Direct evidence for the involvement of 5-HT systems in pain came from 
observing the effects of electrical stimulation or lesion of serotonergic 
brainstem nuclei; electrical stimulation of the PAG produced sufficient 
analgesia to carry out abdominal surgery in the rat in the absence of general
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anesthesia (Reynolds 1969) and stimulation in the region of the dorsal raphe 
blocked excitatory locus coeruleus responses to noxious stimuli (Segal 
1979), whilst electrolytic lesions of the RMg have been shown to cause a 
significant reduction in autoanalgesia (behaviourally activated analgesia) 
(Chance 1980). However, recent studies would suggest that although 5HT 
can mediate inhibitory effects, its predominant action is more likely to be 
facilitatory.
Cells in the RVM have been classified, according to responses to rat tail 
withdrawal to noxious heat, into ‘on’, ‘off’ and ‘neutral’ groups (Fields et al. 
1983). After a long period of thermal stimulation, there is increased ‘on’ cell 
discharge suggesting that these cells facilitate nociception via a descending 
pathway (Morgan and Fields 1994). Furthermore, selective activation of 
these cells using low doses of neurotensin has been shown to produce 
thermal hyperalgesia confirming a facilitatory role for ‘on’ cells (Neubert et al. 
2004). Some of these cells probably contain 5-HT as following formalin 
injection and noxious heat stimulation of the rat hind paw, 5-HT-positive 
RMg neurones are also labeled with FOS (Suzuki et al. 2002). However 
there is contradictory evidence suggesting that serotonergic raphe magnus 
cells responding to noxious heat are neither ‘on’ nor ‘off’ (Gao and Mason 
2000). This illustrates the fact that descending 5-HT pathways and their 
pharmacology represent an area which needs further investigation to be 
clarified and better understood.
As mentioned in the introduction, more than 15 subtypes of 5-HT receptors 
have been identified which not only suggests a diverse role for 5-HT systems 
in pain processing but also goes some way to account for the complicated 
pharmacology. For example, 5-HTm receptors are coupled negatively to AC 
and hyperpolarise neurones by opening K+ channels, whilst 5-HT2A and 5- 
HT3 receptors activate PLC and depolarise cells by closing K+ channels 
and/or opening VGCCs (Millan 1999). Therefore, when co-localised on 
neurones, these receptors will have opposing modulatory effects on 
nociceptive transmission in the DH.
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4.1.2 5-HT3 receptor-mediated excitation Pharmacological studies 
have demonstrated the 5-HT3 receptor to be pronociceptive in the spinal 
cord, as selective blockade of these receptors results in a reduction of 
nociceptive neuronal and behavioural responses (Ali etal., 1996).
This excitatory serotonergic system has been shown to be enhanced 
following formalin-induced inflammation (Green et al., 2000) and peripheral 
nerve injury (Suzuki et al., 2004), but not following carrageenan-induced 
inflammation (Green et al., 2000; Rahman et al., 2004) suggesting that, in 
some pain states, selective inactivation of descending facilitatory pathways 
might offer analgesia that is complementary to the more traditional method of 
activating the descending inhibitory pathways (Millan 1999).
In addition, it has been demonstrated that lamina I dorsal horn (DH) 
neurones expressing the NKi receptor form the origin of a spino-bulbo-spinal 
loop which, relaying in the rostroventral medulla (RVM) and having a 
facilitatory action at spinal 5-HT3 receptors, modulates mechanical and 
thermal nociceptive transmission and is necessary for full coding of inputs by 
deep DH neurons (Suzuki et al., 2002). Furthermore, this circuit will receive 
input from centres such as the parabrachial area and amygdala involved in 
the affective component of pain (i.e. the fear, anxiety, emotional aspect) to 
amplify and prolong the sensation to a painful stimulus so that emotional 
state may alter the perception of pain (Suzuki et al. 2004b).
This is particularly significant with respect to CIBP. In the DH 
characterisation studies in the previous chapter, I have shown that the 
general hyperexcitability of the spinal cord is driven by changes in SDH 
populations with previously NS cells becoming WDR. As some of these 
superficial cells will be NKi-expressing projection neurones it translates to 
increased transmission of signals to the brain areas involved in the affective 
component of pain, as well as access of lower threshold inputs. This does in 
fact fit with the clinical condition of CIBP correlating with increased anxiety 
and depression (Mercadante 1997) and the low threshold access may be
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important in terms of the mechanical allodynia seen behaviourally in the 
animal models.
The aim of this next study was to measure the effects of spinally 
administered ondansetron, a selective 5-HT3 receptor antagonist, on 
electrical- and natural-evoked DH neuronal responses in CIBP, in order to 
assess the role of the descending serotonergic facilitatory pathway.
4.2 Methods
Electrophysiological experiments were carried out between days 15-17 in 
MRMT-1-injected and sham-operated rats as described in Chapter 2, at 
which time all animals in the cancer group show significant allodynia. Tests 
on superficial and DDH neurones, carried out every 20 minutes, consisted of 
electrical stimuli followed by natural stimuli (brush, von Frey, thermal, and 
cold). After three consecutive stable control trials (< 10% variation) neuronal 
responses were averaged to give pre-drug control values. Ondansetron 
(Zofran; Glaxo-Wellcome: 10, 50 and 10Ojug) was administered directly onto 
the exposed spinal cord in a volume of 50pl using a Hamilton syringe. The 
response of the neurone was followed for 50 minutes (testing at t = 10, 30, 
and 50 minutes) before the next dose was given.
4.3 Results
As described in chapter 3, all MRMT-1-injected rats showed progressive 
development of hyperalgesia and allodynia to mechanical and cooling stimuli, 
as well as ambulatory-evoked pain assessed on the rotorod, whilst sham- 
operated rats showed no change from pre-operative baseline behaviour (data 
not shown). A total of 39 DH neurones were used for pharmacological study 
and were separated according to depth and animal group, thus 6 neurones
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were used in each of the sham-operated rat groups (DDH, NS SDH, WDR 
SDH) and 7 in the MRMT-1-injected rat groups as above.
4.3.1 Electrical-evoked responses Ondansetron had no
significant effect on the control electrical-evoked responses for either SDH or 
DDH neurones (Table 4.1) at any of the doses tested.
Table 4.1 Mean control electrical-evoked responses of superficial and
deep dorsal horn neurones in sham-operated and MRMT-1-injected rats.
Cell group Input A-beta A-delta C-fibre Post­
discharge
Wind­
up
DDH WDR
(n=6)
301 ± 45 102 ±5 95 ±10 374 ±21 198 ±16 256 ± 49
SHAM SDH NS 
(n=6)
90 ±26 96 ±11 29 ±9 129 ±36 49 ±12 80 ±26
SDH WDR 
(n=6)
153 ±34 85 ±9 48 ±12 133 ±25 54 ±22 94 ± 14
DDH WDR
(n=7)
421 ±27 112 ± 14 112 ± 15 428 ± 20 279 ± 32 331 ± 42
MRMT SDH NS
(n=7)
151 ±42 94 ±21 34 ±11 158 ±39 63 ± 17 123 ±23
SDH WDR
(n=7)
247 ± 36 133 ±8 45 ±9 248 ± 26 136 ±49 161 ±32
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4.3.2 Natural-evoked responses
The highest dose of ondansetron 
(100|ig) significantly reduced (P<0.05) 
noxious mechanical-evoked neuronal 
responses to von Frey 75g of DDH 
and SDH in sham-operated rats 
(Figure 4.1).
In MRMT-1-injected rats, ondansetron 
also significantly reduced noxious 
mechanical-evoked neuronal
responses to von Frey 30g and 75g in 
DDH neurones (P<0.001). In WDR 
SDH neurones there were marked 
effects with significant reduction by the 
middle dose of ondansetron (50jng) of 
neuronal responses to von Frey 9g 
(P<0.05), 15g (P<0.001), 30g (P<0.05) 
and 75g (P<0.001). The
mechanical-evoked responses of 
NS SDH neurones were also 
sensitive to ondansetron at 50pg 
(von Frey 30g, P<0.05) and 1OOpg 
(von Frey 30g and 75g, P<0.05). 
Figure 4.2 shows the effects of 
ondansetron on mechanical- 
evoked responses of DH neurones 
in MRMT-1-injected rats.
•  control
■ 50ug ondansetron
*  10Oug ondansetron
200-
100-
45
250- SDH-WDRCl
o 200-
150
100
45 60
Z  200- SDH-NS
150-
100-
50*
30 45
von Frey (g)
60
Figure 4.1 Mechanical-evoked 
DH neuronal responses are 
mediated by 5HT3 receptors in 
sham-operated rats. Spinal 
ondansetron reduced mechanical- 
evoked responses in sham- 
operated rats, n = 6, *(P<0.05) 
significant reduction compared to 
pre-drug control.
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Figure 4.2 5HT3 receptor- 
mediated facilitation of 
mechanical-evoked neuronal 
responses is enhanced in 
CIBP. Spinal ondansetron 
reduced mechanical-evoked 
responses of DDH and SDH 
neurones in rats with CIBP at a 
lower dose (50|ig) and over a 
wider range of stimuli than in 
sham-operated rats, suggesting 
an enhanced drug effect in this 
pain state, n = 7. *(P<0.05), 
***(P<0.01) significant reduction 
compared to pre-drug control.
Similar effects were seen with 
ondansetron in the thermal-evoked 
DH neuronal responses. In sham- 
operated rats, the middle and top 
doses of ondansetron significantly 
reduced (P<0.001) DDH responses to 
thermal stimuli in the noxious range of 
45-50°C. In WDR SDH neurones the 
top dose of ondansetron significantly 
reduced (P< 0.05) thermal-evoked 
responses at innocuous (40°C) and 
noxious (48°C) temperatures. In NS 
SDH neurones the top dose of 
ondansetron significantly reduced 
(P< 0.05) the thermal-evoked 
response to 50°C. The effects of 
ondansetron on thermal-evoked 
responses in sham animals are 
shown in Figure 4.3.
In MRMT-1-injected rats ondansetron 
had similar effects on DDH neurones 
as in the sham-operated rats with 
significant reductions (P<0.01) to 
thermal stimuli in the noxious range 
between 45°C and 50°C. In WDR 
SDH neurones the effects were more 
marked than in shams with the middle 
dose significantly reducing (P<0.001) 
the response to 40°C, and the top 
dose significantly reducing (P<0.001) 
responses to thermal stimuli from 40- 
50°C.
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In NS SDH cells the response to 50°C was significantly reduced by the 
middle (P<0.05) and top dose (P<0.001) of ondansetron.
•  control
■ 50ug ondansetron
*  100ug ondansetron400*
200*
200*1 SDH-WDR
150-
100-
50-
4535 40 50
300-1 SDH • NS
200-
100-
Temperature (degrees C)
Figure 4.3 Thermal-evoked DH 
neuronal responses are mediated by 
5HT3 receptors in sham-operated 
rats. Spinal ondansetron reduced 
thermal-evoked dorsal horn neuronal 
responses in sham-operated rats, n = 
6, ***(P<0.01) significant reduction 
compared to pre-drug control.
750-1 DDH
•  control
■ 50ug ondansetron
*  100ug ondansetron500-
250-
Q.
SDH-WDR
«  300-
c  200-
C l
40
SDH - NS
200-
100-
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Temperature (degrees C)
Figure 4.4 5HT3 receptor- 
mediated facilitation of thermal- 
evoked neuronal responses is 
enhanced in CIBP. Spinal 
ondansetron reduced thermal- 
evoked responses of SDH neurons 
in rats with CIBP at a lower dose 
(50pg) and over a wider range of 
stimuli than in sham-operated rats, 
suggesting an enhanced drug 
effect in this pain state, n = 7. 
*(P<0.05), ***(P<0.01) significant 
reduction compared to pre-drug 
control.
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4.4 Discussion
All animals injected with MRMT-1 developed behavioural signs of 
hyperalgesia, allodynia and ambulatory-evoked pain, and the electrical- and 
natural-evoked responses in these animals were elevated compared to 
sham-operated rats (Table 4.1, Figures 4.1 - 4.4). These results therefore 
confirm the findings from the characterisation study that this is a reliably 
reproducible model of CIBP, in which mechanical allodynia, cold allodynia, 
and ambulatory-evoked pain can be measured behaviourally, and with a 
characteristic electrophysiological feature of dorsal horn hyperexcitability.
Research into descending inhibitory and facilitatory influences on spinal 
nociceptive processing has improved our understanding of chronic pain 
states and provided new approaches to their pharmacological treatment. 
This study provides electrophysiological evidence of a role for descending 
facilitation in a rat model of CIBP.
Antagonism of 5-HT3 receptors, using ondansetron, has previously been 
shown to inhibit neuronal activity and pain behaviour (Ali et al. 1996; Green 
et al. 2000; Rahman et al. 2004; Suzuki et al. 2004a). These results clearly 
demonstrate that ondansetron selectively inhibits natural-evoked DH 
neuronal responses in sham-operated rats suggesting that this pathway is 
normally active. The effects however were much greater in animals injected 
with MRMT-1 with significant reductions at lower doses of ondansetron and 
encompassing both the innocuous and the noxious range, thus clearly 
showing that the effect of ondansetron is enhanced in CIBP. These findings 
are comparable with findings in other chronic pain models as denoted below.
A model of spinal cord injury, in which chronic tactile hyperalgesia and 
allodynia are observed in the absence of changes in density or distribution of 
primary afferent fibres in the region surrounding the injury, has been shown 
to alter descending antinociceptive serotonergic tracts that modulate pain 
transmission, with decreased 5-HT immunoreactivity caudal to the injury site 
and a threefold increase rostral to it (Bruce et al. 2002). Subsequent studies
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in the same model showed that intrathecally administered ondansetron 
produced a robust long-term reduction of mechanical allodynia whereas the 
5-HT3 agonist m-chlorophenylbiguanide (m-CPBG) exacerbated allodynia 
(Oatway et al. 2004). The reduction of allodynia with exogenous 5-HT was 
only transient compared to the long-term reduction with ondansetron and was 
opposed by methysergide, the non-selective 5-HTi/5-HT2 receptor 
antagonist. This suggests that increased 5-HT fibre density immediately 
rostral to the injury site in this model could have transient effects to reduce 
mechanical allodynia via actions at 5-HTi and/or 5-HT2 receptors, whereas 
the more long-lasting effects of this enhanced serotonergic input may 
facilitate chronic allodynia via the 5-HT3 receptor.
In a model of carrageenan-induced inflammation it has been shown that 
intrathecal ondansetron has no effect on electrical-evoked responses but 
reduces punctuate mechanical and thermal-evoked responses of DDH WDR 
neurones in both sham and carrageenan-inflamed rats (Rahman et al. 2004). 
However, unlike in CIBP, there was no difference in drug effect between the 
animal groups. In a spinal nerve ligation model (SNL) of neuropathic pain, 
however, it has been shown that intrathecal ondansetron selectively inhibits 
mechanical and thermal-evoked responses to a greater degree in SNL 
compared to sham-operated rats (Suzuki et al. 2004a). As with the 
carrageenan and CIBP models, the electrical-evoked responses were not 
affected in either group of animals in the SNL model. The inability of 
ondansetron to reduce the electrical-evoked responses may be due to the 
intensity of the stimulus. In all of these studies transcutaneous electrical 
stimuli were given at three times the threshold for C-fibre activation. 
Although ondansetron clearly reduced noxious level mechanical and thermal 
stimuli these were delivered over a 10 second period, whilst the electrical 
pulses were 2 milliseconds wide, therefore representing a much more intense 
time-locked stimulus that would be harder to inhibit.
It is interesting to note that in the inflammatory model electrophysiological 
experiments were carried out 3 hours after intraplantar injection of 
carrageenan when pre-drug characterisation revealed no difference in
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evoked responses of dorsal horn neurones between inflamed and sham- 
operated rats. In the neuropathy model however, experiments were carried 
out two weeks after surgery when it has been demonstrated that DH neurons 
are electrophysiologically distinct to those in sham-operated rats (Chapman 
et al. 1998b). In this model electrophysiology experiments were carried out a 
similar length of time after surgery when we have also shown DH neurons to 
be distinct from those in sham-operated animals, though the changes are 
different to those observed in the model of neuropathy.
This would therefore suggest that plasticity of the descending facilitatory 
pathway, contributing to abnormal natural-evoked responses in neuropathy 
and CIBP, does not occur immediately after tissue injury and is more likely to 
be involved in the maintenance rather than the generation of these chronic 
pain states.
Results in the previous chapter demonstrated that neuronal alterations in the 
SDH in CIBP correspond temporally with behavioural signs of allodynia and it 
has been suggested that inappropriate activation of descending excitatory 
pathways may be a contributory mechanism to abnormal behaviour 
associated with chronic pain states (Porreca et al. 2002). The results 
presented here are therefore in agreement with a role of descending 
facilitation in pain behaviour; the elevated neuronal responses characteristic 
of CIBP, occurring only when behavioural alterations are present, were more 
sensitive to ondansetron than the normal neuronal responses of the sham- 
operated animals which do not at any point show behavioural deficits. Given 
the temporal correlation between neuronal and behavioural deficits in this 
model, it may therefore be of interest to study the effects of ondansetron at 
earlier time points in CIBP to establish when serotonergic facilitatory control 
begins to exert its effect on spinal processing and pain behaviour.
In summary, these findings suggest a role for descending facilitation in the 
elevated mechanical and thermal-evoked responses observed in CIBP and, 
by virtue of the correlation of this hyperexcitability with behavioural allodynia,
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provide further evidence for the involvement of 5-HT3 receptor systems in 
pain behaviour.
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Chapter 5.
GABAPENTIN: EFFECTS ON DORSAL 
HORN NEURONAL RESPONSES AND PAIN
BEHAVIOUR.
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5.1 Introduction
Gabapentin, 1-(aminomethyl)cyclohexane acetic acid, (Neurontin™) was 
designed as a structural analogue of GABA for the treatment of epilepsy, and 
introduced in the UK in 1993 as an anticonvulsant to reduce seizure 
frequency when co-administered with existing antiepileptic drugs. However, 
the drug was also found to be an effective antihyperalgesic and in May 2000 
it became the first agent in the UK to be approved for the treatment of all 
types of neuropathic pain. By 2002 gabapentin had been approved for 
treatment of neuropathic pain in five more European countries as well as 
Australia, New Zealand, and several parts of Latin America, and in 
September 2001 Morgan Stanley predicted sales of US $1871 million in 2002 
falling to US $413 million in 2006 (Wheeler 2002).
As well as being used widely in clinical neuropathies, gabapentin has been 
shown to be effective in a variety of animal models of chronic pain. The work 
in this chapter focuses on the effects of systemic gabapentin on evoked 
dorsal horn neuronal responses and pain behaviour in CIBP.
5.1.1 Structure and function of GBP Gabapentin (GBP) is derived
by the addition of a cyclohexyl group to the backbone of GABA (Taylor 1997) 
resulting in a lipophilic GABA analogue that is able to cross the blood brain 
barrier. At physiological pH, GBP is a zwitterion, i.e. an amino acid 
containing both acidic and basic groups in the same molecule that undergoes 
an internal acid-base reaction, existing primarily as a dipolar ion (Taylor et al. 
1998).
GBP, although a structural analogue of GABA, does not interact with either 
GABAAor GABAb receptors (Taylor 1997). It does not have an effect on [3H]- 
GABA uptake into neuronal or glial cultures (Su et al. 1995) nor does it inhibit 
GABA transaminase, the GABA-metabolising enzyme (Taylor et al. 1998). 
Furthermore, the antiallodynic actions of GBP are not sensitive to either 
GABAa or GABAb receptor antagonists (Hwang and Yaksh 1997) and, unlike
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several other antiepileptics, GBP does not affect voltage-gated Na+ channels. 
However, there is some evidence that it acts as an agonist at the GABAb 
gb1a-gb2 heterodimer coupled to inwardly rectifying K+ channels (kir3.1/3.2) 
in Xenopus oocytes (Ng et al. 2001).
Autoradiography studies have shown that [3H]-GBP binds with high affinity to 
the outer layers of the cortex (frontal, parietal, occipital and entorhinal) with 
lower levels in the white matter, and some binding in the dentate gyrus, 
cerebellum, and CA1 region of the hippocampus (Hill et al. 1993). The high 
affinity binding site was identified as the 0128 subunit of VGCCs (Gee et al. 
1996). Some other drugs acting at VGCCs, such as flunarizine, have also 
been shown to prevent seizures in animal models, but GBP is different to the 
other ligands in that it acts at the (X28 rather than the ai subunit (Gee et al. 
1996).
5.1.2 The (X28subunit of VGCCs As mentioned in Chapter 1, VGCCs 
are made up of a number of subunits; the ai-subunit forms the basic 
structure of the channel containing amino acids that form the pore and 
voltage sensor determining the major functional properties of the channel and 
its subtype, and the auxiliary subunits (p, 0x26, and y) modulate the function of 
the ai-subunit (Catterall 2000b). As shown in the figure below, the 5 subunit 
is anchored into the lipid bilayer, but most of the 012 amino acids are exposed 
extracellularly.
The 0C28 family consists of three genes; the first subunit, 0C28- I , was identified 
in rabbit skeletal muscle in the late 1980s (Ellis et al. 1988) and two more 
family members, 0126-2 and 0128-3, were identified in the late 1990s 
(Klugbauer et al. 1999). GBP has been found to bind specifically to the 0C28-I 
subunit (Gee et al. 1996), with a much lower affinity for 0128-2 and no binding 
to 0128-3 (Marais et al. 2001). R217A mutant mice, which have a single 
amino acid substitution at position 217 in the 012 protein, have been shown to 
be insensitive to the actions of GBP after neuropathy (Bramwell et al. 2004). 
Autoradiography studies with [3H]-GBP in R217A mice have shown a global
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reduction in signal (compared to wild type litter mates) with 80% reduction in 
the cortex and hippocampus, 70% reduction in the spinal cord, and 30% 
reduction in the cerebellum (Melrose et al. 2004). This study highlighted the 
superficial dorsal horn as an area of intense binding which, as discussed in 
previous chapters, is a particularly important junction in the nociceptive 
pathway.
Binding site for 
N  f V------ c  P subunit
w
s-s  cystein link
Figure 5.1 Schematic representation of the transmembrane topology of 
calcium channel subunits. The pink oval area on the intracellular loop 
between domains I and II of ai represents the binding site for the (3 subunit. 
The transmembrane regions of the ai subunit with + symbols are the S4 
segments, which contain positively charged amino acids and are thought to 
make up the voltage sensors. Adapted from (Canti et al. 2003).
5.1.3 GBP in animal models of pain GBP has been shown to
reduce neuronal responses and nocifensive behaviour in a number of pain 
models. In the SNL model of neuropathy for example, GBP reduced 
withdrawal responses to von Frey (Hunter et al. 1997), and in other studies it 
inhibited electrical- and mechanical-evoked DDH neuronal responses
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(Chapman et al. 1998a; Matthews and Dickenson 2002). The latter 
investigation underlined the antiallodynic effects of GBP which had significant 
effects in neuropathic rats, mild effects in sham-operated rats (perhaps 
indicating the presence of some minor post-operative inflammation), but was 
totally ineffective in normal rats. In the same model, GBP had no effect on 
spontaneous ectopic discharges in the injured peripheral nerve suggesting a 
mechanism of action primarily at the spinal or supraspinal level (Abdi et al. 
1998). In another model of neuropathic pain, CCI, GBP dose-dependently 
reduced heat hyperalgesia and mechanical allodynia (Xiao and Bennett 
1995), as well as cold allodynia (Hunter et al. 1997).
The effects of GBP have also been investigated in models of inflammatory 
pain. It has been shown to dose-dependently block the late phase of the 
formalin response (Field et al. 1997) which is correlated with increased C- 
fibre activity (McCall et al. 1996). It has also been reported that GBP strongly 
and dose-dependently inhibits C-fibre and post-discharge responses (but not 
the Ap-fibre response) in the carrageenan model of inflammation (Stanfa et 
al. 1997). Furthermore, behavioural studies have shown that GBP, 
administered 2.5 hours after carrageenan, reduces thermal and mechanical 
hyperalgesia (Field et al., 1997).
As CIBP shares some features of neuropathic and inflammatory pain, the aim 
of this study was to determine the efficacy of systemic GBP on the 
hyperexcitable dorsal horn neuronal responses and behavioural alterations in 
the rat intra-tibial MRMT-1 model, and to gauge the relationship between 
spinal plasticity and behaviour.
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5.2 Methods
Preparation of the MRMT-1 cell line and surgery to induce CIBP (or sham 
surgery) were carried out as described in Chapter 2.
5.2.1 Drug administration GBP (a gift from Pfizer,
Sandwich,UK) was dissolved in saline to give 30mg kg'1 (in a volume of 1ml 
kg'1) for the chronic behavioural study, and 10mg kg'1, 30mg kg'1 and 100mg 
kg'1 (in the same volume of 250 pi) for the acute pharmacologic study. All 
injections were given subcutaneously in the scruff of the back of the neck.
Rats were divided into three treatment groups. The first group (n = 15), all 
having received intratibial injection of MRMT-1 cells, were given bi-daily 
injections (every 12 hours 8am and 8pm) of GBP 30mgkg'1 between days 11 
and 14 post-surgery, with a single injection on the morning of day 15. Twelve 
of the animals in this group were subsequently used for electrophysiological 
characterisation of superficial dorsal horn neurones. A second group (n = 6) 
acting as a control for the GBP-treated animals were inoculated with MRMT- 
1 cells and received bi-daily injection of saline according to the same 
schedule. The third group of animals made up of MRMT-1-injected (n = 7) 
and sham-operated rats (n = 6) received no post-operative treatment and 
were used for electrophysiological pharmacologic study of the acute systemic 
effects of GBP.
5.2.2 Behavioural testing The methods for behavioural testing were 
exactly as described in Chapters 2 and 3. Tests were performed pre- 
operatively and on post-operative days 1, 5, 7, 11, 12, 13, 14, 15, and 18. 
Between days 11 to 15 behavioural testing took place 1 hour after drug 
administration (morning).
5.2.3 Spinal cord electrophysiology Characterisation of SDH 
neurones was carried out on the final day of GBP treatment (i.e. post­
operative day 15) and on the third day after cessation of treatment (i.e. post­
operative day 18) exactly as described in Chapter 2. Acute pharmacology
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studies with GBP were carried out in the same way as described in Chapter 4 
for ondansetron, with the exception that GBP was given systemically (see 
above).
5.2.4 GBP autoradiography studies Two sham-operated and two
MRMT-1-injected rats were used for the autoradiography studies. On post­
operative day 17 the rats were deeply anaesthetized with an intra-peritoneal 
injection of 200 mg ml'1 pentobarbitone (Rhone Merieux). Upon cessation of 
respiration a thoracotomy was performed to expose the heart. The right 
atrium was cut and the left ventricle cannulated for transcardial perfusion 
which, initially, was with 0.9% saline and then 4% paraformaldehyde in 0.2M 
phosphate buffer (pH 7.4). The lumbar spinal cord was exposed and spinal 
insertion points L4-L6 were identified and removed, a pin was inserted to 
make a hole in the dorsal area of the spinal cord contralateral to the tumour 
so that ipsi- and contralateral sides could thereafter be easily identified. 
Tissue was post-fixed for at least 1 hour in 4% paraformaldehyde and 
cryoprotected for at least 24 hours in 20% sucrose.
For cutting, tissue was covered in OTC embedding medium (Tissue-Tek) and 
frozen on a freezing sledge microtome at -16°C (Leica, Switzerland). 
Transverse sections were cut at 30pm thickness and collected freefloating in 
0.1M phosphate buffered saline with 5% sucrose and 0.02% azide in 96 well 
plates, 1 section per well. Sections were mounted serially onto glass slides 
such that each slide contained eight sections 360pm apart. Slides were then 
left to dry at room temperature and stored at -70°C until autoradiography 
experiments.
Before the binding assay slides were thawed at room temperature for 
approximately 30 minutes and pre-incubated in 10mM Hepes pH 7.4 at 4°C 
for 15 minutes. Slides were then incubated in the same buffer containing 
40nM [3H]-GBP (50Ci/mmol, Amersham Biosciences, custom synthesis) at 
room temperature for 30 minutes. Adjacent sections were incubated in the 
presence of 10pM [3H]-pregabalin (78Ci/mmol, Amersham Biosciences,
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custom synthesis) to define non-specific binding. The slides were washed 
four times for 1 minute in 0.1 M NaCI followed by a final rinse in cold dhfeO to 
remove excess salt. The slides were dried at room temperature and exposed 
along with a [3H] microscale ranging from 0.09 to 95.44 nCi/mg (Amersham) 
to [3H] hyperfilm (Amersham) for 4 weeks. Films were developed in a dark 
room with Kodak D19 developer for 3 minutes, washed in tap water for 30 
seconds and then fixed for 5 minutes with Unifix (Kodak). The film was then 
rinsed with running water and hung to dry.
Optical densitometry was performed using a microcomputer imaging device 
(MCID-M5+ 5.1 Rev 1.2) image analysis system and software (Imaging 
Systems Incorporated, St. Catherine’s, Ontario, Canada). Illumination of film 
images was supplied by the Northern Light Precision Illuminator model B95 
(Imaging Systems Inc). A Sony CCD monochrome camera model XC-77 
(512x480 pixels, 30Hz frame) with a micro-Nikkor 55mm lens (Nikon, Japan) 
was used to capture the images.
Quantification of film images allows the rapid gathering of anatomical binding 
data at the regional level. The optical density of the film images produced by 
the labelled sections is related to the regional radioactivity concentration and 
therefore represents the relative amount of bound ligand present, although 
this is not necessarily a linear relationship. For accurate quantification of film 
images it is necessary to correct for illumination and shading errors. 
Illumination and shading differences were corrected by digitizing a blank field 
(flat field correction) with the lighting set so that optical density of the blank 
field was around the mid range of the values encountered in the analysis. To 
obtain relative values, the values produced by the images must be compared 
with those produced by samples of known radioactivity content. A calibration 
curve was constructed by plotting densitometry measurements (relative 
optical density) obtained from [3H] standards (which were co-exposed in the 
cassette with the slides) against the given concentration of radiation (nCi/mg) 
for each standard. Once the calibration is established all sample 
measurements are collected in nCi/ng. The MCID software flags 
measurements that are at the level of film saturation.
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At the end of the autoradiography study sections were stained with toluidine 
blue for standard photography of the slides. Sections were dehydrated in 
absolute alcohol for 3 minutes and then industrial methylated spirit (IMS) for 
a further 3 minutes. The sections were then rehydrated in running tap water 
for 5 minutes before incubation in Toluidine blue for 1 minute. The slides 
were then rinsed in tap water, dehydrated in (IMS) for 30 seconds, absolute 
alcohol for another 30 seconds, and cleared in xylene for 5 minutes. Slides 
were mounted using DPX permanent mountant.
5.3 Results
5.3.1 Chronic systemic GBP -  behaviour A total of 21 MRMT-1 -
injected rats were used in the chronic behavioural study, 15 of which 
received bi-daily injection of GBP 30mgkg'1 between post-operative days 11 
to 15, and 6 of which received bi-daily injection of saline. The GBP-treated 
MRMT-1 animals showed an attenuation of the enhanced withdrawal 
responses to mechanical stimuli caused by CIBP compared to saline-injected 
animals, which was significant (P<0.05) by post-operative day 12 for von 
Frey 1g (Figure 5.2A) and by day 13 for higher von Frey filaments (Figure 
5.2B). We would interpret this as indicative of inhibition of 
allodynia/hyperalgesia. It is notable that GBP did not abolish the withdrawal 
response to mechanical stimuli but returned it to the pre-operative/sham 
baseline level (Figure 5.2B). The results for the ambulatory-evoked pain (as 
assessed by the rotorod test) mirrored the von Frey results with a significant 
reduction of the deficits (P<0.05) in the GBP-injected group compared to 
saline-injected rats by post-operative day 13 (Figure 5.2C). The withdrawal 
response to acetone was also significantly lower (P<0.05) in the GBP-treated 
animals by day 14 (Figure 5.2D). Unlike with the mechanical and 
ambulatory-evoked pain responses, GBP did not normalise the response to 
acetone but prevented it from further increasing beyond the level it had 
reached at the time treatment was initiated.
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Figure 5.2 The effect of 
chronic GBP treatment on 
mechanical allodynia (1A, 
1B), ambulatory-evoked 
pain (1C) and cold allodynia 
(1D) in MRMT-1-injected 
rats. Each data point in the 
saline-treated group (open
circle) represents the mean ± 
s.e.m. of 6 rats and in the 
GBP-treated group (closed 
circle) the mean ± s.e.m. of 
15 rats. Animals received bi­
daily subcutaneous (s.c.)
injection of saline/GBP 
30mgkg'1 between post­
operative days 11 to 14 
inclusive at 12-hour intervals, 
with a final injection on the 
morning of day 15. GBP- 
treated rats show a reduction 
in withdrawal responses to 
von Frey 1g (1A) compared to 
saline-treated rats significant 
(P<0.05) from day 12, and to 
von Frey 9g (1B) significant 
from day 13. The
ambulatory-evoked pain score 
(1C) in GBP-treated rats was 
also significantly reduced 
compared to saline-treated 
rats from day 13, and the 
withdrawal response to 
acetone (1D) from day 14. 
On day 18, two days after 
cessation of treatment, there 
was no longer a significant 
difference between the 
groups with GBP-treated rats 
returning to the same level of 
mechanical and cold 
allodynia, and ambulatory- 
evoked pain, as saline-treated 
rats.
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The results from day 18 (from a total of 9 rats, two days after cessation of 
GBP treatment) revealed the re-emergence of hyperalgesia and allodynia in 
this group that was equivalent to the saline-treated rats (i.e. rats never having 
received GBP) for all of the behavioural tests (Figures 5.2A-D).
In four normal animals treated with GBP according to the same dosing 
regime, there was no alteration in motor function (i.e. normal performance on 
the rotorod) nor responses to Von-Frey filaments or acetone when compared 
to non-treated, or GBP solute (normal saline) injected normal animals (data 
not shown).
5.3.2 Chronic systemic GBP -  SDH neurone characterisations A
total of 30 SDH neurones were characterised (from 6 rats) on post-operative 
day 15 after the final dose of GBP at the time point when pain behaviour was 
reduced to the level of sham-operated rats. A total of 32 cells (from another 
6 rats) were characterised on post-operative day 18 (and 2 days after 
cessation of GBP) by which time pain behaviour had returned to the same 
level of allodynia / hyperalgesia as the saline-treated MRMT-1 rats. Thirty 
cells were characterised from 6 animals receiving MRMT-1 cells and normal 
saline vehicle, and a total of 31 cells from 6 sham operated animals.
In the initial characterisation study (Chapter 3), in sham operated animals the 
ratio of WDR:NS was 26%:74%, which altered in MRMT-1 treated animals to 
47%:53%. Here, almost identical results were seen in that the ratio of 
WDR.NS in GBP-treated CIBP rats on day 15 was 33%:66% and on day 18 
had returned to 50%:50% (Figure 5.3). This suggests that chronic treatment 
with GBP attenuates spinal cord plasticity and so shifts the abnormally high 
WDR neuronal population (characteristic of this rat model of CIBP) back 
towards the predominant high-threshold situation seen in sham animals. 
Importantly, cessation of treatment and the re-emergence of pain-related 
behaviour, results in a return to the CIBP state and increased WDR ratio.
I l l
Sham MRMT-1
740/0 53%
■  WDR ^ -----
□  NS
MRMT-1 + GBP d15 MRMT-1 + GBP d18
33%
Figure 5.3 The effect of chronic GBP treatment on proportions of WDR and NS 
neurones in the SDH of MRMT-1-injected rats. In MRMT-1-injected rats receiving 
GBP treatment (bi-daily s.c. injection GBP 30mgkg'1 post-operative days 11-14 and 
a single injection on day 15), characterisation of superficial DH neurones on day 15 
(n=30 cells), when pain-related behaviour was returned to a normal (i.e. sham- 
operated rat) level, revealed a WDR:NS ratio of 33%:67% approaching the normal 
ratio seen in sham-operated animals. Characterisation on post-operative day 18 
(n=32 cells), two days after cessation of GBP treatment when animals had returned 
to the same level of pain behaviour as saline-treated rats revealed a return to the 
characteristic CIBP state with a WDR:NS ratio of 50%:50%.
The WDR cells characterised in GBP-treated rats on day 15 (number of 
animals=6, total of 30 neurones, of which 10 were WDR) showed significantly 
reduced (P<0.05) input and C-fibre evoked responses to electrical stimuli 
compared to cells characterised in MRMT-1-injected animals receiving no 
post- operative drug treatment (number of animals=6, total number of 
neurones 30, of which 14 were WDR) (Figure 5.4).
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Figure 5.4 The effect of chronic GBP treatment on electrical- and 
natural-evoked responses of WDR SDH neurones in MRMT-1-injected 
rats. Electrophysiological characterisation of WDR SDH neurones in MRMT- 
1-injected rats having had chronic GBP treatment (bi-daily s.c. injection GBP 
30mgkg'1 post-operative days 11-14 with a single injection on day 15) on the 
final day of treatment (n=10 cells) showed a significant reduction (P<0.05) in 
electrical- (input, C-fibre) and brush-evoked responses compared to MRMT- 
1-injected rats receiving no drug treatment. The A-beta and post-discharge 
evoked responses to electrical stimuli were reduced such that there was no 
longer a significant difference to the level of response of neurones in sham- 
operated rats. Characterisation of WDR SDH neurones in MRMT-1-injected 
rats two days after cessation of GBP treatment (post-operative day 18, n=16 
cells) revealed that the electrical- and natural-evoked responses had 
returned to the same level as in MRMT-1-injected rats receiving no drug 
treatment. The input and C fibre evoked responses were significantly 
increased (P<0.05) compared to the responses at day 15 (final day of GBP 
treatment).
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The WDR cells characterised in GBP-treated rats on day 15 (number of 
animals=6, total of 30 neurones, of which 10 were WDR) showed significantly 
reduced (P<0.05) input and C-fibre evoked responses to electrical stimuli 
compared to cells characterised in MRMT-1-injected animals receiving no 
post-operative drug treatment (number of animals=6, total number of 
neurones 30, of which 14 were WDR) (Figure 5.4). The A-beta and post­
discharge evoked responses to electrical stimuli were also reduced such that 
there was no longer a significant difference to sham-operated rats (Figure 
5.4). In addition, by day 18, two days after the cessation of GBP the evoked 
neuronal response (input, C-fibre, post-discharge) had returned to the same 
level as MRMT-1 treated rats with no GBP treatment (Figure 5.4).
On day 15 post-surgery, the mean response to mechanical stimuli (von Frey 
filaments) of WDR neurones in the MRMT-1 GBP-treated rats was 
significantly reduced (P<0.05) compared to MRMT-1 rats receiving no 
treatment (Figure 5.5A), and this reduction was such that the level of 
response was similar to that seen in sham-operated animals. 
Characterisation of WDR cells (number of animals =6, total number of 
neurones =32 of which WDR=16) on day 18 (2 days after cessation of GBP) 
revealed that the mechanical-evoked response was returning to the level of 
response in untreated MRMT-1 rats (Figure 5.5A).
Similar normalisation of the CIBP-induced increases in brush responses was 
also seen suggesting that the drug can influence both the abnormal static 
and dynamic mechanical responses. It is of note that GBP normalises both 
the A-beta response to noxious electrical stimulation and the brush-evoked 
response in CIBP. However in order to investigate the effect of GBP on A- 
beta fibre evoked responses it would be necessary to carry out the test at 
supra-A-beta thresholds not at the supra-C-fibre thresholds used here. 
Chronic GBP treatment did not have a significant effect on the thermal- 
evoked response of WDR neurones at either day 15 or day 18 (Figure 5.5B).
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Figure 5.5 The effect of chronic GBP treatment on mechanical- (A) and 
thermal- (B) evoked responses of WDR SDH neurons in MRMT-1-injected rats.
WDR SDH neurones in MRMT-1-injected rats (n=13 cells) show significantly 
increased (P<0.05) responses to mechanical- (A) and thermal- (B) evoked stimuli 
compared to sham-operated rats (n=9 cells). The mean response to mechanical 
stimuli (A) of WDR neurones in the MRMT-1 GBP-treated rats (bi-daily s.c. injection 
GBP 30mgkg'1 post-operative days 11 to 14 with a single injection on day 15) on 
the day of the final injection was significantly reduced (P<0.05) compared to MRMT- 
1 rats receiving no treatment, such that the level of response was similar to that 
seen in sham-operated animals. Characterisation of WDR cells (n=16) on day 18 
(2 days after cessation of GBP) revealed that the mechanical-evoked response was 
returning to the level of response in untreated MRMT-1 rats. Chronic GBP 
treatment had no significant effect on thermal-evoked responses of WDR SDH 
neurones at any time point (B).
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5.3.3 Acute systemic GBP -  electrophysiology In each of the
two groups, MRMT-1 operated animals (n=7) and sham operated animals 
(n=6), a single WDR neurone was isolated per rat per experiment. These 
cells showed increased responses in the MRMT-1 group compared to 
shams, consistent with the previous characterisations and drug study. This 
was particularly notable for input and C-fibre-evoked responses to electrical 
stimuli where cells in the sham group gave average pre-drug control action 
potential (AP) values of 131 ± 19 and 133 ± 9 respectively, and those in the 
cancer group were 201 ± 2 3  and 206 ± 41 respectively. Post-discharge and 
wind-up responses also showed a tendency to be increased in MRMT-1- 
injected animals. Again, corresponding with earlier findings, the non-noxious 
brush-evoked and the noxious mechanical-evoked responses were greater in 
the cancer group compared to sham (Figure 5.6).
GBP had no significant effect on A-fibre-evoked responses to electrical 
stimuli, or thermal-evoked responses; mean control Ap- and A5-fibre 
responses to electrical stimuli and the mean control response to 50°C were 
112 ± 28, 46 ± 9, and 340 ± 42 respectively, and after 100mg kg’1 GBP these 
were 91 ± 27, 51 ±10,  and 311 ±51 respectively. The input, C-fibre, post­
discharge and wind-up responses to electrical stimuli in the MRMT-1 group 
were significantly reduced (P<0.05) compared to shams with the highest 
dose of GBP (100mg kg'1). Furthermore the C-fibre-evoked response was 
significantly reduced (P<0.05) (113 ±11 AP in sham-operated rats and 82 ± 
11 AP in MRMT-1-injected rats) with GBP 30mgkg'1 (Figure 5.6).
The increased responses to noxious mechanical stimuli seen in MRMT-1- 
injected animals were reduced to sham level with 30mg kg'1 GBP (Fig 5.6). 
The brush-evoked response was also reduced in MRMT-1-injected rats from 
468 ± 36 AP to 247 ± 34 AP (sham pre-drug control was 243 ± 74 AP) with 
100mg kg'1 GBP (Fig 5.6).
As found with the chronic treatment study, GBP did not have a significant 
effect on thermal-evoked responses at any dose.
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Figure 5.6 The effect of acute systemic GBP on electrical- (A) and mechanical- 
(B) evoked responses of WDR SDH neurones in MRMT-1-injected rats.
Electrical-evoked responses (A) of WDR SDH neurones (n=7) in MRMT-1-injected 
rats were reduced compared to pre-drug control values, significant (P<0.05) at 
30mgkg'1 GBP for C-fibre-evoked responses and 100mgkg'1 for input, post­
discharge and wind-up. The reduction was such that the level of response was 
similar to sham-operated rat controls. Mechanical-evoked responses (B) were also 
significantly reduced (P<0.05) with GBP (at 30mgkg'1 for von Frey 30g and 
100mgkg'1 for brush).
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5.3.4 GBP Autoradiography These preliminary studies revealed
binding of GBP in the superficial dorsal horn layers of both sham-operated 
and MRMT-1-injected rats. Sections co-incubated with pregabalin showed 
no radioactivity on the films. There was no difference in intensity or area of 
binding between the ipsilateral and contralateral side (with respect to injected 
limb) of the cord in sections from sham-operated rats (Figure 5.7).
Figure 5.7 [3H]-GBP binding in the SDH of sham-operated rats. Panel A shows 
a pseudo-colour photomicrograph of whilst panel B shows a black and white 
photograph of the same section after staining with toluidine blue. The pale circle on 
the right-hand dorsal horn is the pin hole in the contralateral side. Graph C shows 
that there is no difference in the area of binding between ipsilateral and contralateral 
sides. Scale b a r=  1mm.
However, in spinal cord sections from MRMT-1-injected rats, there was a 
marked increase in the area of binding on the ipsilateral compared to 
contralateral side, whilst the intensity of binding in these areas was the same 
(Figure 5.8).
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Figure 5.8 [3H]-GBP binding in the SDH of MRMT-1-injected rats. Panels A1 
and B1 show pseudo-colour photomicrographs of [H3]-GBP binding in spinal 
cord sections from MRMT-1-injected rats whilst panels A2 and B2 show black 
and white photographs of the same sections after staining with toluidine blue. 
The contralateral sides are identified by the pale circular areas in the ventral 
part of the cord. As shown in graph C, there is no difference in binding intensity 
between ipsilateral and contralateral dorsal horn. However, there seems to be a 
marked increase in the area of binding on the ipsilateral side (graph D).
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5.4 Discussion
As with the previous chapter, the results here confirm that injection of MRMT- 
1 cells into the rat tibia results in the progressive development of mechanical 
and cold allodynia as demonstrated by behavioural testing, and a 
characteristic dorsal hom pathophysiology of increased proportion of WDR 
neurones in the superficial lamina and hyperexcitability of these cells in 
response to electrical and natural stimuli.
These behavioural studies show that chronic systemic administration of GBP 
reduces the aberrant behavioural responses to mechanical-stimuli (von Frey 
filaments) to normal pre-operative baseline level and also significantly 
reduces cold allodynia as assessed by the acetone test. The 2 day lag seen 
before GBP significantly reduced behavioural responses is in agreement with 
other published findings in a model of neuropathic pain, where multiple doses 
of GBP were necessary to produce behaviourally measurable 
antihyperalgesia (Christensen et al. 2001; Levendoglu et al. 2004). GBP at 
30mg kg’1 did not affect normal motor function in a group (n=4) of normal 
animals (data not shown). The impairment of ambulation seen on the rotorod 
in the MRMT-1 group was therefore due to the destruction of the tibia not any 
side-effect of GBP. In addition, the attenuation of pain is reversed when GBP 
treatment is stopped with the return of mechanical allodynia and grade 3 
ambulatory-evoked pain on the rotorod after two days. Thus, after GBP, the 
improvement in the rotorod performance is most likely to be due to an 
attenuation of the pain-evoked motor impairment caused by the bone cancer.
Characterisation of SDH neurones at the time of maximum anti-hyperalgesia 
(day 15 post-surgery and the fifth day of GBP treatment) confirmed that GBP 
reversed the dorsal horn pathophysiology, significantly reducing electrical- 
and mechanical-evoked responses of WDR neurones as well as normalising 
the ratio of WDR to NS neurones. Two days after cessation of GBP 
treatment the dorsal horn returned to the hyperexcitable state with an 
increased proportion of superficial WDR neurones. This shows that the 
changes occurring after GBP treatment are not due to permanent changes
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such as anatomical reorganisation. Indeed, the rapid return to the 
uninhibited pain state would suggest that neuronal physiology may be a 
major determinant of the behavioural allodynia/hyperalgesia. These findings 
provide further evidence for a correlation between the dorsal horn neuronal 
pathophysiology and pain behaviours in CIBP. In addition, they suggest a 
pivotal role for plasticity in superficial SDH neurones in CIBP pain behaviour 
development.
The shift in the ratio of NS:WDR would appear to be due to a de novo gaining 
in the ability of low threshold mechanical inputs to activate NS neurones 
(either due to an increase in excitatory inputs and/or a reduction in inhibition). 
This is paralleled by increased responsiveness of the overall WDR neurone 
population at the same time as pain-related behaviour. GBP abolished the 
aberrant behaviour and re-set the neuronal responses. This is consistent 
with the idea that the allodynia/hyperalgesia seen after CIBP is in part due to 
spinal hyperexcitability and that central sensitisation is responsible for the 
pain behaviour. GBP removed the behaviour but rather than abolishing the 
neuronal responses it normalised them. Finally, the data further support the 
concept that GBP is antihyperalgesic as when the treatment ceased and the 
neuronal excitability was re-established, there was a re-emergence of pain 
behaviour.
The neuronal plasticity probably results from peripheral mechanisms that 
then drive central spinal changes. For example, peripheral mechanisms may 
reflect a large area of primary hyperalgesia, extending from the tibia into the 
adjacent paw. In addition the increased afferent drive into the spinal cord 
and the subsequent excitation and central sensitisation could evoke a 
secondary hyperalgesia over the hind paw. Although with the methods used 
here it is impossible to prove or disprove these ideas, one important factor 
must be the increased primary afferent input into the superficial (and thus 
indirectly to the deep) lamina. The shifting ratio of WDR:NS neurones in the 
superficial lamina that appears to drive the CIBP behavioural changes may 
be due to a combination of increased excitation (arising from primary 
afferents and/or descending facilitation) and/or decreases in intrinsic
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inhibition. Chronic treatment with GBP causes a decrease in the number of 
WDR neurones along with a reduction of the hyperexcitable state of the 
remaining WDR neurones.
As detailed in the introduction, GBP binds to the 0128 subunit of VGCCs (Gee 
et al. 1996) and thus the expected action would be a reduction of transmitter 
release and neuronal activity. The significantly increased input response 
(representing the excitability produced by afferent activity) seen in MRMT-1 - 
injected rats could be indicative of increased neurotransmitter release as a 
result of the cancer-induced osteoclast activation and subsequent bone 
destruction (Mantyh et al. 2002) which this study has shown to be normalised 
by GBP. N- and P-type calcium channels have been reported to be involved 
in neuropathic and inflammatory pain states (Chaplan et al. 1994b; Cizkova 
et al. 2002; Diaz and Dickenson 1997; Malmberg and Yaksh 1994; Matthews 
and Dickenson 2001). In addition, nerve injury-induced upregulation of the 
0128-1 subunit is reported to correlate with the anti-allodynic effects of GBP 
(Luo et al. 2001). The ability of GBP to normalise and reduce these 
enhanced responses could result from potential actions on altered VGCC 
activities so reducing transmitter release and the monosynaptic activation of 
the spinal superficial neurones that drive the plasticity.
The acute effects of systemic GBP in CIBP can be compared directly with 
other animal models of neuropathy and inflammation. GBP has been shown 
to reduce the evoked responses of dorsal horn neurones and have anti- 
allodynic effects in the spinal nerve ligation (SNL) and chronic constriction 
injury (CCI) models of neuropathic pain (Abdi et al. 1998; Chapman et al. 
1998a; Hunter et al. 1997; Matthews and Dickenson 2002). It has also been 
shown to block the late phase of the formalin response (Field et al. 1997), 
inhibit C-fibre and post-discharges (Stanfa et al. 1997), and reduce both 
thermal and mechanical hyperalgesia in the carrageenan model of 
inflammation (Field et al. 1997).
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As discussed in previous chapters, the dorsal horn alterations in Cl BP have 
been shown to have unique characteristics that differentiate it from 
neuropathy or inflammation (Medhurst et al. 2002; Schwei et al. 1999). The 
data here show the acute effect of GBP in CIBP is similar to that reported in 
both neuropathy and inflammation, although in CIBP there was no effect on 
the neuronal responses to thermal stimuli, which agrees with some studies 
in animal models of inflammatory and neuropathic pain (Nagakura et al. 
2003; Villetti et al. 2003), as well as clinical investigations (Attal et al. 1998; 
Werner et al. 2001), but not others (Cho et al. 2002; Field et al. 1997; 
Partridge et al. 1998). In addition, the acute doses of GBP used in this study 
are the same as those used in an inflammatory pain model (Stanfa et al. 
1997) and the chronic behavioural dose used was the minimum effective 
dose in the acute study. The data suggest that GBP inhibits hyperexcitable 
neuronal response in animal models of chronic pain ‘regardless’ of underlying 
pathology. Thus, at normal adjuvant doses GBP may be helpful in controlling 
CIBP in humans. It is of interest that a single systemic dose of GBP 30mg/kg 
had no effect on behavioural responses (shown by the lag period), although 
had some effect on reducing DH excitation (deep lamina C-fibre responses). 
This could be an effect of dose as for a single dose of GBP to have an effect 
on all DH responses it was required to be given at 100mg/kg. The acute 
reduction in DDH C-fibre responses may not be sufficient to translate into 
behavioural responses, however with multiple doses GBP (30mg/kg) 
normalises the DH response and this neuronal change may be pre-requisite 
for behavioural responses to alter.
The autoradiography studies were preliminary and so limited conclusions can 
be drawn from them. However, the effects seen were consistent for tissue 
from both of the animals in each group. In agreement with findings from 
other investigations (Melrose et al. 2004), GBP binding was highest in the 
superficial laminae of the DH. Although there was no increase in binding 
intensity on the ipsilateral compared to contralateral spinal cord in MRMT-1- 
injected rats, there seemed to be a marked increase in the area of binding in 
the SDH which implies an increased number of binding sites and thus is 
consistent with the upregulation of the 0128 subunit shown to correlate with
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antiallodynic effects of GBP in neuropathic pain (Luo et al. 2001). It is 
interesting that the area of binding seems to be expanding in the part of the 
dorsal hom that undergoes significant plasticity in CIBP.
As detailed previously, one of the characteristic features of the rodent models 
of CIBP is massive astrocyte hypertrophy, (Medhurst et al. 2002; Schwei et 
al. 1999). Astrocytes express VGCCs, calcium currents in cultured 
astrocytes have been shown to be enhanced by cAMP which also induces 
the morphological transformation from flat to process-bearing (MacVicar 
1987). It is clear from the results that it is necessary to further investigate 
GBP autoradiography in CIBP, and it would also be of interest to be able to 
compare these binding assays with glial fibrillary acidic protein staining in the 
same sections in order to assess whether this increased area of GBP-binding 
is a result of interaction with activated astrocytes.
In summary, these data show that GBP normalises DH neuronal responses 
and pain behaviour in the rat MRMT-1 model of CIBP. That increased 
excitation, arising from primary afferents and/or descending facilitatory 
pathways, may be responsible for the plasticity in superficial DH neuronal 
populations with an increase in the WDR population. The results provide 
strong evidence to support a correlation between SDH hyperexcitability and 
behavioural allodynia / hyperalgesia. Preliminary GBP binding studies 
demonstrate that there seem to be changes in the total area of binding in 
CIBP consistent with upregulation of 0C28 in this pain state. Finally, the ability 
of GBP to normalise SDH neuronal responses and pain behaviour in this 
model at clinically relevant doses suggests that it could be effective in 
treating humans with CIBP.
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Chapter 6.
MORPHINE: EFFECTS ON DORSAL HORN 
NEURONAL RESPONSES AND 
BEHAVIOUR.
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6.1 Introduction
Opium, extract of the poppy plant Papaver somniferum, has been used 
medicinally and socially for thousands of years. The second-century Greek 
physician Galen administered it to relieve pain from headaches, gallbladder 
maladies, colic and kidney stones (Snyder 1996). Morphine, a derivative of 
opium, was first obtained from the poppy plant in 1805 by 20-year-old 
German chemist Friedrich Sertumer who named it after Morpheus, the Greek 
god of dreams (Snyder 1996). It has become the most widely used analgesic 
for severe pain, the ‘gold standard’ to which other drugs are compared.
Opioids are one of the mainstay therapies (along with radiotherapy and 
bisphosphonates) in the clinical treatment of CIBP (Mercadante 1997; 
Portenoy and Lesage 1999). Although effective in the treatment of 
background pain, control of incident pain remains a problem. The presence 
of breakthrough pain is in fact predictive of reduced opioid efficacy (Portenoy 
et al. 1999) and at doses sufficient dose to control the movement induced 
pain the patient will suffer severe side-effects (Mercadante 1997). Some of 
the lack of efficacy is due to the pharmacokinetics of morphine, with a 
relatively slow onset and prolonged action, meaning that clinically the pain 
will have peaked and may be fading before the opioid has any effect. Even 
oral-transmucosal fentanyl citrate, which has a faster onset and shorter 
duration of action than morphine, is often ineffective at controlling severe 
movement-induced pain (Rhiner et al. 2004). One important issue here is 
that another reason for the reduced efficacy of morphine on movement- 
induced or breakthrough pain may be the underlying neuronal substrates 
compared to those for pain at rest. Thus, a given dose of opioid may be 
sufficient to inhibit sensory neurones active at rest. When movement 
commences, inputs and so neuronal activity will increase, and compounding 
the problem will be the neuronal hyperexcitability to both low and high 
threshold inputs induced by CIBP that I have described in chapter 3. Higher 
doses may predictably be required to control breakthrough pain but the 
actions of opioids on neuronal activity in this model have never been 
examined.
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As discussed in section 1.4.6, opioids act at both peripheral and central sites. 
It has been demonstrated that the peripheral actions of opioids are an 
important active pathway in CIBP, as local administration of morphine and 
loperamide have been shown to abolish thermal hyperalgesia in the 2472 
murine model (Menendez et al. 2003b). Systemic morphine has also been 
shown to reduce the behavioural signs of hyperalgesia in the same model 
(Luger et al. 2002; Vermeirsch et al. 2004).
The actions of morphine vary widely between different pain states with 
enhanced efficacy reported after inflammation and poor efficacy in 
neuropathic pain (Matthews and Dickenson 2002; Stanfa and Dickenson 
1995; Suzuki et al. 1999). In CIBP the local destruction of the bone, 
activation and sensitization of peripheral nerves, and dorsal horn 
pathophysiology indicate that this pain state is unique but has elements of 
both neuropathy and inflammation.
Although there is evidence from the 2472 murine model of CIBP that higher 
doses of morphine are required to control pain from cancer in the bone 
compared with inflammation (Luger et al. 2002), there as been nothing 
published on the effect of chronic morphine on pain behaviour or dorsal horn 
pathophysiology. This study investigates the effect of chronic systemic 
morphine administration on behaviour and dorsal horn neuronal responses. 
As with the GBP study, systemic morphine was commenced after 
hyperalgesia had been established, akin to the clinical situation. As 
peripheral and central actions of morphine would all contribute to the altered 
behaviour, acute spinal morphine was also investigated to establish the effect 
locally on the dorsal hom.
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6.2 Methods
Preparation of the MRMT-1 cell line and surgery to induce CIBP (or sham 
surgery) were carried out as described in Chapter 2.
6.2.1 Drug administration Morphine sulphate (Evans Medical)
was prepared for use in chronic (3 mg kg'1) and acute (0.1 pg, 1pg and 10pg 
in a volume of 50pl) studies. Chronic morphine injections were administered 
subcutaneously in the scruff at the back of the neck, whereas in the acute 
studies morphine was applied directly to the spinal cord, i.e. the intrathecal 
route.
A total of 27 animals were used in the chronic morphine behavioural study, 6 
of which were sham-operated and 21 receiving intratibial injection of MRMT1. 
MRMT1-injected rats were divided into three groups. The first group (n=9) 
received bi-daily (7.30am / 7.30pm) subcutaneous injection of morphine (3 
mg kg'1) commencing on day 11 continuing through to day 14, with a single 
injection on the morning of day 15. The second group (n=6) received bi-daily 
injection of saline according to the same schedule. The final group of cancer 
animals (n=6) received a single injection of morphine (3 mg kg'1) on the 
morning of post-operative day 15.
The sham-operated rats received bi-daily injection of morphine according to 
the same chronic schedule as described for the cancer animals.
Behavioural testing was carried out exactly as described for gabapentin, with 
the exception that this experiment was terminated on the fifth day of drug 
treatment, i.e. post-operative day 15, on which day electrophysiological 
characterisations were made of SDH neuronal responses. Four out of the 9 
MRMT-1-injected rats chronically treated with morphine were used for the 
characterisations and an average of 5 neurones was characterised per rat.
For the acute study 7 rats were assigned to each experimental group (DDH 
cancer and sham, SDH WDR cancer and sham, SDH NS cancer and sham).
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Pharmacological study of SDH and DDH neurones with morphine was as 
described for ondansetron and gabapentin, recording electrical- and natural- 
evoked responses and testing at t=10, 30 and 50 minutes after each dose. 
After the maximum effect of morphine was observed with the top dose, 
naloxone (10pg in a volume of 50|xl) was applied to the spinal cord, the 
neuronal response followed as for morphine and the maximum reversal was 
recorded.
6.3 Results
6.3.1 Chronic systemic morphine -  behaviour The sham-
operated animals, receiving bi-daily injection of morphine 3mg/kg between 
post-operative days 11 to 14 and a single dose on day 15, showed no 
changes to the stable baseline responses indicating that this dose of 
morphine does not cause somnolence (rotorod) or changes in normal 
baseline sensitivity to mechanical or cold stimuli (data not shown).
Of the 21 animals in the cancer group, 6 received bi-daily injection of saline 
between post-operative days 11 to 14 and a single dose on day 15 and 9 
received morphine 3mg/kg according to the same treatment schedule. The 
final 6 rats received a single injection of morphine on day 15. The cancer 
animals not receiving morphine injections (i.e. those injected with saline or 
those only injected with morphine on day 15) developed mechanical allodynia 
and cold sensitivity over the ipsilateral hind paw and ambulatory-evoked pain 
as described previously for non-treated animals in this model (Figure 6.1). 
Conversely, the cancer animals receiving bi-daily morphine injection did not 
show development of pain behaviour as responses to all behavioural tests 
were maintained at the pre-operative baseline (Figure 6.1).
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Figure 6.1 The effect of 
chronic systemic 
morphine (3mg/kg) on 
mechanical allodynia 
(1A, 1B), cold
allodynia (1C) and 
ambulatory-evoked 
pain (AEB) (1D) in 
MRMT-1-injected rats. 
Each data point in the 
saline-treated group 
(open circle) represents 
the mean ± s.e.m. of 6 
rats and in the 
morphine-treated group 
(closed circle) the mean 
± s.e.m. of 9 rats. 
Animals received bi­
daily subcutaneous 
(s.c.) injection of saline 
or morphine 3mgkg'1 
between post-operative 
days 11 to 14 inclusive 
at 12-hour intervals, with 
a final injection on the 
morning of day 15. 
Morphine-treated rats 
show a reduction in 
withdrawal responses to 
von Frey 1g (A) and to 
von very 15g (B) from 
the first day of 
treatment. The
response to acetone (C) 
in morphine-treated rats 
was also significantly 
reduced compared to 
saline-treated rats from 
the first injection 
onwards, as was the 
ambulatory-evoked pain 
score (D). *P< 0.05,
*P<0.01,*P<0.001.
Post-operative day
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Pre-injection compared with post-injection behavioural testing on day 15 
showed a significant difference in the chronically treated morphine group 
suggesting that the effects of the drug are wearing off between injections. 
Although these data show that the level of analgesia is not stable, it is clear 
that some analgesic action remains with the chronic morphine injection 
schedule as there was still a significant difference in von Frey withdrawal 
response between vehicle treated animals and morphine treated animals 
tested prior to injection of the drug on day 15 (Figure 6.2).
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Figure 6.2 Withdrawal responses to von Frey 15g on post-operative day 
15 in MRMT-1-injected rats. Withdrawal responses to von Frey 15g pre- and 
post-morphine in the chronically treated group (n=9) and 1hour post-morphine in 
the acutely treated group (n=6) were all significantly lower than in rats 
chronically treated with saline (vehicle, n=6). There was also a significant 
difference between the pre- and post-morphine withdrawal responses in the 
chronically treated group suggesting that the analgesic effect is waning between 
doses. However, there is a significant difference between the post-morphine 
responses in the acute and chronic groups suggesting that there is some 
advantage to chronic dosing. *P<0.05, **P<0.01, ***P<0.001
Acute injection of morphine on day 15 also resulted in a significant reduction 
of behavioural responses, although to a lesser extent than animals receiving 
chronic morphine treatment (Figure 6.2).
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6.3.2 Chronic systemic morphine -  SDH neurone characterisations A
total of 20 SDH neurones were characterised from 4 of the MRMT1-injected 
rats chronically treated with morphine on post-operative day 15 after the final 
injection of morphine. For statistical analysis these data were compared with 
the previous characterisations of SDH cells in MRMT-1 and sham-operated 
rats detailed in Chapter 3.
The characterisations on the final day of morphine treatment in MRMT1- 
injected rats revealed that the ratio of WDR SDH neurones is still abnormally 
high compared to shams but that some of the hyperexcitable responses have 
been normalized (Table 6.1).
Table 6.1 Electrical-evoked responses of WDR SDH neurones in MRMT- 
1-injected rats treated chronically with systemic morphine (3mg/kg).
% of 
population
Input A-beta C-fibre Post­
discharge
Sham 26 139±36 75±8 162±29 62±15
MRMT-1 53 *239±26 *120±13 *243±24 *121±28
MRMT-1 
+ morphine
45 176±23 86±9 189±12 66±20
Results are the mean ± S.E.M action potentials evoked by electrical stimuli at 
three times C-fibre threshold. *Significantly elevated responses compared to 
sham-operated rats (P<0.05).
6.3.3 Acute intrathecal morphine A single dorsal horn neuron
was isolated for experimentation per animal, giving a total of 42 neurones. 
Consistent with previous characterisations, WDR neurones located in both 
the SDH and DDH showed hyperexcitable responses compared to sham- 
operated rats.
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Acute spinal morphine had similar actions in all groups of neurones with no 
significant effect on electrical-evoked A-beta fibre responses or brush-evoked 
responses (Tables 6.2-4) but dose-dependent reductions of all other 
electrical and natural-evoked responses (Tables 6.2-4; Figures 6.3-6.5).
Table 6.2 Comparison of the effects of morphine on the electrical- 
evoked responses of DDH neurones in MRMT1-injected and sham- 
operated rats.
Morphine
SHAM 0.1 pg 1^9 10pg Naloxone
A-beta 93 ±15 98 ±16 107 ±11 102 ±17
A-delta 94 ±15 53 ±11 *28 ±19 103 ± 10
Input 95 ±15 *37 ± 11 **19 ±14 137 ±23
C-fibre 89 ±16 *49 ±16 **16 ± 7 107 ±15
Post­
discharge 102 ±18 **37 ±16 **27 ±14 124 ±16
Wind-up 84 ±23 *35 ±19 **15 ± 8 117 ± 19
MRMT 0.1 pg 1^9 lOpg Naloxone
A-beta 116 ± 11 127 ±10 130 ±13 120 ±12
A-delta 97 ±16 70 ± 9 **32 ±12 81 ±10
Input 102 ±22 58 ±17 **10 ±18 82 ±12
C-fibre 99 ±12 77 ±10 **14 ±12 74 ±17
Post­
discharge 124 ±12 68 ±11 **33 ±13 113 ± 18
Wind-up 105 ±10 75 ±11 **20 ±12 116 ± 11
Data shown are mean action potentials ± SEM from a total of 7 rats in each 
group. Responses are expressed as % of pre-drug control value.
The magnitude of effect of morphine on SDH NS cells was the same in 
sham-operated and cancer animals (Table 6.3, Figures 6.3-6.5). However, 
for WDR cells only the top dose of morphine (lOpg) significantly reduced the 
hyperexcitable electrical-evoked responses in MRMT1-injected rats, whereas 
the electrical-evoked responses in sham animals were sensitive to a lower 
dose of 1pg (Tables 6.2 and 6.4).
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Table 6.3 Comparison of the effects of morphine on the electrical- 
evoked responses of SDH NS neurones in MRMT1-injected and sham- 
operated rats.
Morphine
SHAM 0.1 ng 1^9 10pg Naloxone
A-beta 89 ±23 88 ±21 91 ±19 103 ±24
A-delta 82 ±16 64 ± 13 *52 ±12 126 ±23
Input 94 ±24 58 ±10 *40 ±12 128 ±22
C-fibre 80 ±10 **54 ± 9 **48 ± 8 94 ±10
Post­
discharge 66 ±17 **26 ±16 **11 ±10 80 ±21
Wind-up 55 ±27 *34 ±15 **9 ±14 99 ±18
MRMT 0.1 jig ipg lOpg Naloxone
A-beta 104 ±11 129 ±16 95 ±24 105 ±13
A-delta 103 ±26 64 ± 10 *49 ± 6 101 ±10
Input 127 ±21 55 ±18 *28 ± 21 141 ±26
C-fibre 88 ±15 *51 ±17 *41 ±12 97 ±21
Post­
discharge 71 ±18 *33 ± 21 *24 ±18 93 ±16
Wind-up 66 ±26 *43 ± 22 *21 ±18 111 ±11
Data shown are mean action potentials ± SEM from a total of 7 rats in each
group. Responses are expressed as % of pre-drug control value.
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Table 6.4 Comparison of the effects of morphine on the electrical- 
evoked responses of SDH WDR neurones in MRMT1-injected and sham- 
operated rats.
Morphine
SHAM 0.1 pg ipg lOpg Naloxone
A-beta 90 ±7 89 ±10 69 ±16 106 ±12
A-delta 81 ±14 *47 ±14 **32 ±10 90 ±11
Input 82 ±12 **44 ±13 **15 ±9 102 ±19
C-fibre 111 ±11 *58 ±13 **28 ±13 83 ±11
Post­
discharge 113 ± 19 51 ±11 **18 ±12 71 ±28
Wind-up 123 ± 16 59 ±11 **20 ±12 88 ±20
MRMT 0.1 pg ipg lOpg Naloxone
A-beta 109 ±19 102 ±17 88 ±17 103 ±9
A-delta 116 ± 16 95 ±15 *49 ±9 95 ±10
Input 139 ±28 72 ±14 *37 ±10 92 ±14
C-fibre 115 ± 18 87 ±17 *40 ±8 114 ±32
Post­
discharge 136 ±35 79 ±23 *38 ±11 83 ±27
Wind-up 99 ±23 67 ±23 **34 ± 11 92 ±23
Data shown are mean action potentials ± SEM from a total of 7 rats in each 
group. Responses are expressed as % of pre-drug control value.
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Figure 6.3 The effect 
of morphine on 
natural-evoked 
responses of DDH 
neurones in sham- 
operated and MRMT-1 - 
injected rats. In both 
sham-operated and 
MRMT-1-injected rats 
morphine (1 jug and 
1Opg) significantly 
reduced both
mechanical- and
thermal-evoked 
responses of DDH 
neurones. Each data 
point represents the 
mean ± S.E.M of 7 
animals. *P< 0.05, 
*P<0.01, *P<0.001.
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Figure 6.4 The effect 
of morphine on 
natural-evoked 
responses of SDH NS 
neurones in sham- 
operated and MRMT-1- 
injected rats. In both 
sham-operated and 
MRMT-1-injected rats 
10|ig morphine
significantly reduced 
both mechanical- and 
thermal-evoked 
responses of SDH NS 
neurones. Each data 
point represents the 
mean ± S.E.M of 7 
animals. *P< 0.05,
*P<0.01, *P<0.001.
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Figure 6.5 The effect 
of morphine on 
natural-evoked 
responses of SDH 
WDR neurones in 
sham-operated and 
MRMT-1-injected rats. 
In both sham-operated 
and MRMT-1-injected 
rats morphine (1pg and 
10pg) significantly 
reduced both
mechanical- and
thermal-evoked 
responses of SDH WDR 
neurones. Each data 
point represents the 
mean ± S.E.M of 7 
animals. *P<0.05, 
*P<0.01, *P<0.001.
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6.4 Discussion
This study demonstrates that acute spinal administration of morphine in the 
rat tibia model of CIBP significantly reduces electrical- and natural-evoked 
DH neuronal responses. Reductions of similar magnitude were also seen in 
sham-operated animals (which have neuronal and behavioural responses 
similar to normal rats) and at lower doses than in cancer animals, thus 
suggesting that the efficacy of morphine is lower in CIBP than in normal 
states. This is in contrast with results from acute spinal administration of 
morphine (at similar doses to those administered in this study) in the spinal 
nerve ligation (SNL) model of neuropathy in rat where it has been reported 
that there is enhanced potency of intrathecal morphine after nerve injury 
(Suzuki et al. 1999). In the same study it was shown that systemic morphine 
was less effective at inhibiting the evoked neuronal responses of spinal nerve 
ligated rats compared to shams. This finding was mirrored by another 
investigation in the same model which showed systemic morphine to be less 
effective at reducing evoked neuronal responses in neuropathic rats 
(Matthews and Dickenson 2002). Electrophysiological studies have shown 
the antinociceptive effects of spinal morphine to be more potent following 
carrageenan inflammation in rats compared to normal animals (Stanfa and 
Dickenson 1994). All of these results therefore suggest that the efficacy of 
morphine at attenuating dorsal horn neuronal responses is related, at least in 
part, to the route of administration with spinal administration possibly being a 
more appropriate approach to pain control in neuropathic and inflammatory 
states since high local concentrations will be achieved in areas critical for 
opioid analgesia. The effects of spinal morphine in this CIBP model are 
therefore more like those seen in inflammatory pain than neuropathic pain, 
but this finding still underlines the fact that although CIBP shares some 
features of neuropathy and inflammation it is in fact a unique pain state 
(Luger et al. 2002; Schwei et al. 1999) reflected by the differing efficacies of 
spinal morphine in SNL, carrageenan inflammation, and malignant bone pain 
models.
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These data also show that in a rat model of CIBP, systemic morphine (at a 
dose that does not cause somnolence or alter normal withdrawal responses) 
is effective at attenuating behavioural signs of pain. For all of the MRMT1- 
injected rats receiving bi-daily subcutaneous injection of morphine (3mg/kg) 
between post-operative days 11 to 15 the behavioural responses were 
maintained at the pre-operative baseline level, significantly different to the 
responses of MRMT1-injected rats receiving saline injection showing 
progressive development of mechanical and cold allodynia as well as 
ambulatory-evoked pain. Systemic morphine has been used, with varying 
efficacy, in other rodent models of CIBP. In a murine model employing 
injection of sarcoma cells into the femur, doses of systemic morphine 
required to block pain behaviours were ten times higher (30mg/kg) than 
needed to block peak inflammatory behaviour in the complete Freund’s 
adjuvant (CFA) model (Luger et al. 2002). In a similar model using intratibial 
injection of osteolytic fibrosarcoma cells in mice, systemic administration of 
both morphine and the peripherally acting opioid loperamide have been 
shown to attenuate behavioural thermal hyperalgesia (Menendez et al. 
2003b). More recently, another group using the mouse femur model has also 
shown that systemic morphine (10mg/kg) significantly reduced spontaneous 
flinching behaviour in cancer animals and the rather high dose of 40mg/kg 
significantly improved limb use on the rotorod (Vermeirsch et al. 2004). The 
overall picture, therefore, is that systemic morphine does attenuate pain 
behaviours in the different models of CIBP, although the doses required vary 
widely between the models. This is probably due, at least in part, to the 
different animal species being used and the different cell lines.
The advantage with the chronic dosing schedule used here, over acute 
administration at just a couple of time points at advanced stages of pain 
behaviour as employed by other studies, is that it has enabled the monitoring 
of the efficacy of morphine over time. Interestingly, the pre- versus post­
injection behavioural testing carried out on the final day of morphine 
treatment showed that although there was a significant difference, indicating 
that the analgesic effects are wearing off between doses, some drug action 
remained as the withdrawal responses prior to the final morphine injection
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were still significantly lower than in cancer animals receiving saline injections 
according to the same schedule. The loss of analgesic effect with the 12- 
hour dosing schedule is unsurprising given that systemic morphine in 
Sprague-Dawley rats has a half life of 15 minutes and morphine-6- 
glucoronide (its active metabolite) has a half life of 11.2 minutes 
(Hasselstrom et al. 1996). Despite the slight wearing off of drug effect, over 
this 5 day schedule it is clear that no dose escalation is necessary to achieve 
the same level of analgesia suggesting that there is no development of 
tolerance to the analgesic effect of morphine. It would be interesting 
however to carry out the same study over a longer period in order to assess 
whether, and if so when, dose escalation would become necessary to 
maintain stable analgesia.
Acute systemic injection of morphine on post-operative day 15 significantly 
reduced pain behaviour although not to the same extent as the chronically 
treated cancer animals at this time point. Furthermore there was no 
significant difference in behavioural responses between the pre-injection 
tests in cancer rats chronically treated with morphine or those of cancer rats 
receiving acute systemic morphine on day 15. These data not only support a 
chronic opioid treatment schedule in CIBP, but may also add to the 
explanation of why higher doses of systemic morphine were necessary in the 
other studies to attenuate pain as they were carried out on later post­
operative days when the pain has reached a more severe level, and which 
although was sensitive to acute morphine in this investigation, was less so 
than with chronic administration.
The SDH cell characterisations in MRMT1 -injected rats chronically treated 
with morphine demonstrate that evoked neuronal responses that were 
sensitive to acute spinal morphine were also significantly reduced with 
chronic systemic administration. It should be noted however that in the acute 
electrophysiological study it is the immediate effect of morphine that is being 
measured with evoked neuronal responses being followed for 1 hour after 
each dose tested. With the chronic morphine electrophysiological 
characterisations on the other hand, the neuronal responses are being
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recorded at the earliest 3 hours after systemic injection of the final dose of 
morphine and up to 7 or 8 hours after injection for the last cell characterised 
in an animal. These characterisations are therefore representative of the 
effects of chronic morphine administration rather than the acute drug effect 
on the dorsal horn. Although chronic systemic morphine reduced the 
hyperexcitablility of SDH cells, the abnormally high ratio of WDR neurones 
characteristic of CIBP was not reversed unlike the case with chronic systemic 
gabapentin treatment. So although my study shows that morphine can 
attenuate neuronal activity in this model, its inability to reverse the induced 
neuronal hyperexcitability may relate to the problems of control of 
breakthrough pain. The analgesic effect of chronic morphine differed from 
that of chronic gabapentin treatment since with gabapentin although there 
was a lag before it significantly reduced pain behaviours, once the 
antihyperalgesic effect was established it was maintained throughout the 
treatment schedule. The effects of morphine, as discussed tended to ‘reset’ 
between the daily tests. These points further substantiate the proposal that 
pain behaviours in CIBP are driven by changes in populations of SDH cells 
with abnormally high numbers of hyperexcitable WDR cells in this pain state, 
which may provide a pharmacological target. However, it implies that for 
more adequate pain control in CIBP combination therapy of an opioid with 
gabapentin for example may be useful, particularly if as has been shown to 
be the case in neuropathic pain there is a synergistic action between 
morphine and gabapentin (Matthews and Dickenson 2002).
In summary, the data presented here agree with the findings that CIBP, 
although sharing some features of neuropathy and inflammation, is a unique 
pain state reflected by the differences in efficacy of spinal and systemic 
morphine between these models. The data show that a chronic morphine 
treatment regime is necessary to treat CIBP but suggest that in order to re­
set the dorsal horn to a totally normal state combination therapy of opioids 
with another drug class would be necessary.
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Chapter 7.
GENERAL DISCUSSION.
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The dorsal horn of the spinal cord is an important hub in the intricate network 
of nociceptive pathways that run from the peripheral nociceptors at the site of 
the pain, through the spinal cord circuits and then on to higher centres where 
perception is established. Investigation of neuropathological alterations 
occurring in this area in chronic pain states is helping to shed light on 
mechanisms driving these conditions, and hand in hand with behavioural 
studies is identifying novel drug candidates for use in the clinic. Although 
pain itself is a product of conciousness, the requisite activity in the higher 
centres relies on inputs to the forebrain and cortex that can be dramatically 
altered by spinal mechanisms, underlining the importance of understanding 
dorsal horn mechanisms in pain states. Clearly, for such investigations it is 
essential to have a reliable animal model that is representative of the clinical 
condition. The recent development of suitable rodent models of CIBP has 
brought this major clinical problem to the forefront, and the aim of this thesis 
was to contribute to a better understanding of a pain state that severely 
decreases the quality of life of so many patients.
The results from the characterisation studies in Chapter 3 have agreed with 
previous findings in the rat MRMT-1 model of CIBP that there is progressive 
development of behavioural hyperalgesia and allodynia that emulates the 
clinical progression of disease (Medhurst et al. 2002). I have demonstrated 
here that the electrophysiological characteristics of DH neurones in CIBP are 
different to those reported in any other pain state, in line with the unique 
neurochemical signature reported in this state (Medhurst et al. 2002; Schwei 
et al. 1999). Around the time of maximum pain behaviour in MRMT-1 - 
injected rats, there are also altered evoked responses of WDR neurones in 
the deep and superficial dorsal horn. My results show that dorsal horn 
neurones are hyperexcitable in the CIBP state, in agreement with the idea of 
an ongoing central sensitization (Clohisy and Mantyh 2003).
Perhaps the most interesting finding from the characterisations was the shift 
in SDH neuronal populations in favour of an abnormally high proportion of 
WDR cells in the pain state compared to sham animals (which reflect the 
normal non-malignant pain-free state). This has been interpreted as
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previously NS cells becoming WDR. However, it is important to recognise 
that other cellular populations do exist in the DH and the view presented here 
is a simplified one based on the types of neurones that can be identified with 
this methodology. It is possible that the changes in populations involve 
previously silent cells becoming active and it would be very interesting to use 
a multi-electrode setup to test this hypothesis. Regardless of the exact 
dynamics between populations, it seems to be clear that the shift to the 
abnormal WDR state in the SDH is driving the general spinal 
hyperexcitability.
This raised the possibility that increased excitability may be generated in both 
spinal and supraspinal pathways; lamina I NKi-expressing neurones have 
been shown to be the origin of a spinal-supraspinal loop important in evoking 
descending facilitation, via spinal 5-HT3 receptors, back down to superficial 
and DDH laminae, which is necessary for full coding of inputs by deep DH 
neurons (Suzuki et al. 2002). The changes in the SDH in CIBP may 
therefore contribute to the increased excitability of the DDH. Also, as lamina 
I neurones project preferentially to the PAG, parabrachial area and CVM 
which are important circuits contributing to the affective and nocifensive 
responses to noxious stimuli (Bernard et al. 1995; Craig 1995; Hylden et al. 
1985; Mouton and Holstege 1998), it suggested that in CIBP there is 
increased activation of these areas as well as access of lower threshold 
inputs.
The monitoring of SDH changes in parallel with behavioural signs of 
hyperalgesia showed that the two are occurring in parallel in this pain state. 
These results agree with a key role of the SDH in the regulation and 
behavioural expression of pain sensitivity (Mantyh and Hunt 2004; Yezierski 
et al. 2004) and also validated neuronal responses as the most suitable 
substrate for pharmacological study, being suprathreshold responses more 
clinically relevant than the threshold level behavioural responses.
In order to assess the role of the descending serotonergic facilitatory 
pathway in CIBP, I measured the effects of spinally administered
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ondansetron, a selective 5-HT3 receptor antagonist, on electrical- and 
natural-evoked DH neuronal responses in MRMT-1-injected and sham- 
operated rats. Ondansetron inhibited the natural-evoked responses in sham- 
operated rats indicating that this pathway is active in the normal pain-free 
state. The effects however were much greater in animals injected with 
MRMT-1, significant reductions being seen at lower doses of ondansetron 
and encompassing both the innocuous and the noxious range, thus showing 
that the effect of ondansetron is enhanced and suggesting that there is 
increased activation of this excitatory serotonergic pathway in CIBP. 
Comparing these results to other pain models it seems that the effects of 
ondansetron are only enhanced at longer time points after induction of the 
model in question when alterations have been reported in DH neuronal 
responses, implying that plasticity in the 5-HT3 descending pathway does not 
occur immediately after tissue injury and is more likely to be involved in or 
produced by the maintenance phase rather than the generation phase of 
chronic pain.
A common thread to the investigations throughout this thesis has been 
comparison of the results to observations in neuropathic and inflammatory 
pain states, due to the supposed contribution of these processes to CIBP. 
The neurochemical and dorsal horn signatures of CIBP do confirm that some 
features are common to these pain states, but show that the individual profile 
of each is unique. GBP having been demonstrated to be effective in models 
of neuropathy and inflammation was therefore an interesting subject for 
pharmacological study.
Acute systemic GBP at higher doses was able to attenuate some of the 
hyperexcitable responses of WDR neurones in both the SDH and DDH and 
had no effect on responses in the remaining NS cells in MRMT-1-injected 
rats (that are not hyperexcitable), or any cells in sham-operated rats, thus 
fitting the anti-hyperalgesic profile of this drug. Chronic systemic 
administration of GBP (at a clinically relevant dose), starting when significant 
pain behaviour had developed, brought behavioural responses back to the 
pre-operative normal baseline after a 2 day lag. As GBP normalised rather
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than abolished withdrawal responses, these studies provided further 
confirmation of the antihyperalgesic action of the drug. Cessation of 
treatment, after another 2 days, resulted in a return to the uninhibited pain 
state showing that permanent changes, such as anatomical reorganisation, 
are unlikely to account for CIBP and that neuronal physiology probably has a 
more prominent role.
As well as removing pain behaviour, chronic systemic GBP re-set the DH 
neuronal responses causing a decrease in the number of WDR neurones 
along with a reduction of the hyperexcitable state of the WDR cells still 
remaining. A single systemic dose of GBP 30mg/kg had no effect on 
behavioural responses (shown by the lag period), although had some effect 
on reducing DH excitation. The acute reduction in DDH C-fibre responses 
may not be sufficient to translate into behavioural responses, however with 
multiple doses GBP (30mg/kg) normalises the DH response and this 
neuronal change may be pre-requisite for behavioural responses to alter, 
supporting the idea that abnormal SDH neuronal responses correlate with 
pain behaviour.
Preliminary autoradiography studies with [3H]-GBP demonstrated that there 
seem to be changes in the total area of binding in CIBP which would be 
consistent with an upregulation of the 028-1 subunit. In a model of 
neuropathy, upregulation of DRG (X28 has been shown to correlate with 
allodynia, and expression of distinct 0128 subunits in DRG and spinal cord with 
presence of neuronal 012S mRNA in both places suggests that the subunit is 
synthesised in a tissue-specific manner, possibly having a different functional 
role in each (Luo et al. 2001). It would therefore be of great interest to further 
study gabapentin autoradiography in the CIBP model, first of all to confirm 
the changes in area of binding and secondly to see if there are changes in 
the DRG.
Comparison of the effects of GBP in CIBP with other chronic pain models 
raises an important question: is a mechanism-based approach essential in
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treating pain? All of the work presented in this thesis, along with many 
published studies, show that CIBP, inflammation, and neuropathy although 
sharing some features, are unique pain states with different underlying 
processes. GBP, however, has been shown to be effective at reducing pain 
and neuronal responses in animal models of all of these states, with the 
common substrate seeming to be neuronal hyperexcitability. Unfortunately, 
GBP does not provide the ‘magic bullet’ for pain in the clinic as, whilst it 
seems to be effective in 100% of animals in these different pain models, it is 
only effective in about 30% of patients with neuropathic pain. This is 
probably a reflection of the genetic similarity of animals used as well as the 
identical nature of the neuropathy, inflammation, or general tissue injury in 
the models. For example, within Sprague-Dawley rats, one substrain shows 
a marked fast onset persistent allodynia after nerve injury whereas the other 
displays a short weak allodynia (Valder et al. 2003). It is not certain whether 
genes protect or predispose, but it does seem that in mice genes contribute 
to symptoms rather than neuropathy or inflammation per se (Mogil et al. 
2000). Clearly systematic investigation requires repeatability in the 
laboratory, but it does not reflect the patient population with a non uniform 
genetic background and widely varying underlying injuries, diseases and 
symptoms, as well as very different locations, areas, and durations of their 
pains.
The final pharmacological study presented here is with morphine. Acute 
spinal administration of morphine significantly reduced electrical- and natural- 
evoked DH neuronal responses. Reductions of similar magnitude were seen 
in sham-operated animals but at lower doses than in cancer animals, thus 
suggesting that the efficacy of morphine is lower in CIBP than in normal 
states, consistent with breakthrough pain correlating with reduced opioid 
efficacy (Mercadante 1997). SDH cell characterisations in MRMT1-injected 
rats chronically treated with morphine demonstrated that evoked neuronal 
responses that were sensitive to acute spinal morphine were also 
significantly reduced with chronic systemic administration. Chronic systemic 
morphine significantly reduced pain behaviour and pre- versus post-injection 
behavioural testing carried out on the final day of morphine treatment showed
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that although there was a significant difference, indicating that the analgesic 
effects are wearing off between doses, some drug action remained as the 
withdrawal responses prior to the final morphine injection were still 
significantly lower than in cancer animals receiving saline injections. 
However, these data imply that for more adequate pain control in CIBP 
combination therapy of an opioid with gabapentin for example may be useful, 
particularly if as has been shown to be the case in neuropathic pain there is a 
synergistic action between morphine and gabapentin (Matthews and 
Dickenson 2002).
In conclusion the neuronal plasticity seen in CIBP probably results from 
peripheral mechanisms, that then trigger central spinal changes. Peripheral 
mechanisms may produce a large area of primary hyperalgesia, extending 
from the tibia into the adjacent paw. The increased afferent drive into the 
spinal cord and the subsequent excitation and central sensitisation could 
then evoke a secondary hyperalgesia over the hind paw. Although with the 
methods used here it is impossible to prove or disprove these ideas, one 
important factor must be the increased primary afferent input into the 
superficial (and thus indirectly to the deep) lamina. The shifting population of 
WDR neurones in the superficial lamina that appears to drive the CIBP 
behavioural changes may be due to a combination of increased excitation 
(arising from primary afferents and/or descending facilitation) and/or 
decreases in intrinsic inhibition.
These changes in SDH neurones have important implications in terms of 
CIBP in its clinical context. As mentioned in the introductory chapter, an 
important facet of pain is the affective component. Although this is separable 
from sensory aspects of pain sensation, the pathways that are involved are 
interlinked. SDH neurones project preferentially to the parabrachial area 
which contacts the amygdala and hypothalamus. These regions are involved 
in the emotional and autonomic responses to pain. Lower threshold and 
hyperexcitable inputs to these areas in this model of CIBP correspond with 
increased anxiety and depression in patients with breakthrough pain. The
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spinal-supraspinal loop that feeds back to the dorsal horn via a descending 
excitatory serotonergic pathway is activated in CIBP thus increasing the 
hyperexcitability and amplifying the pain. The emotional state of patients is 
therefore probably important in determining the severity of their pain by the 
level of activity in this descending excitatory pathway. This suggests that in 
order to treat chronic pain more effectively the emotional and sensory 
aspects should be considered and treated with equal importance. Figure 7.1 
provides a schematic diagram summarising the processes driving CIBP 
discussed above.
The aims of this thesis have been met as the work set out here has provided 
some novel insights into mechanisms involved in CIBP, correlating 
behavioural signs of pain with alterations in SDH neuronal responses, and 
highlighting GBP as a possible novel treatment for CIBP in the clinic. The 
studies presented here have also raised many questions and there is 
obviously still much to be learned about CIBP. What is clear is that 
pharmacological modulation of neuronal responses in animal models is a 
valuable tool in the quest to understand, and thus alleviate, chronic pain.
Figure 7.1 Schematic summary of the processes involved in driving
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T it le  Correlation between behavioural responses and dorsal horn pathophysiology
in a rat model of cancer-induced bone pain.
T e x t The development of animal models of cancer-induced bone pain (CIBP) has
shed light on the underlying pathophysiology. We have used in vivo 
electrophysiology in a rat model of CIBP to investigate plasticity of spinal 
dorsal horn nociceptive neurones correlation with bone destruction and 
behavioural alterations.
Intra-tibial injection of MRMT-1 carcinoma cells resulted in progressive bone 
destruction and pain behaviour. Withdrawal responses to low mechanical 
stimuli and cold increased significantly over the post-operative period 
(significant by day 11).
Dorsal horn (DH) neurones were characterized at days 7, 9, 11, 15. At the 
time of maximal pain behaviour (15-17days) deep DH had significantly 
increased C-fibre and thermal evoked responses in MRMT-l-injected rats 
compared to sham injected rats. Superficial DH cells were classed as wide 
dynamic range (WDR) or nociceptive specific (NS). The proportion of WDR 
cells doubled in the MRMT-1 group to 47%. Responses of NS cells did not 
differ between the groups. The WDR cells in MRMT-1 rats had significantly 
increased A-beta, C-fibre, thermal and mechanical response. Receptive field 
size was also significantly increased.
The plasticity of superficial WDR cells in MRMT-1 rats developed during the 
post-operative period in parallel with the behavioural hyperalgesia and 
allodynia and bone destruction. In CIBP the spinal cord is significantly more 
excitable compared to sham animals, possibly driven by changes in the 
characteristics and response profiles of superficial DH neurones. It  is of note 
that many of these neurones project to areas of the brain involved in 
emotional responses to pain and drive some descending pathways.
Urch et al, Pain 103, 2003 
Donovan-Rodriguez T et al, Neurosci. Lett. 2004
Syngeneic MRMT-1 rat mammary gland carcinoma cells were donated by 
Novartis, London. This work was supported by The Wellcome Trust and a 
Pfizer PhD studentship.
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rat model of cancer-induced bone pain.
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INTRODUCTION
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cam r- rel*»«d ^ klk akd ^ dxi a <1 IbkaJ cn (1J.
•T Ik ^ cyelay n  kicfd  Mk awdeli of Cl BP laa RKikd a aktrjsc 
p.JJ.
•We fosc rented eleetVTtoyafoasfcal c fo kps I k dor»J Ivrk(DH) 
apl lad cord toe a no ha IfeatadeW ao^cl af Cl BP,*llhakarcnl1 
tm-cased esc Ustollly i Wi  Toalte hi atoll* Ik avpertkbl drrmd fora 
(SDH) toe a iota) IK h lk la  grcalc r keabc r in  afck
dylamtc rskge (WDR), -day Itog Ikboc o auve il ma kcat« itlad I 
dkelly loecblnl gftlbcehlica^ J.
•Here ve fosc at adkd IIk time coarse of Vac (wbml aflody kk tH  
kyTemlgcablhpuaJIcl vkktfo motofcorlk,ofWDF SOH edl Jar 
rcapotoae a. Wc vbfo d lo w s  Ifo tesvjvral correlates of tfo beam tod 
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METHODS
SURGERY
IbimtfaU lkJe<lfatf>rMRMT-l ic m rn l l i l tM i ih k .
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BEHAWOUPAL TESTING
Be has band al 1st d I ay^ fcd lo I he biar sarfacc or I to: h Itod pava.
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Gabapentin normalises the dorsal horn neuronal response in a rat model of cancer- 
induced bone pain
Tansy Donovan-Rodriguez, Anthony H. Dickenson, Catherine E. Urch
Departmert of Pharmacology, University Colege London, United Kingdom A
INTRODUCTION
a r^cllfefcal •  Ife « k lr b'Cxfccc r- Ihd w ri’i  fec**c p a l*  (C IB P ) l i a  « 
cartaM  I real arc bla lac k U l cfTfeacj.
*Reectil?-developed »odefet ac^rlivkkiiatak Ibe dltofca! ^ agRabhvr 
dbcaac akd pal b fca»c a hcrr b I lat Cl BP baa a a bl^ ac 
iRBiBpklle^aUe^, bal abarcaaaaic fcalorcaof fee ■•opal hie abd 
Mam m lb7 ptbilelci Ca*sa*j*c bilb |C BP) blfccbved brae lb
bcarvpalbk pa lb a bd b also c Ifce I be agaltwl I blaai aialarj al laid I lb 
ablaiala. Thbdragaia? ik c b n  pier* Id: & tacvd licalaicbl ferCIBP.
'Wc have reported p»cw b d r > hal saperlbbl dorsal tor b (SOH) bsarokaJ 
ftaaikli; develop* IbparaMd w U bbe l*v fe aral l^pe ralgca b abd died? bb lbCIBP (4j-
'Hcre wc Ibvcal^ plc the c ffec taofm* ole p^atcmk CBPobSDH abd deep 
d,r»J barb (DOH) be aaabal a^pobaea Iba ral model of Cl BP.
METHODS
SURGERY
'  E a * .  « »  «  emeekri pal pb n k  5 0  n b v c  Ig k l^  rely
ITOgal Ike llaic r fs a rp : r j .
■JalO’ •n « « i7 «VIRMT.|) n il. l t >Kl i «  p! ICpI labeled
lare. .he eFb-al ifehpfhripilmbe-abe.tbelkeri.»i,,bellhe M t IWeripbh 
bo be re a (oral be oialcrbJ.
•Shaa»-a^ raledabla»ala iccc bed cell medium alobc.
ELECTRORHYStOLOC Y:
•SHOe a r i l  u l m i r u  reepndthp marie Irppt D H  be a e b  pb 90.1. 
B ^ rb lh e  W r .  IS U  (Pig. I)  . h e .  J l  M R M T -1- Ib je e le r i.b lm .! . .hew eri 
afebHkabl meehabkal abd eri d .Ile a *  b k . R e ^ p b e .  Ip e le e lrk r i, 
m eelmbkal abd thermal a llm ril ere re . e n d e d
Rgura 1. Ic!i«m*tlc diagram ilioMng m atiodolog;for 
»i* ctroplv; iiologie al rwording from dor iai Morn
n»uron«i in ana»itli»tla>d rat ^
•AkfJeMeeelhe ataWe IrW a  (R»% aarhlkrb), be .petal realtor, 
pe re are -iyd  Ne ghe pre -dr u b  ml ral Cell. *c re elaml Ik el. .  
hrekeplhe ^pellk (MS) er.Ue ^ b . k  r>bF  (WDR) eee.HI^ Ip 
re ^ b e . l.  a r e c k e k d  >bd i k m k  .lip  J  L
•C B P  | ID. JO abd IO O .^ kg -1) p a a g h e b  aabe alahepariy 1b Ike « r . f f p |  
I k t K l n l l k  b e k  I t e . e l r . e  e  U S O d , abd Ihe b e p H  
. r t l k r e J  b r  SDm lb . (I = 10,  JO, SOm lb.)
RESULTS
• lb a gree trre b ip h b p re> h >_  Uadi »g. ( J ^ j.  e k e  I rk a l-eap icd  e ^ h e  .  
pFW DR riremi fe e . bearpbea laaperlk U  mW deep) peee afebirkahlly  
greale r la M R W T -1- lb(ee led n l .  epotgared lo .k e e p p e  leleel ablmaja 
( r ( f j ) . le e u lk e  • »  RrdlTfcrelare lb r e a g M c .prOI5S D H  n il. 
be b e e  b I he g n re^ .
•C B P d ld  hbl Imae .  alg b llk .b 1 effceI pbeepked re ap p b e . plaby e e h  
lb > k . P 9 e a l e d l e l . i J e p N S  WDR n it. lb M RMT-F- Ibjee k d  
anim al., b ra k y  al Iordan a l abr 4 r *  (da la hbl aherpb).
MRMT conlroi ^  
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MRMT. GBP 100m ghg"1 
Sliam control •
nput C-flbn» Poit-diicliarg* -Alnd-iTi
Rgur*J. Gicup*nlmnon**tii*i*i*ct*:»i-*vo)**d 
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rati. a
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nelan e l (P « X S )  e n j a e d  Ip  alm m . p  li K C  BF ICO mg kg' IF Ig . 3) .
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C BF- JOmgkg'.
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re d o n d p llh C B F  IDOmg kg" Id .  I a bpl a le p e ).
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'A .  re v e le d  o re . b . J j  (JjiJ Ike meehabkal (Fig. J) abd Ikermal-eapicel 
re ^ m b m .p fW D R  be arp tea p e  re a^ b  Ifkab lly  hlg he r lb IMRIMT - 1*
Ibfre ted ra l. ecron9ared Ip ahama
■ MRMT control
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Sliam control
n
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MRMT-1-ln)»ct»d ra t i___________
•C B P .^ b llk a b ll7 reeJneel (Pe»J5S) Ike m eelahka l (Fig. J) b . l  Iprl 
Ike the ratal-eapked re ^ p b p :. pr W D R  S D H  be arpbe. lb M R M T .I-  
lb)ec led »*.!*.
‘ (Mcc Jmbksl-cvohcd rcsppfaKS p fW D R  D D H  he i n b i  wc re aJx? 
»lgb irks-bllj rcdcccd w ll h C  BP ( d i l»  bol akrerb).
JAa with I Wc dec I rfcaJ-evoked rca^bsca. Ik: sbhwrmdly high
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lo ahoLva Ic vd .
CONCLUSIONS
•H e re  p e  ha.e ep b llrm ed p a rp te .k ro . flbdlbg. Ikbl W D R  D H  
be arpbe. are h, 90 reae HaUe lb C l BP [3. * ] .
•C 8 P  had a b i r k a b l  clfcclapH? lbee«Bar gpgrialkrtb  IIm l are 
reacllaUe lb C I BP, red ec lag 1 h; elee I r U -  abd me e habka). 
e wheel rea^baea Ip  ahem leael, I k s  I I I  k g  lire abl I- hj 9c ralge.k9foBc o r I lib drog.
•The a^gaUkabl reriac lbapT Ike 1.9.1 reayarlm. arpririagree p l ih a  
yreekrm lm ely p re rp S p lk  alle pfae Ike
•A a p e  tp .c  k b .  fc r Iml Ike SO H  Be i p  bri 5-1 h n p lp .H c g , pee are lb  
gpeallel p llkbekm akaraj ailcefr b k  (4]  a b rirk  mpbri rale here Itm lC B P  
re rise a Ike treerptnj bT9C reae llab l I17 IbC I BP, ll aogjeala 1 Iml Ik b  
drag m ej grpetde a  bpael I real me hi lb I | r  e llbk .
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